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Abstract 
 
Since the completion of the human genome project in 2001, the field of genomics has 
advanced exponentially, largely in part to the introduction of next generation sequencing 
(NGS); a technique that has revolutionised the ways in which genetic disease is 
investigated. NGS enables the simultaneous sequencing of multiple reads in parallel, 
which provides researchers with the opportunity to interrogate vast numbers of candidate 
genes in order to establish the genetic eitiology and key components of disease.  Exome 
sequencing in particular offers an efficient method to investigate disease, as the exomic 
regions make up 1% of the whole genome, but can contain up to 85% of functional 
variants responsible for disease. Next generation sequencing has been employed to 
investigate and identify the genetic cause of Acrocallosal syndrome (a rare autosomal 
recessive disorder). Exome sequencing was then also applied to investigate the genetic 
associations with both familial and sporadic pheochromocytomas and paragangliomas 
(neuroendocrine tumours). This study describes s the various applications, challenges 
and potential benefits that can be achieved by using exome sequencing as a tool to 
investigate rare autosomal recessive disorders in addition to more complex disorders 
including familial and sporadic cancer.  This study aims to employ cutting edge 
technology to investigate human disease, in order to enhance current understandings of 
disease biology and pathogenesis. Through this, it is hoped that these findings may help 
to contribute to on-going efforts to develop novel therapeutic strategies and improve the 
clinical management of these disorders. 
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1.1 The Genetic Epidemiology of Inherited Disease 
It has been 150 years since Gregor Mendel performed his unknowingly ground-breaking 
investigations into the hybridisation of pea plants. Through his observations and 
investigations into the patterns of heritability from one generation to the next, Mendel 
inadvertently formed the foundations and basis of modern day genetics. He managed to 
establish that alleles are inherited in pairs (one from each parent), and also that certain 
traits are inherited in a dominant fashion while others are recessive and remain ‘hidden’ 
until subsequent generations. Mendel also determined that the inheritance of one 
characteristic is not influenced by the inheritance of another. Through these 
observations, he managed to establish three main theories of inheritance; these are now 
known as the law of segregation, the law of independent assortment and the law of 
dominance (Mendel & Bateson 1865). These principles, although now often considered 
to be a vast oversimplification, remain the fundamental principles around which all 
genetics studies revolve around today.   
 
1.1a Mendelian Diseases: Clinical Aspects 
According to Mendel’s principles, diseases can be classified into groups based on their 
mode of inheritance, including autosomal recessive disorders, autosomal dominant 
disorders, X-linked and Y-linked.  
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1.1a.i Autosomal Recessive Disorders 
Autosomal recessive disorders refer to those that are caused by the inheritance of two 
mutant alleles for a particular disease gene. For example, if two parents are carriers of a 
pathogenic variant in a disease gene, their offspring will have a 50% chance of being 
born as an unaffected heterozygous carrier, 25% chance of being born an unaffected 
non-carrier, and a 25% chance of being born homozygous for both mutant alleles 
resulting in disease manifestation.  Cystic fibrosis (CF), a disorder characterised by the 
secretion of thick mucus in the lungs and airways of affected individuals, is one of the 
most well recognized autosomal recessive disorders, and is known to affect 
approximately 70,000 individuals globally (Cutting 2014). The inheritance of two 
mutated copies (alleles) of the CFTR gene is required for the development of CF; 
although the degree of severity of the disorder is known to be variable.  
 
1.1a.ii Autosomal Dominant Disorders  
Autosomal dominant disorders manifest when only one mutant allele from a disease 
gene is inherited. For example, Huntington’s disorder, a neurodegenerative disease, can 
manifest in individuals who have inherited a single pathogenic mutation in the HTT gene 
(Burgunder 2014).  Affected individuals with a pathogenic mutation will have a 50% 
chance of passing their mutation on to any offspring.   
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Vast and rapid advances in the abilities of sequencing technologies have enabled 
researchers to apply Mendel’s principles in order to elucidate the genetic landscape of 
many inherited disorders, and progress our understanding of the biological mechanisms 
involved in their pathogenesis. However, with such advancement in our abilities to 
sequence DNA and ascertain information regarding the human genome, has also come 
the realisation that the inheritance and development of genetic disease can be much more 
complex than Mendel originally believed. Concepts such as incomplete penetrance, 
variable expressivity, multi-gene traits, modifier genes and oligogenic inheritance are 
but a few genetic phenomena that can play roles in genetic disease. Advancements in our 
understanding of these concepts have shifted our perceptions of disease transmission in 
recent years, and it is now beginning to become apparent that an expanding number of 
diseases cannot be completely explained by simplistic Mendelian inheritance alone. 
Rather, it is more common that genetic diseases are the products of a convoluted and 
often highly individualised genetic web of interacting factors, that collectively contribute 
to the final expression of the clinical phenotype.  
 
1.1a.iii Variable Penetrance and Variable Expressivity  
In some disorders, mutations in the same gene can generate different clinical effects in 
different individuals. For example, certain carriers of a mutation may express the disease 
phenotype while others might not. In other cases, the phenotype may be expressed in all 
individuals, but there may be a high degree of variability between their clinical features. 
15 
 
These phenomena are referred to as incomplete penetrance and variable expressivity; 
both of which are likely to occur as a result of a unique combination of both genetic 
contributory factors and environmental exposures. As these factors are likely to be 
highly personalised, it is notoriously difficult to predict the likely clinical and 
phenotypic outcome of each carrier of a specific genotype.  
 
1.1a.iv Penetrance 
Penetrance can be defined as the proportion of carriers of a given genotype that express 
the associated characteristic phenotype (Zlotogora 2003). If a disease is described to 
have complete penetrance, this indicates that every carrier of a pathogenic mutation in 
the disease gene will always express the associated phenotype. For example, 
Neurofibromatosis type 1 is a highly penetrant disorder and almost all carriers of a 
pathogenic mutation in the NF1 gene will express clinical features to a certain degree 
(K. Boyd, B. Korf, A. Theos 2009).  
 
Conversely, a disease or gene is said to have incomplete or reduced penetrance when a 
proportion of carriers of a pathogenic mutation fail to express the associated 
characteristics (Shawky 2014). An example of this can be found in carriers of mutations 
in the BRCA1 and BRCA2 genes. All carriers have an increased lifetime risk of 
developing cancer, and although the majority do develop cancer at some stage in their 
lives, some carriers do not (Antoniou et al 2004, Cooper et al. 2013). This incomplete 
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penetrance is likely to be due to a complex interplay of both genetic and environmental 
factors; however the complete mechanisms that give rise to these situations remains 
unknown. For this reason, it is impossible to predict which BRCA1/BRCA2 carriers will 
develop cancers and which will not; although, this is an area of research where further 
clarification could provide an extensive degree of clinical benefits.   
 
 1.1a.v Pseudoincomplete Penetrance 
In some cases, non-penetrance can be incorrectly assumed in an individual due to an 
incomplete clinical examination or delayed onset of the phenotypic expression (e.g. age-
dependent onset of cancers in BRCA1/BRCA2 mutation carriers) (Shawky 2014). In such 
cases, this is referred to as pseudoincomplete penetrance. This can also arise when 
incomplete penetrance is wrongly assumed for a patient that is in-fact a mosaic carrier 
for a mutation. Thus in individuals with germline mosaicism, some of their gametes 
carry a mutation in a disease gene, and although not clinically affected themselves, they 
may have multiple affected children (Biesecker & Spinner 2013). In this way, it appears 
that the disease may be non-penetrant, but it is really due to the fact that the healthy 
parent does not carry the mutation in their somatic cells.  
 
1.1a.vi Variable Expressivity  
In some cases, although a disorder may be highly penetrant and manifest symptoms in 
most carriers, there can be a high degree of variability between the clinical features, 
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degree of severity and age of onset between patients (Cooper et al. 2013). This concept 
is described as variable expressivity, and in some disorders, such as CF, even high 
degrees of intrafamilial variation can be observed. CF patients exhibit wide and variable 
degrees of severities, can manifest an array of different physiological complications and 
can unpredictably different lengths of survival (Cutting 2014). This phenotypic 
variability can also occur in patients who harbour identical disease genotypes, which 
indicates that the phenotypic differences in these individuals must be due to 
environmental or genetic influences that are independent from the original disease 
mutation. Examples such as these reinforce the notion that even in monogenic disorders 
with apparent Mendelian inheritance, there can still be a wide variety of genetic 
contributory factors involved in determining multiple aspects to the disease.  
 
1.1a.vii Mechanisms that Give Rise to Variable Penetrance and Expressivity 
Although the complete mechanisms giving rise to variable penetrance and expressivity 
have not been completely elucidated, some of the contributory factors have been 
identified which can explain a proportion of some disorders. In some instances, it can be 
simple to comprehend the mechanisms giving rise to variable penetrance and 
expressivity. For example, it is understandable why male carriers of mutations in BRCA2 
may have a lower lifetime risk of acquiring breast cancer (6%), than female carriers 
(86%) (Feldman et al 2014). In other less obvious cases, the intragenic location of a 
mutation can affect disease penetrance (e.g. the common pathogenic mutation, 
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p.Phe508del in CFTR is highly penetrant, while the alteration p.Arg117His is associated 
with reduced penetrance) (Cutting, 2015). The type of mutation in itself can also have an 
effect; in general more deleterious types of mutations (nonsense and frameshifts) are 
associated with higher penetrance and more severe phenotypes than missense mutations 
as they are more likely to disrupt protein function. These influences are fairly simple to 
discern, particularly as clear, singular “cause and effect” relationships can be 
established. However, in many instances there are more complex factors that can 
influence expressivity and penetrance.  
 
Digenic and oligogenic inheritance refers to the situation in which more than one gene 
contributes to a disease phenotype. These types of inheritance pattern can present 
considerable challenges when trying to establish genotype-phenotype relationships, and 
they can also be largely responsible for variations in expressivity and penetrance in some 
disorders. In Nephronophthisis (NPHP) for example, 6 disease genes have been 
identified. In addition, a case of digenic inheritance has been documented, in which one 
affected individual carried two separate mutations in two different disease genes that 
both contributed individually to disease manifestation (Hoefele et al. 2007).  
 
In disorders that exhibit oligogenic and digenic patterns of inheritance, the resulting 
clinical phenotype that develops is dependent on which particular mutation or 
combination of mutations is inherited. The presence of modifier genes (although not 
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required for disease manifestation) can alter the effects of an existing mutation, either 
exacerbating or reducing their physiological consequences. For example, a recent study 
in Neurofibromatosis (NF1) patients managed to establish that several common 
polymorphisms were enriched in patients with higher counts of “café-au-lait” macules 
(hyperpigmented patches on the skin); through this, they were able to establish that these 
particular polymorphisms were contributing directly to a specific aspect of the variable 
expressivity seen in this disorder (Pemov et al. 2014). Distinguishing modifying 
alterations (which can also be present in healthy individuals with no observable effects) 
from a vast number of additional background variants can be a mammoth task; however 
studies like the one carried out by Pemov et al. 2014 demonstrate that the genetic 
influences that modify disease phenotypes can be elucidated with careful and thorough 
investigative approaches.   
 
Both somatic and germline mosaicism can have an effect on the relative penetrance and 
expressivity of some disorders. Somatic mosaicism occurs when an individual harbours 
a different genotype in a small proportion of their cells, while germline mosaicism 
describes the situation in which some of an individual’s gametes harbour a different 
genotype to their own (Biesecker & Spinner 2013). For example, in somatic mosaicism, 
the disease phenotype may be less severe due to the fact that the pathogenic mutation is 
only present in a reduced proportion of cells. In germline mosaicism, as the carrier 
parent may not exhibit clinical features of the disorder as the mutation is only present in 
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some of their gametes, and so the disease can appear to have reduced penetrance; 
however, any offspring that inherit this mutation will harbour it in all of their cells, 
resulting in disease manifestation.  
 
Of all the factors influencing expressivity and penetrance in disease, environmental 
modifiers are arguably the most challenging to determine. This is largely because 
environmental exposures are highly individualised and their influential consequences 
can also have variable effects in different individuals. Furthermore, environmental 
modifiers cannot easily be replicated in research, and it is therefore difficult to reliably 
establish direct associations. Nevertheless, some clearly established associations have 
been made between environmental stimuli and disease manifestations. For example, it is 
commonly accepted that repeated exposures to certain carcinogens, such as UV 
raditation and cigarette smoke can introduce genetic mutations that will convey an 
increased susceptibility to cancer.  
 
Another clear example of how environmental factors can be modified to alter a disease 
phenotype can be found in individuals affected with phenylketonuria; a rare genetic 
condition in which sufferers cannot metabolise phenylalanine. In this disease, new-born 
babies with high levels of phenylalanine can adopt a special phenylalanine-free diet 
which enables them to prevent the on-set of the severe effects of this disorder, including 
brain damage (Cooper et al. 2013). In this way, a clear modification to the environment 
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of a carrier can directly influence and reduce the penetrance of their disorder. The 
examples outlined here present clear-cut, simplistic associations; however in many 
disorders, combinations of many different environmental factors can interact with many, 
(often unknown), genetic modifiers, collectively resulting in an extremely complex and 
unpredictable genetic landscape that can present vast clinical challenges with regard to 
disease management. 
 
1.2 Identification of the Genetic Basis of Disease 
There are many types of genetic alteration that can occur within the genome that can be 
associated with disease, including base level mutations, copy number alterations, 
amplifications, deletions and translocations. For this reason, genetic disorders can 
loosely be categorised into 3 separate groups depending on their mode of pathogenesis; 
single gene or Mendelian disorders, chromosomal disorders and multifactorial disorders.  
 
The use of cytogenetic and molecular laboratory techniques has enabled the discovery of 
many of these types of alterations at both the base pair and chromosomal level. The 
discoveries of such alterations and their roles in disease have not only enabled clear 
clarifications of many genes and pathways, but have provided novel therapeutic and 
diagnostic opportunities that have had major patient benefits.  
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The field of cytogenetics aims to identify the genetic causes of disease on a larger scale 
by enabling the detection of both structural and numerical chromosomal alterations, 
while molecular methods act on a smaller scale to detect single base substitutions and 
small indels at the DNA level. 
 
1.2a Cytogenetics 
Traditional cytogenetic approaches such as fluorescent in situ hybridization (FISH) and 
comparative genomic hybridization (CGH) have played major roles in the discovery of 
aberrations related to cancer. FISH is a technique that uses fluorescently labeled probes 
to bind to regions of interest on a chromosome, so that they physical chromosomal 
location of that region may be visualised. CGH is a technique used to identify copy 
number variation and unbalanced chromosomal anomalies by comparing and observing 
differences between two DNA samples; tumour and corresponding normal DNA for 
example. CGH is often used to identify specific chromosomal regions that are frequently 
lost or gained during tumour progression; information that can then be used to guide 
clinical decisions. 
  
Chromosomal rearrangements are a common occurrence often observed in leukaemias 
and lymphomas, and have been shown to lead to the formation of gene fusions, or hybrid 
genes with oncogenic characteristics (Michels et al. 2007).  The use of cytogenetic 
techniques led to the identification of the chromosomal locations of the genes associated 
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with the occurrence of this oncogenic event, which exposed novel therapeutic targets, 
and facilitated the development of the tyrosine-kinase inhibitor, Imatinib (Mitelman et 
al. 2007; Michels et al. 2007). This had a hugely positive impact on many patient lives, 
as the drug enabled a less harmful and more efficient means of treatment for chronic 
myeloid leukaemia. Discoveries such as these highlight the potential benefits that can be 
achieved through the identification and clarification of cancer genes and pathways 
implicated in the pathogenesis of cancer.  
 
 
1.2b Molecular Methods for the Investigation of Genetic Disease 
Mutations at the DNA level can arise in many different forms, including single 
nucleotide alterations as well as insertions and deletions. These alterations can have 
different functional impacts based on the changes they exert within the gene, and their 
subsequent effects on the translation of the protein encoded. To succeed in identifying 
these alterations and their roles in disease, there have been a number of molecular 
techniques that have been developed over the years.  
 
1.2b.i Positional Cloning 
In the days prior to the completion of the human genome project, the traditional method 
of gene detection was performed through positional cloning.  This technique is used to 
identify the position of a disease gene through comparative studies in large family 
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pedigrees containing both affected and unaffected individuals. By using known 
polymorphic genetic markers, the region of the genome thought to contain the variant of 
interest can be identified based on which genetic markers are consistently co-inherited 
with disease phenotypes (Little 2005).  
 
1.2b.ii Candidate Gene Approach   
The candidate gene approach refers to the selection of a potential disease gene based on 
current understandings of the disease. This technique requires a priori knowledge in 
order to make an educated and informed prediction of which genes may be associated 
with disease. For example, a list of candidate genes can be selected based on their 
functional relevance (i.e. involvement in relevant biological pathways). Genes can also 
be selected using a position-dependent approach, in which candidate genes are selected 
based on prior linkage information (although this may not be effective for genetically 
heterogeneous disorders).  Candidate genes can also be selected using information 
obtained from comparative genomics, basing decisions on the notion that mutations in 
genes that are highly conserved across many species are more likely to be detrimental.  
 
Although many of these approaches seem logical, the candidate gene approach has been 
criticised by many for being a highly subjective technique that can be prone to bias 
during gene selection. Nevertheless, it remains a technique that has had some successes, 
and continues to be developed (Pasche & Yi 2010). 
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More recently, computational tools have been developed to combine an array of web-
based information from public databases in order to prioritise candidate genes. This 
strategy is known as the digital candidate gene approach (DigiCGA); some of the 
programs developed including ENDEAVOR and SUSPECTS among others, utilise 
biological ontology data to compile their list of candidates (Zhu & Zhao 2007). They can 
also filter lists of candidates based on their expression in certain tissues, pathway 
involvements, known interacting partners and known associations with similar diseases. 
The programs can then use all of this information to perform complex statistical 
calculations in order to form prioritised lists of candidate genes. These programs are still 
in their infancy, and their track history of success has been highly variable; particularly 
with regard to more complex and multifactorial diseases (Zhu & Zhao 2007).  
 
As with many scientific procedures, the strengths of the candidate gene approach can be 
found when using a combination of all of these techniques to identify candidates. In this 
way, the advantages of each strategy can be exploited in the hope that a less biased 
selection of candidate genes may be achieved. These approaches are particularly useful 
when analysing vast numbers of candidate genes such as that created by next generation 
sequencing.
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1.3 Cancer as a Genetic Disease  
Cancer develops following an accumulation of specific genetic alterations that enable a 
cell to become unresponsive to normal regulatory mechanisms. These alterations initiate 
uncontrolled growth and proliferation in the affected cells. Cells which have acquired 
these abilities subsequently undergo positive selection, resulting in the creation of small 
populations of cellular clones. As these clones grow and multiply they can ultimately 
lead to the formation of a tumour (Tabassum Kornelia Polyak, 2015).  
 
The first coherent descriptions of cancer as a genetic disease came from studies 
performed by Theodor Boveri, who was the first to notice that different chromosomes 
can transmit different inheritable aspects that can have a unique influence on cell fate. 
Boveri later suggested that abnormal chromosomes contribute to tumour growth when 
he noticed that some cells with a “particular incorrect combination of chromosomes” 
resulted in the generation of a cell which displayed the ability to grow without restriction 
or limits, and that this abnormality was being passed to the cell’s progeny (Boveri 1914). 
Even though the concept of a gene had not yet been described by 1914, Boveri 
accurately suggested that ‘chromosome’ imbalances or abnormalities were leading to 
tumour growth; this was the very first description of cancer occurring and progressing as 
a direct result of a genetic mutation.  
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Genes associated with cancer can be loosely classified into two groups; oncogenes 
(genes involved in promoting cell growth) and tumour suppressor genes (protective 
genes that can inhibit cell growth, initiate apoptosis and repair DNA). Mutations leading 
to cancer often provide a specific growth advantage either by causing activation or 
increased expression of oncogenic protein products, or by causing loss of function and 
reduced expression of proteins encoded by tumour suppressor genes. 
 
1.3a Oncogenes  
The first retroviral oncogene was discovered in the Rous Sarcoma Virus, which had 
been isolated from sarcomas in chickens by Peyton Rous in 1911 (Rous 1911).                                     
Later studies performed by Michael Bishop revealed that oncogenes carried by viruses 
were not actually viral genes, but mutated forms of genes that exist inherently in many 
organisms, including humans (Bishop 1989). The realisation was then made that cancer 
was different from other diseases in that it could arise in the absence of a foreign agent 
through specific alterations to normal cellular genes.  
 
Non-mutated forms of oncogenes are known as proto-oncogenes; these genes are often 
involved in promoting cellular growth and proliferation. Therefore, in order to generate 
a pro-tumourigenic effect, they must acquire a gain-of-function alteration that causes 
constitutive activation or amplified expression of the encoded protein. These alterations 
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can occur through genetic mutation, gene amplifications and chromosomal 
rearrangements.  
 
Activating mutations in human tumours often occur in the form of single base 
substitutions. Only very specific mutations can result in a gain-of-function, and 
therefore, cancer-related mutations in oncogenes are often found to cluster at, or within, 
specific regions of the gene encoding critical functional domains. These mutations can 
cause conformational changes within the essential regulatory domains, which then 
prevents their recognition and targeted degradation by E3 ubiquitin ligases; this is the 
mechanism by which activating HIF2A muations exert their tumourigenic effects in 
PCC/PGL tumours (Crona et al. 2013). Other mechanisms of gain-of-function can occur 
through activating mutations that enable the protein to activate itself, as is the case for 
activating RET mutations in multiple endocrine neoplasia (MEN); in these cases, RET 
mutations enable RET protein homodimerization, enabling auto-activation of the protein 
and subsequent initiation of downstream pathways (Donis-Keller et al 1993).  
 
1.3b Tumour Suppressor Genes and Knudson’s 2-hit Hypothesis 
Tumour suppressor genes encode proteins that are protective to the cell, in that they can 
either repress cell growth, initiate apoptotic pathways or initiate DNA damage repair. 
Inactivation of a tumour suppressor gene through mutation, deletion or translocation can 
therefore lead to uncontrolled growth and proliferation, evasion of apoptosis or the 
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inability to repair damaged DNA; all of which are pro-tumourigenic characteristics 
(Hanahan & Weinberg 2011).  
 
Some of the first descriptions of tumour suppressor genes in cancer occurred when 
Alfred Knudson released his famous “2-hit hypothesis” in 1971. While investigating 
retinoblastoma cases, Knudson made the observation that two rate-limiting events 
appeared to be necessary for disease manifestation; he subsequently postulated that in 
the inherited cases, one of the mutations had been passed through the germline and a 
second mutation was acquired during life in the somatic cells; he then reasoned that in 
non-hereditary cases, both mutational events had been acquired in somatic cells, 
possibly through the environment (Knudson 1971). Consistently with this, after the 
identification of the RB1 TSG, molecular studies by other investigators revealed that the 
majority of those with familial or bilateral disease carried a germline mutation in the 
Rb1 gene (the first hit), and their tumours showed loss of heterozygosity, confirming the 
presence of a second hit. The same types of investigations into non-inherited cases 
revealed that both of the “hits” had occurred somatically, as the patients did not carry 
any germline Rb1 alterations. Knudson’s 2-hit hypothesis therefore provides an 
explanation as to why the inheritance of a pathogenic mutation increases susceptibility 
to cancer, and also explains why those with inherited cancer often develop tumours at a 
young age.  
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1.3c Intratumoural Heterogeneity  
It is well known that the cancer genome contains an extensive degree of genetic 
diversity; both between tumour types (intertumoural heterogenetity) and also within 
individual tumours (intratumoural heterogeneity).  This is often a consequence of high 
levels of genomic instability, which increase the rates with which new mutations 
develop (Burrell et al. 2013). As tumourigenesis advances, vast numbers of new 
mutations can be acquired; however, not every new mutation will be present in every 
tumour cell. An increasing amount of evidence now suggests that contrary to prior 
belief, tumours are not simply clonal expansions from a single cell containing pro-
tumourigenic mutations; but rather, tumours can contain many different clones, each 
with a unique set of tumour-related mutations, as displayed in figure 1 (Yates & 
Campbell 2014, McGranahan & Swanson 2015, Burrell et al. 2013). A study by 
Gerlinger et al. 2012, showed that from 9 different regions of a single kidney tumour, 
only 34% of the 118 different mutations identified were present in all cells from the 9 
regions. This demonstrated that a high degree of subclonal diversity could exist within a 
single tumour, and that each clonal population could harbour very different and 
individualised genetic mutations (Gerlinger et al. 2012).  
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Figure 1. Multiclonal Populations in a Tumour Cell (adapted from Burrell et al. 
2013) 
 
Some of these clonal populations will harbour the key mutations that played an initiating 
role in tumour development, while other clones, which may have been acquired at a later 
stage, contain mutations that have played roles in driving tumour progression. These 
mutations that play an active role in tumourigenesis are known as drivers. These 
advantageous driver mutations will co-exist with numerous ‘passenger’ mutations 
(biologically neutral mutations that offer no selective growth advantage) and other 
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alterations that are also present in genomically normal non-cancer cells (Greenman et al. 
2007; Stratton et al. 2009).  
 
A major challenge in genomic studies of cancer is, primarily, to have the ability to 
identify the presence of potentially low-level mutations whose frequency may appear 
diluted due to the mosaic nature of tumour genetics; and secondly to distinguish between 
driver and passenger mutations in an environment of extensive intratumoural genetic 
heterogeneity.   
 
1.4 Familial Cancer 
Approximately 5-10% of cancers are associated with some form of inheritance pattern 
(Nagy et al. 2004). There are certain criteria that are strongly suggestive of a familial 
cancer syndrome; namely the presence of two or more relatives with the same cancer, 
several affected generations and the individuals have been diagnosed at a young age 
and/or have developed multiple primary tumours. The fact that there are families which 
display clear clusterings of similar cancers that fulfill most of the above criteria provides 
strong evidence that cancer can be a heritable disease. In the majority of cases, 
hereditary cancer syndromes are passed with an autosomal dominant inheritance pattern 
with incomplete penetrance.  
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In familial cancer syndromes, the inheritance of a pathogenic mutation provides an 
increased predisposition to a cancer; however, as cancer is a multistep process, the 
accumulation of further genetic events are required in order for tumourigenesis to occur. 
These additional genetic events are usually acquired through environmental exposures to 
carcinogens, or through lifestyle habits. Most familial cancer syndromes are associated 
with mutations in tumour suppressor genes (most commonly P53) (Vogelstein et al. 
2013); however there are some familial cancer syndromes, such as MEN2 that are 
known to be associated with mutations in oncogenes (e.g. RET). Continued efforts to 
identify and characterise genes associated with familial cancer syndromes, will provide a 
wealth of preventative, diagnostic and therapeutic benefits that can be applied clinically 
to improve both the quality and length of life of cancer patients and their families.  
 
1.5 Sporadic Cancer  
Most cancers occur sporadically in the absence of any familial history. In these cases, 
the pathogenic mutations that are responsible for initiating tumourigenesis will have 
been acquired throughout the patient’s life as opposed to inherited. Mutations can be 
acquired through many different stimuli, including exposure to carcinogens, such as 
harmful radiation, x-rays, UV-rays or through certain lifestyle habits including lack of 
exercise, high fat diets etc.  
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As previously described, cancer manifests following an accumulation of multiple genetic 
alterations; and therefore, unsurprisingly, the risks of cancer increase with age. Unlike 
familial cancer, where the successful identification of a susceptibility gene can offer 
relatives the opportunity to predict and prevent the onset of cancer, investigations into 
sporadic cancers usually aim to identify tumour-specific mutations that are absent from 
the germline DNA. The successful characterisation of a tumour driver’s role in cancer 
progression may then help to identify potential molecular targets that can be exploited 
therapeutically. Furthermore, successful identification of mosaic mutations 
representative of smaller subclonal populations may provide information that can be 
used to combat the issues of chemotherapy resistance, by creating personalised, 
combinational therapies to target separate clones.  
 
 
1.6 Next Generation Sequencing    
Historically, the traditional method of investigating the genome was through the use of 
Sanger sequencing; a technique developed by Fredrick Sanger in 1977. Sanger 
sequencing involves base-specific termination of the DNA chain through the use of 
dideoxy nucleotides (ddNTPs). The ddNTPs lack the hydroxyl group necessary to 
elongate the DNA, and therefore terminate the chain each time one is incorporated, 
resulting in DNA fragments of varying lengths. These fragments are then separated 
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according to size by gel electrophoresis (Bayés et al. 2012).  The Sanger method of 
sequencing was initially used with radioactively labelled ddNTPs that were detected 
using slab-gel electrophoresis. This method was later replaced by the dye-terminator 
method in which ddNTPs were instead fluorescently labelled and detected using 
capillary electrophoretic systems (Tucker et al. 2009). This revolutionised the field of 
genomics, and instigated the sequencing of the entire human genome, which initially 
took 13 years to complete, and cost approximately $2.7 billion (Zhang et al. 2011). 
 
As sequencing technology continues to advance and the main companies compete for 
market share, costs are continually decreasing while throughput is increasing, resulting 
in a trend originally described to be similar to Moore’s law; however since 2010, next 
generation sequencing technological trends have now even outpaced Moore’s law, 
emphasizing the speed with which sequencing costs are falling while capabilities 
advance (figure 2). Within the last 50 years, the genomics field has advanced at such an 
astounding rate, that it has progressed from Watson and Crick’s discovery of DNA to  
Illumina’s most recent announcement that, with their new technology, they can sequence 
a full genome for $1000 (approximately £640) within a couple of days. This remarkable 
progression has now led on to the initiation of the next big genetic venture; The 100,000 
Genomes Project. This is an enormous project that aims to sequence 100,000 genomes 
from 75,000 patients and 25,000 tumours (Siva 2015). The 100,000 genomes project is 
an undertaking that will provide an invaluable wealth of information with regard to 
36 
 
many genetic diseases, and propel the advances and achievements in the genetics field 
even further. 
 
 
Figure 2. A graphical representation of the falling cost of genome sequencing in 
comparison to Moore’s law. (as displayed from National Human Genome Research 
Institute, 2015)   
 
Next generation sequencing has revolutionised the genomics field; it has generated an 
abundance of genetic information with regard to disease and has even enabled the 
identification of naturally occurring variants in plants that can be exploited to provide 
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growth advantages to certain types of crop. However, even though costs of sequencing 
continue to decrease rapidly, carrying out whole genome sequencing to a depth 
sufficient enough to identify disease-associated variants in large numbers of individuals 
still remains prohibitively expensive for most research projects. Therefore, with regard 
to disease gene discovery, the most commonly adopted approach involves the use of 
exome sequencing. 
 
Exome sequencing only targets the coding regions of the genome; a region which makes 
up 1% of the genome, but contains approximately 85% of the functional variants 
responsible for disease (Majewski et al. 2011). Exome sequencing enables deeper 
sequencing, which therefore permits base calling with higher confidence levels. 
Furthermore, exome sequencing is more cost-effective, as a much smaller region is 
sequenced, which also means that the overall redundancy of information is greatly 
reduced, as WGS would generate larger quantities of variants of unknown significance.  
 
1.6a Main Principles of Exome Sequencing 
The basic concept of next generation sequencing is very similar to Sanger sequencing in 
that DNA polymerase is used to catalyse the incorporation of fluorescently labeled 
deoxynucleotides (dNTPs) during the extension of a strand of DNA from a template 
strand (Illumina 2015). Each of the fluorescently labeled dNTPs will emit a specific 
fluorophore during the sequencing process so that each base can be distinguished from 
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one another. Unlike Sanger sequencing, this process can be carried out in a massively 
parallel manner, enabling the analysis of multiple reads simultaneously. This 
‘sequencing by synthesis’ method has become the most widely used technique across the 
NGS industry (Illumina 2015). 
 
1.6b Exome Sequencing Process 
The full process of exome sequencing can be broadly separated into 3 major stages: 
sample preparation and sequencing, raw data processing, and final data interpretation 
(figure 3). 
 
 In brief, the library preparation and sequencing stage includes the creation of a DNA 
library, capture of the exomic regions and targeted enrichment for the captured regions, 
followed by sequencing. The processing of the raw data then includes the alignment of 
the sequence to a reference genome followed by the use of in silico tools and programs 
to call variants. The final stage is to analyse the data and filter the variants in order to 
identify the variants of interest and interpret the findings.  
 
There are numerous variations with regard to the different protocols, processes and 
analytical tools that can be applied when carrying out exome sequencing; therefore, this 
thesis will predominantly focus on the methods that are directly applicable to this study. 
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The specific methods used for the exome sequencing performed in this study can be 
found in section 2.3. 
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Figure 3. A Summary of the Main Stages Involved in the Process of Whole Exome 
Sequencing 
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1.4c Library Preparation and Sequencing 
Currently, the most prevalent method used to prepare a DNA library for exome 
sequencing is by a hybridisation-based enrichment process (Rykalina et al 2014). The 
main commercial providers of exome enrichment kits include Agilent, NimbleGen and 
Illumina; and although there are certain variable details between each kit, the 
fundamental principles of each protocol remain the same.  
 
To begin with, genomic DNA is sheared into fragments of varying length, followed by 
the ligation of platform-specific adapters to the ends of the fragments. These steps are 
sometimes combined into a single step known as ‘tagmentation’, which enable DNA 
fragmentation and adapter ligation to occur in the same reaction; this greatly increases 
the efficiency of the library preparation process (Rykalina et al. 2014). The tagmentation 
method also has other advantages in that it minimizes the need for large concentrations 
of DNA, and can work with DNA concentrations as low as 50ng/µl. This is because the 
tagmentation process means that less DNA is lost at the fragmentation stage (Rykalina et 
al. 2014). The DNA library is then formed from the collection of adapter-ligated 
fragments; this library is then amplified by PCR and hybridised to biotinylated RNA 
baits, which have been specifically designed to target exomic regions. The hybridized 
exomic regions can then be pulled down efficiently through the use of streptavidin 
coated magnetic beads, which then allows unhybridized and intronic regions to be 
washed away. This library, now containing only exomic regions, can then be ‘enriched’ 
42 
 
through another PCR amplification step in order to generate a sufficient concentration 
for sequencing.  
 
During sequencing, each fluorescently labeled dNTP added will emit a specific 
fluorophore; the intensity of which is proportional to the number of nucleotides added. 
This fluorescence data is then processed by the computer and imaged. The raw data 
produced by the sequencing machines is often received in a complex format, requiring a 
large amount of processing before it is ready to be analysed and interpreted.  
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Figure 4. The Exome Sequencing Workflow. A diagram summarising the processes of library preparation, exome capture, 
target enrichment and sequencing; (adapted from an image displayed at http://www.genomics.agilent.com).  
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1.6b.i Raw Data Processing 
In order to process the large amounts of complex raw data generated, there are a series 
of steps and computer-based tools that must be applied. There are many variations and 
different combinations in which tools can be used, and therefore, as mentioned 
previously, only the tools and programs relevant to this study will be discussed. 
 
The raw exome sequencing data is primarily received in the form of FASTQ files; a file 
format that contains biological sequence. Prior to the alignment to the reference genome, 
the FASTQ files are analysed using applications such as FASTQC in order to determine 
various parameters and aspects to the quality of the data. For example, FASTQC enables 
the user to ascertain the Phred score (an algorithm to measure the quality score of each 
base call), and also provides information regarding the GC content and read length 
distribution, in addition to the degree of sequence duplication (Bao et al. 2014). The pre-
processed data is then aligned to a reference genome in order to determine regions of 
variation. In order to ensure a high degree of sensitivity, accuracy and efficiency, there 
have been many different tools developed to map short reads to the reference genome; 
Novoalign is one such example, and was the tool used in this study.  
 
After alignment, different computer-based tools such as SAMtools are used in order to 
convert the large SAMfiles (approximately 20-30Gb) to the more compressed binary 
BAM file format (approximately 4-10Gb); this enables much more efficient usage of the 
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data. At this point, the aligned data is then screened and quality filtered to remove 
duplicates and to realign indels that may have caused sequencing slippage. Variant 
calling and annotation is then performed using another tool, such as ANNOVAR, which 
incorporates information from various public databases including dbSNP, 1000genomes, 
ClinVar, COSMIC and PolyPhen. A summary of the raw data analytical process is 
outlined in figure 5. 
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Figure 5. Steps involved in processing raw exome sequencing data. Programs used are 
written in brackets in purple.  
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1.6b.ii Sequencing Depth and Breadth of Coverage 
As technological advances and abilities continue to progress, the demand for more 
accessible sequencing at a lower cost per base also grows. Unsurprisingly, sequencing to 
a greater depth increases the costs, and therefore there have been several studies carried 
out to assess the minimum amount of coverage required to identify the maximum 
number of variants; thereby enabling scientists to gain the most accurate and efficient 
degree of data at the lowest cost.  
 
Coverage refers to the average number of times each nucleotide is sequenced, while the 
breadth of coverage refers to the percentage of the targeted region of interest that has 
been sequenced (Sims et al. 2014). During the sequencing process, it is inevitable that 
technical sequencing errors will be introduced within the data; therefore, for this reason, 
it is important to sequence a read several times so that the percentage error becomes 
diluted, and provides a more accurate and reliable result.  
 
When performing exome sequencing to identify disease-associated variants, there is 
often a delicate balance that needs to be achieved between the degree of coverage, which 
clearly will improve the accuracy of the variant calls, and the cost per run. This is 
because the statistical power of disease-gene identification is greatly increased with 
larger sample sizes; therefore, the lower cost per run allows for a greater number of 
patients to be sequenced. There have been studies performed with the aim of 
48 
 
ascertaining the ideal limits of this balance. For example, one of the first studies to 
sequence a human genome using short read methodology was published in 2008; and it 
found that at a read depth of 15X, nearly all homozygous single nucleotide variations 
could be identified, and that a read depth of 33X was required to find the same number 
of heterozygous SNVs (Bentley et al. 2008). It was later determined that a depth of 
approximately 35x was required to achieve good quality results, and it has since become 
the standard for the majority of sequencing projects (Sims et al. 2014).  
 
1.6c Applications of Exome Sequencing to Investigate Disease 
Next generation sequencing has provided the essential tools necessary to define 
comprehensive maps and databases of genetic variation including single nucleotide 
polymorphisms, small insertions and deletions, and structural variants (Cooper & 
Shendure 2011). Although the majority of these variants are common within the general 
population, each individual genome will also harbour numerous novel mutations; some 
of which may be associated with disease. One of the fundamental aims of many human 
genetic studies is therefore to identify causal variants from a vast quantity of background 
alterations and to elucidate the roles they play in disease.  
 
1.6c.i Inherited Mendelian Disease and Exome Sequencing 
The use of exome sequencing to identify causal variants responsible for Mendelian 
disease is one of the circumstances in which this technique has had its greatest 
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successes. This is particularly the case for autosomal recessive disorders, often because 
all affected individuals will be homozygous carriers of the pathogenic mutation and 
therefore both parents will be obligate (and most likely heterozygous) carriers of the 
mutation. For the genetic investigation of Mendelian disorders, large families provide a 
powerful tool for gene discovery, by providing the opportunity to carry out segregation 
studies. This technique is made even stronger by the use of consanguineous families, 
which are known to have more limited gene pools.  
 
This technique has had many successes; one example, Walsh et al 2010, used a 
combination of exome sequencing and homozygosity mapping in a consanguineous 
Palestinian family, which enabled them to identify the pathogenic mutation (p.Arg127*)  
in GPSM2 to be responsible for their recessive deafness (Walsh et al. 2010). Many 
causal variants continue to be identified in this way, and are proving to be invaluable 
when providing genetic counselling to both those affected and unaffected carriers. 
Further identification of disease variants will enable improved pre-conceptive and 
prenatal screening and counselling, and also may provide information that could lead to 
novel treatments; at the very least, the identification of previously unreported disease 
genes can provide affected individuals with a greater understanding of their condition. 
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1.6c.ii Application of Exome Sequencing in Cancer 
Exome sequencing has also made many notable contributions to the genetic 
investigation of both familial and sporadic cancer. It is more complex to investigate 
cancers using exome sequencing for several reasons; firstly, the tumour 
microenvironment is highly genetically heterogeneous, and therefore carries a much 
larger number of alterations than would be found in constitutional blood DNA. 
Secondly, most cancer-associated variants have variable penetrance, and so not all 
carriers of the mutation will have cancer, which means segregation studies are not as 
powerful as with Mendelian disease. The situation is complicated further by the fact that 
cancer occurs as a result of both genetic and environmental contributions. Due to the 
vast numbers of candidate genes received and the limited number of options that can be 
used to confidently exclude variants, it can be very challenging to successfully identify a 
candidate gene, and then furthermore, to provide a sufficient amount of evidence that the 
gene is genuinely involved in increased tumour predisposition or progression. 
Nevertheless, there have been many achievements in this field which have been due to 
the abilities of exome sequencing projects. For example, Varela et al 2011, used the 
exome sequencing data of 7 cases of clear-cell Renal cell carcinoma (ccRCC) in addition 
to the matching normal DNA, and managed to identify a new, major ccRCC gene; 
PBRM1 (Varela et al. 2011).  
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Projects that have been successful have had these achievements largely through the 
successful identification of variants playing a driver role in initiating or driving tumour 
progression. By examining the differences between both tumour and normal 
constitutional blood DNA from an individual, in combination with the DNA of affected 
individuals with cancer and those without, it is hoped that further cancer-associated 
alterations may be identified. As this work continues to contribute information, and we 
continue to learn more about the biological processes involved in the development of 
cancer, it is hoped that substantial improvements will be made to the predictive, 
diagnostic, prognostic and therapeutic management of cancer patients. 
 
 
 
1.7 Main Aim of Project 
The main aim of this study is to employ cutting edge technology to investigate human 
disease, in the hope that novel disease genes and variants may be identified. Successful 
identification of disease-associated genes may shed light on new aspects to disease 
biology and pathogenesis; this information could potentially improve the prevention, 
screening and diagnosis of these conditions, and could enable the development of novel 
therapeutic strategies. Exome sequencing has been used to investigate the genetic cause 
of an autosomal recessive disorder in a consanguineous family, and it has also been used 
to investigate novel susceptibility genes and genes associated with tumour progression in 
both familial and sporadic forms of pheochromocytoma and paraganglioma (PCC/PGL). 
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This study aimed to evaluate the use of exome sequencing as a tool to investigate 
disease, and through this, demonstrate the future of this technology in modern day 
genetics. In an ever-approaching era of personalised medicine, it was also hoped that this 
study could generate potentially useful results that could ultimately be used to improve 
the lives of those affected by genetic disease.  
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Chapter Two:  
MATERIALS AND METHODS 
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2.1 Materials  
2.1a Patient Material  
2.1a.i Acrocallosal Syndrome  
Extracted DNA was provided by Dr. Neil Morgan for a consanguineous Israeli-Arab 
family with Acrocallosal syndrome, and was made up to a concentration of 20ng/µl for 
each family member.  
 
2.1a.ii Pheochromocytoma 
 Extracted tumour DNA was received for 31 unrelated patients with sporadic 
pheochromocytoma, and 25 patients with sporadic paraganglioma. Of these samples, 
twenty-two were from Japanese patients with sporadic pheochromocytoma, which had 
been sent by post from Japan by Dr. Masah Yao.  Nine of the sporadic 
pheochromocytoma and five of the sporadic paraganglioma DNA samples were sent 
from Spain by Dr. Mercedes Robledo, and the final 20 paraganglioma samples were 
provided by Dr. Tom Martin of the Queen Elizabeth Hospital, Birmingham. Matched 
normal blood DNA samples were available for all samples apart from the 22 
pheochromocytoma patients from Japan.  
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Anonymised DNA from constitutional blood of 77 unrelated individuals withfamilial 
pheochromocytomawas obtained from the West Midlands Regional Genetics Lab in 
Birmingham Women’s Hospital.  
 
All DNA samples were received post DNA-extraction at various concentrations. The 
samples were all diluted to an average and approximate concentration of 50ng/µl and 
stored at -20°C. The complete clinical history was unavailable for some of these 
patients.  All patients studied gave written research consent and the study was approved 
by the South Birmingham Research Ethics Committee. Ethical approval was obtained 
from institutional and local research committees for the collection and use of all 
samples. Research was conducted according to the principles expressed in the 
Declaration of Helsinki.  
 
2.1a.iii Control DNA samples 
Two 96 well microtitre plates containing approximately 50ng/µl of anonymised control 
DNA samples from presumed healthy individuals per well were obtained from the West 
Midlands Regional Genetics Lab. One of the plates contained 96 samples of DNA from 
Caucasian individuals and the second plate contained 96 samples of DNA from 
individuals of South Asian ancestry.   
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2.2 Chemicals, Reagents and Suppliers   
Agarose Gel Reagents       Supplier   
10 x TBE Buffer (Tris-borate/EDTA) 
Agarose 
Ethidium Bromide 
1 kb DNA ladder (1µg/µl) 
PCR Reagents 
Primers 
Biomix Red  
GC Rich Solution 
Solutions for Sequencing Reactions 
Ethanol 
microCLEAN 
BigDye Terminator  
Big Dye Sequencing Buffer (25mM Tris 
pH8.7, 4mM MgCl2) 
Hi-Di Formamide 
Whole Genome Amplification 
Repli-g mini Kit  
Nuclease-Free Water 
Filter Pipette Tips  
National Diagnostics 
Invitrogen 
Sigma 
Bioline 
Supplier 
Sigma Aldrich / Alta Bioscience 
Bioline 
Roche 
Supplier 
Fischer Scientific 
Microzone 
Applied Biosystems 
Applied Biosystems 
 
Applied Biosystems 
Supplier 
Qiagen 
Promega 
Fischer Scientific 
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2.3 Exome Sequencing  
Following informed consent and ethical approval, DNA from 11 patients with familial 
pheochromocytoma was extracted from peripheral blood by the West Midlands Regional 
Genetics lab. Approximately 3µg of the extracted DNA was then sent to the Biomedical 
Research Centre at Guy’s Hospital in London for exome sequencing. In addition, 
approximately 3µg of extracted tumour DNA from 16 patients with sporadic 
pheochromocytoma was also sent for exome sequencing. In brief, as described by 
Michael Simpson of the Biomedical Research Centre at Guy’s Hospital in London, exon 
capture was performed using the SureSelect All Exon 50Mb Target Enrichment System 
from Agilent. Massively parallel DNA sequencing was performed on an Illumina 
Analyser IIx with 76bp paired end reads. Depth and breadth of sequence coverage was 
calculated with custom scripts and the BedTools package; a freely available and open-
source software (http://bedtools.readthedocs.org/en/latest/). Each run was considered 
successful and was used for analysis when >80% of the exome was covered to a 
minimum depth of 20x. Single nucleotide substitutions and small insertion deletions 
were identified and quality filtered within the SamTools software package and in-house 
software tools. Variants were annotated with respect to genes and transcripts using the 
Annovar tool. Filtering of variants for novelty was performed by comparison to 
dbSNP132 and 1000 Genomes SNP calls (June 2011) and variants identified in 150 
control exomes sequenced and analysed by the same method.  
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2.4 Polymerase Chain Reaction (PCR) 
For each candidate gene, primers were designed to flank regions of interest, using 
Primer3 (http://www.frodo.wi.mit.edu/). Where possible, the set of primers with the 
smallest difference between the melting temperature of the forward and reverse primers 
was chosen (supplementary table 1). The primers were then used to amplify the regions 
of interest from the patient DNA samples.  
 
2.4a Standard PCR amplification for Candidate Genes 
All polymerase chain reactions (PCR) were performed on a GeneAmp 9700 thermocycler 
(Tetrad). Each reaction had a final volume of 25l, containing between 30ng and 50ng of 
DNA, 1.5mM Biomix Red and 5pmol forward and reverse primer. Some primers used in 
the PCR amplifications had a high GC content, and therefore to optimise these reactions, 
0.5mM GC Rich Solution was used. To ensure thorough and homogenous distribution of 
contents, the microtitre plate containing the reactions was placed in a centrifuge and spun at 
1000RPM for 30 seconds prior to amplification. For each PCR amplification, an additional 
reaction was performed using distilled water instead of DNA in order to serve as a negative 
control. Positive controls were also included which contained a sample of DNA known to 
amplify well. 
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2.4b Touchdown PCR amplification  
For certain primer sets, a touchdown PCR was required in order to increase the 
specificity of the region amplified. The reaction was set up as described for the standard 
PCR reaction. The annealing temperature was initially set to 65°C in order to provide 
maximum specificity for the primers to bind to the correct region of the DNA. The 
temperature was then decreased by 1°C every cycle for 5 cycles to maximise specificity 
of primer binding to produce a large amount of the template target sequence. The 
annealing temperature then cycled at 55°C to increase the yield further, and in this way 
help to achieve a higher quantity of specifically amplified DNA than would be present 
from a standard PCR.  
 
  
60 
 
30 Cycles 
Temperature Time Purpose 
(a) 
95°C 
 
5 mins 
 
Initial Denaturation 
95°C 45 sec Melting 
Ta°C 45 sec Annealing 
72°C 1 min Extension 
72°C 
 
(b) 
95°C 
95°C 
65°C (-1°C every cycle) 
72°C 
95°C 
55°C 
72°C 
72°C 
5 mins 
 
 
5 mins 
45 sec 
45sec 
1 min 
45 sec 
45 sec 
1 min 
5 min 
Final Extension 
 
 
Initial Denaturation 
Melting  
Annealing  
Extension 
Melting  
Annealing  
Extension 
Final Extension  
 
Table 1. The Stages of a Standard PCR Cycle. This table shows the various 
temperatures involved in a standard PCR reaction (a), and a touchdown PCR (b). The 
temperature during the annealing stage of the standard PCR was altered appropriately 
depending on the annealing temperature (Ta) calculated for each of the primers; this 
was usually between 50°C - 65°C. In the touchdown PCR, the annealing temperature 
started at a high annealing temperature and was decreased by 1°C every cycle before 
amplifying at an annealing temperature of 55°C for the remaining cycles.  
10 Cycles 
25 Cycles 
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2.4c Gradient PCR  
In order to optimise certain primer sets, a gradient PCR was performed so as to visualise 
which annealing temperature yielded the highest concentration of specifically amplified 
DNA. The reaction was set up as described for the standard PCR. The annealing 
temperature was altered for each well, ranging from 45°C to 65°C. See Table 1 for plate 
set up and temperatures.  
 
2.4d Analysis of Products from Standard PCR Cycle 
PCR products were visualised on a 1% (w/v) agarose gel containing Ethidium Bromide. 
5l of PCR product was loaded into the gel, and in addition 5l of 1kb ladder was also 
loaded in order to provide an estimate of the size of the bands present. The contents of 
the gel were then separated by electrophoresis in 1 X TBE buffer at 150v for 
approximately 30 minutes. The gel was then placed under a UV light transilluminator in 
order to illuminate the bands and analyse the results.  
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2.5 Sequencing of PCR Products 
2.5a PCR product clean-up 
An equal volume of microCLEAN was added to 2.4µl of PCR product in a 96 well 
microtitre plate, and centrifuged for 40 minutes at 4000RPM. Following this, the 
supernatant was removed by inverting the plate on to a paper towel, and spinning in the 
centrifuge at 500RPM for 30 seconds.  
 
2.5b Sequencing Reactions 
For each reaction, 2µl of 5 X Big Dye Sequencing buffer was added to 0.5µl of BigDye 
and 5.5µl of water. Following this, 2pmol/µl of the according forward or reverse primer 
was added. A PCR reaction was then carried out with the following conditions: 
 
Temperature Time Purpose 
95°C 
50°C 
60°C 
30 sec 
15 sec 
4 mins 
 
Extension 
 
 
30 Cycles 
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2.5c  Sequencing Reactions Clean-up 
The sequencing reaction was then cleaned up by adding 2µl of 0.125M EDTA 
containing NaOAc to each well along with 30µl of 100% Ethanol, and spinning at 2000 
RPM for 20 minutes. The supernatant was then removed again as before, by spinning 
upside down for 30 seconds at 500 RPM. The pellet was left to air dry for 5 minutes 
before adding 90µl of 70% Ethanol to each well, after which the plate was spun again at 
2000RPM for 10 minutes. The supernatant was then removed again. Finally the pellet 
was re-suspended in 10µl of Hi-Di Formamide. The microtitre plate was then placed in a 
GeneAmp 9700 thermocycler and denatured at 95°C for 3 minutes, and finally snap 
chilled on ice for 5 minutes. Either Dean Gentle or I then loaded the microtitre plate 
containing the samples on to an ABI Prism 3700 Sequencer. The resulting DNA 
sequences were analysed using a combination of three different programs; BioEdit 
Sequence Alignment Editor, ChromasLite and Mutation Surveyor (demo). BioEdit was 
used to determine an approximation of the number of samples which has been sequenced 
successfully, while ChromasLite and Mutation Surveyor (demo) were used to visualise 
the electropherograms and compare them to a reference sequence in order to determine 
regions of variation.  
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2.5d Whole Genome Amplification  
All DNA samples were amplified using the Repli-G Whole Genome Amplification midi 
kit from Qiagen. Each kit amplified a maximum of 100 samples with an estimated yield 
of 40µg. The protocol was followed as per the manufacturer’s instructions.  
 
The following buffers were provided in the Qiagen repli-g midi kits and were used in the 
amplification process: Buffer DLB (contains potassium hydroxide), Buffer D1 
(reconstituted buffer DLB and nuclease-free water), and Buffer N1 (stop solution and 
nuclease free water). In brief, approximately 2.5µl of 30ng of genomic DNA suspended 
in TE is added to a microcentrifuge tube. An equal volume of buffer D1 was added to 
each DNA sample and vortexed before centrifuging briefly at 2000RPM. The samples 
were then incubated at room temperature for 3 minutes. Following incubation, 5µl of 
buffer N1, containing the stop solution, was added to each sample. The samples were 
vortexed and centrifuged briefly at 2000RPM.  
 
The DNA polymerase provided with the REPLI-g midi kit was thawed on ice and 
centrifuged briefly at 2000RPM to ensure homogenous distribution of contents. A 
master mix was then made up consisting of 10µl of nuclease free water, 29µl of REPLI-
g midi reaction buffer and 1µl of REPLI-g midi DNA Polymerase per reaction. To each 
amplification reaction, 40µ of the master mix was added before incubating at 30ºC for 
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approximately 16 hours. Following the incubation, the DNA polymerase is then 
inactivated in each reaction by heating the samples to 65ºC for 3 minutes.  
 
The amplified DNA is then diluted 1:10, and 4µl used in a PCR reaction with a control 
sample of DNA and a well-known set of primers in order to determine the success of the 
amplification. Successful amplifications can be identified by running the samples on an 
agarose gel following PCR amplification, showing a bright band at the expected size. 
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Chapter Three:  
EXOME SEQUENCING AND 
AUTOSOMAL RECESSIVE DISEASE 
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3.1 Introduction to Acrocallosal Syndrome 
3.1a Consanguinity  
Consanguinity is an ancient and deeply rooted societal tradition in certain cultures and 
can be described as the union of two related individuals who share genes inherited from 
at least one identifiable common ancestor (Alkuraya 2013). This means that any 
potential offspring from a consanguineous union will consequentially contain regions of 
homozygosity throughout portions of their genomes and they will therefore be more 
susceptible to the manifestation of an autosomal recessive disorder.  
 
In the early years of human existence, close-kin unions were likely to be an inevitable 
and frequent occurrence as geographical constraints resulted in a limited available gene 
pool (Bittles & Black 2010). However, in present day, regardless of the freedom to 
access wider gene pools, in many parts of the world consanguineous unions still persist 
and they are prevalent across approximately one fifth of the current global population 
(Hamamy 2012); in fact, it is estimated that at least 10.4% of the world’s population 
have been born to consanguineous parents, where the relation coefficient is limited to 
second cousins (Alkuraya 2013). Many people perceive that the socio-economic benefits 
outweigh the genetic health risks associated with a consanguineous union, and therefore 
the practice of consanguinity still occurs in many populations.   
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3.1a.i Prevalence of Consanguineous Unions  
The degree and extent of consanguinity varies between and within countries throughout 
the world, but it has been reported to be occurring at its highest rates within certain 
regions of North Africa, the Middle East and West, Central and South Asia, where close-
kin unions collectively account for between 20-50% of all marriages (Teeuw et al. 
2013). As figure 6 illustrates, certain populations favour consanguinity, and this can be 
attributed to several factors including a religious aspect, that clearly has a strong 
influence on consanguinity, demonstrated by the geographical distribution of its 
prevalence across the globe (Bittles & Black 2010). The populations in favour of 
consanguineous unions often gain many socioeconomic benefits from close-kin 
marriages, which include ease of marriage arrangements, lower divorce rates, lower 
rates of domestic violence, reduced dowry costs, and the ability to retain finances within 
the family (Bittles & Black 2010). 
 
For many people, particularly those residing in regions with limited access to education 
or medical services, the benefits of a consanguineous marriage often far outweigh the 
genetic risks (Bittles & Black 2010). Furthermore, in these regions, it is often that the 
main contributing factors to infant and childhood mortality include contraction of 
infectious diseases and malnutrition; therefore these concerns often overshadow the risks 
of consanguineous-related autosomal recessive disorders (Bittles 2001; Alkuraya 2013). 
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However, even in Western countries where the risks of mortality due to infectious 
disease and malnutrition are rare, some populations, usually minority ethnic groups, 
favour consanguinity. According to Bittles et al 2010, there are approximately 10 
million resident migrants in Western Europe who  favourclose-kin unions regardless of 
the common constraints of the Western laws and opinions. Bittles et al 2010, reported 
that there had been a decline in the preference for consanguinity in the Norwegian 
Pakistani populations recently, possibly due to improved information regarding known 
health risks; however there had been no reports of decline among the UK Pakistani 
populations or in Turkish or Moroccan communities residing in Belgium (Bittles & 
Black 2010).  
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Figure 6. The global prevalence of consanguineous unions (from the global consanguinity/endogamy resource by Bittles 
et al.2014) 
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3.1a.ii Genetic Consequences of Consanguinity  
The genetic implications to offspring born from a consanguineous marriage are 
dependent on the proportion of identical gene pairs inherited from a common ancestor, 
and are therefore also proportionate to the degree of relatedness of the two individuals. 
For example, first cousins are expected to share approximately 12.5% (1/8
th
) of their 
gene loci, and so any offspring will be homozygous at 6.25% (1/16
th
) of their gene loci; 
these genomic regions are then referred to as being identical by descent (Hamamy 
2012).  This theory is sometimes expressed as the coefficient of consanguinity F) of 
0.0625.  An example of this can be seen in figure 7.  
 
The genetic risks involved with possessing portions of genome that are identical by 
descent relate to a higher probability of inheriting two identical and functionally relevant 
pathogenic alleles which will lead to the increased expression of an autosomal recessive 
disorder. Studies have shown that birth defects are 2-3% more common in babies born 
from first cousin relations when compared to other newborns in the general population 
Hamamy 2012).  
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Figure 7. A diagrammatic example of the potential genetic consequences of a 
consanguineous union (taken from the MRes thesis of Walsh, 2010). RM refers to a 
recessive mutation.  
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3.2 The Ciliopathies  
3.2a The Cilium   
The cilium is a multifunctional and evolutionarily conserved organelle that can be found 
on the apical surface of most vertebrate cells (van Reeuwijk et al. 2011). Functional cilia 
are known to be essential for a multitude of biological roles, including whole cell 
locomotion, signal transduction, fluid movement and chemotaxis, among others 
(Badano, Mitsuma, et al. 2006).  Consistent with this fact, genetic mutations resulting in 
dysfunctional cilia often lead to disorders with a diverse array of overlapping 
phenotypes, collectively known as the ‘Ciliopathies’.   
 
Cilia may exist in a variety of different tubular forms indicative of their tissue-specific 
functions (van Reeuwijk et al. 2011). Common to all cilia is a ring-shaped scaffolding 
structure known as an axenome that is enclosed in a sheath referred to as the ciliary 
membrane (van Reeuwijk et al. 2011). Figure 8 outlines the two different structural 
formations that cilia are commonly found to have. In a primary, immotile cilium, the 
axenome contains 9 microtubule doublets and when found in this form, the arrangement 
is commonly known as the 9+0 configuration; however the structure of a motile cilium, 
sometimes called a flagella, comprises an axenome housing two central, singular 
microtubules in addition to the 9 microtubule doublets and this arrangement is referred 
to as a 9+2 configuration (Badano, Mitsuma, et al. 2006; van Reeuwijk et al. 2011).     
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Figure 8. Schematic Representations of the Formations of Primary and Motile Cilia. 
This figures shows the structural formations of cilia. The first shows the 9+0 
configuration of a primary cilium, and the second image shows the composition of a 
motile cilium with the 9+2 configuration showing two central singlet microtubule 
surrounded by 9 doublet microtubules  
 
Primary, non-motile cilia are essential structures that act as signalling centres for a 
variety of different cellular signalling cascades, and they can therefore be found in 
almost every vertebrate cell (van Reeuwijk et al. 2011). The primary cilium has been 
described previously to act in a similar manner to an antenna, by receiving extracellular 
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signals through its specialised transmembrane receptors and transducing the signal down 
through the cilium in order to initiate intracellular signalling pathways which will result 
in the associated cellular response (Baker & Beales 2009; Singla & Reiter 2006). The 
essential signalling pathways that are activated through the primary cilium include the 
Sonic Hedgehog Signalling pathway, the WNT signalling pathway, the FGF signalling 
pathway, the mTOR signalling pathway, and more recently, the Hippo signalling 
pathway (van Reeuwijk et al. 2011). It is therefore understandable, given the array of 
essential signalling pathways communicated through the primary cilia, that mutations 
resulting in defective cilia-associated proteins can consequentially result in severe 
disorders; often with a wide variety of different phenotypes. The fact that cilia are 
known to be so functionally diverse in combination with the fact that research is still 
uncovering new, previously unreported functional roles could explain why there is such 
wide phenotypic variability that exists within the Ciliopathies.  
 
3.2b Oligogenic Inheritance and the Ciliopathies  
Ciliopathies are most often associated with an autosomal recessive inheritance pattern; 
however some studies have suggested a more complicated underlying genetic 
pathogenesis involving oligogenic inheritance. Oligogenic Inheritance refers to the 
circumstance in which the penetrance or degree of expressivity of a particular 
phenotypic outcome is governed by the synergistic effects of more than one gene  
(Badano, Leitch, et al. 2006). Some studies have proposed that the manifestation of 
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certain ciliopathy disorders is dependent on triallelic inheritance (Katsanis et al. 2001). 
This was described in 2001, when Katsanis et al, genotyped 4 different pedigrees 
containing Bardet-Biedl syndrome and found that all the affected individuals carried 
three disease alleles; one homozygous variant in BBS2 in addition to a heterozygous 
variant in BBS6. Furthermore, the study showed two unaffected individuals in two 
different pedigrees that carried the homozygous variant in BBS2, but lacked the 
heterozygous variant in BBS6. Katsanis et al suggested the absence of disease in these 
individuals was due to the nonexistence of the heterozygous BBS6 variant and 
emphasized that it was necessary to inherit all three disease alleles for disease 
manifestation (Katsanis et al. 2001). Since then, there have been further reports of 
oligogenic inheritance in other ciliopathies including nephronophthisis, which suggests 
that this type of inheritance may not be exclusive to Bardet-Biedl syndrome, and may 
well be occurring in additional, unreported ciliopathies (Hoefele et al. 2007). On the 
other hand, there have also been a variety of studies that claim to have carried out 
investigations among large cohorts of Bardet-Biedl patients and found no evidence of 
triallelic inheritance (Abu-Safieh et al. 2012; Laurier et al. 2006; Hichri et al. 2005; 
Nakane & Biesecker 2005).  
 
The concept of oligogenic inheritance within the ciliopathy disorders therefore remains a 
controversial topic. However, given the wide phenotypic spectrum within this group of 
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disorders and the lack of a more feasible explanation, it remains a possibility that could 
benefit from investigations in larger cohorts of ciliopathy patients.    
  
3.2c Clinical Features of Acrocallosal Syndrome   
Acrocallosal syndrome was first described in 1979 by Albert Schinzel (Schinzel 1979); 
it is now recognized as a rare and genetically heterogeneous autosomal recessively 
inherited disorder that is characterised by craniofacial dysmorphism, agenesis or 
hypoplasia of the corpus callosum and duplication of the phalanges of the hallux/or 
thumbs (Gelman-Kohan et al. 1991). As displayed in figure 9, common features of 
Acrocallosal syndrome include craniofacial dysmorphism and polysyndactyly (Hodgson 
et al. 2009). Acrocallosal syndrome has recently been described to be a ciliopathy 
disease, due to its overlapping clinical features with Grieg cephalopolysyndactyly 
syndrome and hydrolethalus syndrome (HLS).  
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Figure 9. Clinical Features of the Patients with Acrocallosal Syndrome from original 
report by Gelman-Kohan et al 1991. The features seen in the first images show evidence 
of prominent forehead, facial dysmorphism, broad nasal bridge and short upper lip with 
open mouth. Also shown, is the polydactyly to the left and right feet.A pedigree of the 
family members for whom DNA was available is also included, displaying the two 
consanguineous parents, the two unaffected siblings, and the affected proband.  
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3.3 Acrocallosal Syndrome and Exome Sequencing: Primary Aims 
The primary task of this part of the study was to carry out a 15-year follow up on a 
previous study carried out on consanguineous family of Israeli-Arab descent comprised 
of several individuals with Acrocallosal syndrome. The aim of this was to try and 
identify a causative gene responsible for the acrocallosal syndrome seen in this family. 
By using next generation sequencing to investigate the exome of an affected individual 
from this family, it was hoped that the causative variant could be identified, screened in 
additional family members and confirmed to segregate with the disease.  
The proband from the family originally described in the study by Gelman-Kohan et al 
1991was said to exhibit range of clinical features consistent with acrocallosal syndrome 
(patient 2 in figure 9). These included macrocephaly, polydactyly of the hands and feet, 
retardation short philtrum with upturned lip, prominent forehead, and absence of the 
corpus callosum.  
By using next generation sequencing to investigate the DNA from this family, it was 
hoped that a genetic causecould be identified, which could then provide the family with 
an identifiable cause for their disease. This information would provide both the family 
and other affected kindreds access to accurate genetic diagnosis and potential access to 
pre-marital and pre-conceptive genetic screening and counselling. Furthermore, the 
identification of a novel variant in a disease gene responsible for acrocallosal syndrome 
80 
 
may shed light on the biology of the disease and potentially provide a novel therapeutic 
target which could be exploited to provide a treatment.  
 
3.2 Results  
3.2a Gene Filtration and Prioritization for Acrocallosal Syndrome  
The exome of an affected individual with acrocallosal syndrome was sequenced by next 
generation sequencing. The raw exome sequencing data was initially analysed at the 
Biomedical Research Centre at Guy’s Hospital; they identified and quality filtered all 
single nucleotide substitutions and small insertion deletions using a combination of the 
SamTools software package and their in-house software tools. They then annotated the 
variants with respect to genes and transcripts using the Annovar tool. They presented all 
of the data and annotated variants in an excel spreadsheet. At this stage, there were 
28,588 variants identified in the proband, and so it was necessary to reduce this number 
by applying a series of consecutive filters to the data in order to exclude unlikely 
candidates (this is outlined in figure 10).  
 
The first clear point of filtration was to exclude all variants with a high minor allele 
frequency (MAF) in the population as it is highly unlikely that a common variant in the 
general population will result in a rare disorder. The MAF of a variant represents the 
rarity of the altered allele in the population cohort included in dbSNP (MAF is also 
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known as GMAF in the population cohort of 1000genomes). It is commonly accepted in 
many studies that variants portraying a MAF ≥5% are considered common, a MAF 
between 1-5% are regarded as low frequency variants, and a variant with a MAF <1% is 
considered to be rare (Wessel et al. 2015; Consortium 2014; Auer & Lettre 2015). The 
variant annotation, performed by the Biomedical Research Centre at Guy’s Hospital as 
part of the exome sequencing service, included all reported minor allele frequencies 
from both dbSNP and 1000genomes project (Dec.2010 release).  
 
Given the rarity of acrocallosal syndrome, we initially focused our attention to novel 
variants only, which reduced the number of candidates to 777. The next filter applied 
was based on the predicted consequence of the variant type, and was based on the 
assumption that nonsynonymous, nonsense, frameshift and splice site mutations would 
be more likely to have a detrimental effect on protein function in comparison to intronic 
and synonymous variants. Following the removal of all intronic and synonymous 
variants, the remaining candidates amounted to 332. With the knowledge that recessive 
disorders are caused by the biallelic inheritance of two mutated alleles in a disease gene, 
the next filter removed all heterozygous variants, leaving 29 potential candidates.  
 
At this point, the more manageable quantity of 29 variants was investigated further using 
a candidate gene approach. Genes previously associated with other ciliopathies and 
those known to play a role in pathways that are commonly aberrant in the ciliopathy 
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disorders were considered high priority. This process highlighted a nine base pair in-
frame deletion (c.653_661delCACGGTCTT, p.(His218_Phe221delinsLeu)) in a gene 
called KIF7. This gene was of particular interest as it codes for a protein that is 
functional within the hedgehog signalling pathway; a pathway reported to be disrupted 
in many ciliopathies.   
 
Figure 10. Filters Applied to Exome Sequencing Data for Gene Selection  
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3.2b Screening of KIF7 in additional family members  
In order to determine if the deletion in KIF7 was likely to be the causative variant, 
primers were designed to flank either side of the coding exon harbouring the mutation 
(primers can be found in supplementary table 1). 
  
DNA was available for 4 additional family members, including the mother, father, an 
unaffected brother and an unaffected sister. Direct sequencing of the PCR amplified 
region of interest in these samples revealed that the mother and father were heterozygous 
carriers of the mutation, the proband was confirmed to be homozygous and the two 
unaffected siblings were both wildtype; the electropherograms of some of the 
individuals are shown in figure 11. 
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Figure 11. KIF7 Mutation Segregation Status in Family 
 
3.2c Investigation of Evidence for Oligogenic Inheritance  
As mentioned previously, some studies have suggested the presence of modifying alleles 
that are predicted to contribute to phenotypic variability in some ciliopathies (Louie et 
al. 2010; Katsanis et al. 2001; Badano, Leitch, et al. 2006). Although the concept of 
oligogenic inheritance within the ciliopathies is a controversial topic, it seemed 
interesting to investigate the exome sequencing data of the proband with acrocallosal 
85 
 
syndrome in order to formulate our own opinion. Therefore, in order to determine if 
KIF7-associated acrocallosal syndrome might also show evidence of oligogenic 
inheritance, the exome sequencing data was inspected to identify the presence of 
previously reported mutations in genes associated with a range of ciliopathies (Joubert, 
Bardet-Biedl and Meckel-Gruber syndromes). The presence of known ciliopathy-
associated variants in the proband, in addition to KIF7, would suggest that these variants 
might be contributing to the phenotypic variability of this disorder.  
 
Interestingly, three heterozygous previously described variants in known ciliopathy 
genes were detected in AHI1, BBS2 and BBS4, all three of which were present in the 
Human Gene Mutation Database, displayed in table 2. 
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Gene 
Amino 
Acid  
Alteration 
Minor Allele 
Frequency 
(MAF) from 
dbSNP 
PolyPhen 
Prediction 
Associated 
Ciliopathies 
AHI1 
p.Arg830Tr
p 
rs13312995  
MAF: 0.0114/57 
Possibly 
Damaging 
Nephronophthisis 
BBS2 p.Ser70Asn 
rs4784677  
MAF: 0.0036/18 
Benign Bardet-Biedl Syndrome 
BBS4 
p.Met472Va
l 
rs2277596 
MAF: 0.0014/7 
Benign Bardet-Biedl Syndrome 
 
Table 2. Additional Ciliopathy-Associated Variants Identified in KIF7-associated 
ACLS.  
 
3.3 Discussion  
The cause of acrocallosal syndrome in an Israeli-Arab consanguineous family was 
investigated using exome sequencing. The DNA from one of the affected individuals 
was sent for exome sequencing and was analysed in an attempt to identify the causative 
variant. An in-frame deletion in KIF7 was selected from the list of candidates and, 
following screening, the deletion was found to segregate with the disease status of the 
rest of the family.  
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3.3a KIF7 as a Cause of Acrocallosal Syndrome  
Our findings confirm that mutations in KIF7 can cause acrocallosal syndrome. 
Accordingly, Putoux et al (2011) also described truncating KIF7 mutations (three 
nonsense and four frameshift mutations spread throughout the gene) in eight families 
with acrocallosal syndrome, which supports our discoveries.  
 
KIF7 is a regulator of the evolutionarily conserved Hedgehog Signalling (Hh) pathway; 
a pathway essential to a variety of embryonic developmental processes. The primary 
cilium contains receptors that are activated by Hh pathway ligands, such as Sonic 
Hedgehog (SHH), resulting in a pathway cascade that is transduced down through the 
cilium tip in order to initiate intracellular responses (He et al. 2014).  
 
The KIF7 protein is 1343 amino acids in length and contains 3 major domains: the motor 
domain, coiled coil region and cargo domain (figure 12A) He et al. 2014, have recently 
shown that functional KIF7 is essential to the structure of the primary cilium, and is in 
particular critical for the formation of a specialised compartment at the cilium tip.  The 
principal Hh signalling regulators are highly enriched at the tip of the cilium and are 
thought to be regulated in the compartment formed by KIF7 (He et al. 2014). It can 
therefore be inferred that mutations that disrupt KIF7 function will prevent crucial Hh 
signalling transduction through the cilia as a result of improper compartment formation 
within the cilium tip. This therefore means that Hh signals cannot initiate the essential 
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intracellular responses necessary to implement their diverse array of developmental 
functions. Consistent with these findings, it has been shown that KIF7-deficient mice 
display phenotypes also found in ciliopathy disorders, including polydactyly, as a result 
of defective Hh signalling (Ingham & McMahon 2009; Liem et al. 2009). 
 
The in-frame deletion identified in the present study is predicted to disrupt the region 
flanking the motor domain and the coiled coil region. The amino acids lost as a result of 
the in-frame deletion (p.(His218_Phe221delinsLeu)) are moderately conserved across 
multiple species, which indicates that loss of these particular amino acids is likely to 
affect protein function (figure 12B). This alteration was also absent from dbSNP, and 
exome variant server, which supports the conclusion that this alteration is not a common 
polymorphism. Liem et al 2009, showed that mutations to KIF7 affecting the motor 
domain resulted in decreased localisation of KIF7 to the cilium tip, resulting in loss of 
KIF7 function and defective hedgehog signalling (Liem et al. 2009). It is therefore 
possible that the deletion might affect the stability of KIF7, consequentially causing 
defective hedgehog signalling transduction, ultimately resulting in the phenotypes 
observed in the affected individuals. In combination with the current literature, our 
finding therefore supports that KIF7 mutations cause acrocallosal syndrome in addition 
to hydrolethalus syndrome and Joubert-syndrome (Dafinger et al. 2011). In addition, our 
finding also suggests that loss or disruption of KIF7 may contribute to the phenotypes 
89 
 
observed in these disorders through a mechanism that prevents appropriate cellular 
responses to hedgehog signalling (Putoux et al. 2011; Dafinger et al. 2011). 
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Figure 12.  A: A Schematic to show the KIF7 gene and the protein domains associated 
(not to scale), The mutation identified in this study is outlined in red, while previously 
reported KIF7 mutations associated with Acrocallosal syndrome and Hydrolethalus 
syndrome are outlined in black.( Taken from Walsh et al. 2013). B: Shows the 
conservation across species of the relevant amino acids associated with the in-frame 
deletion identified in KIF7 p.(His218_Phe221delinsLeu). 
 
 
  
A 
B 
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3.3b Oligogenic Inheritance and Acrocallosal Syndrome  
The ciliopathies are a diverse and genetically heterogeneous group of conditions 
comprising at least 29 known disorders, and associated with mutations in at least 89 
different genes (McIntyre et al. 2013). The disorders are known to be highly pleiotropic 
and the penetrance of the known disease-genes can vary between patients. These 
disorders also exhibit a high degree of variable expressivity, not only between unrelated 
patients, but even between affected individuals from the same family (McIntyre et al. 
2013). In accordance with this, mutations in KIF7 have been shown to play a role in 
hydrolethalus syndrome and Joubert syndrome, which exhibit overlapping but distinct 
clinical features with acrocallosal syndrome including polydactyly, midline brain and 
facial abnormalities (Dafinger et al. 2011; Putoux et al. 2011).   
 
It is a possibility that the variation in the phenotypes and differences in severities reflect 
the effects of specific KIF7 mutations on individual downstream signalling pathways; 
however it is also conceivable that the phenotypic variation is due to a combined 
consequence of the functional effects of KIF7 inactivation and the modifying effects of 
mutations in other ciliopathy genes. 
 
Consistent with this theory, a widening selection of evidence has suggested that primary 
ciliopathy loci can be modified by the presence of additional mutations in other 
ciliopathy genes that can exacerbate phenotypes, intensify severities or alter age of 
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disease onset (Badano, Leitch, et al. 2006; Khanna et al. 2009; Hoefele et al. 2007). Of 
particular interest was a study by Putoux et al 2011 that identified four individuals with 
Bardet-Biedl syndrome who carried mutations in KIF7 in addition to mutations in BBS1, 
BBS7, BBS9 and BBS10. Putoux et al 2011 showed in zebrafish that co-injection of kif7 
morpholinos together with the four BBS genes resulted in a higher proportion of 
embryos with severe phenotypes when compared to injection of kif7 morpholino alone, 
suggesting an epistatic interaction between KIF7 and these BBS loci.  
 
Therefore, taking into consideration the current literature, it seemed logical to examine 
the exome sequencing data in this study to determine whether the potential presence of 
modifying interactions of other genes was likely to be occurring in the family with 
acrocallosal syndrome; particularly as a range of phenotypes and severities had 
previously been reported.   
 
Upon examination of the exome sequencing data of the affected proband, three variants 
were identified that had previously been associated with ciliopathies; AHI1: c.C2488T 
p.Arg830Trp; BBS2: c.G209A p.Ser70Asn and BBS4 c.A1414G p.Met472Val. The 
variant in AHI1 (p.Arg830Trp) was of particular interest, as this variant has previously 
been reported to have a modifying effect on the phenotypes of nephronophthisis cases; 
specifically, the mutant T-allele was found to be significantly enriched in cases with 
nephronophthisis exhibiting retinal degeneration when compared to those cases without 
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retinal degeneration. This indicates that the presence of the p.Arg830Trp alteration in 
AHI1 is interacting with the causative mutations in these nephronophthisis cases to 
influence a different phenotype (Louie et al. 2010).  
 
The p.Ser70Asn (BBS2) and p.Met472Val (BBS4) mutations have both previously been 
associated with oligogenic inheritance in Bardet-Biedl syndrome and a previous study 
tested the variants for evidence of pathogenicity in zebrafish assays (Zaghloul et al. 
2010). Zaghoul et al 2010 demonstrated that both mutations were of functional 
importance based on zebrafish phenotype rescue experiments, in that the phenotypes 
observed following the administration of the relevant BBS morpholinos could not be 
rescued by null mutations (including BBS4: p.Met472Val) and in addition, the 
phenotypes were exacerbated by dominant negative mutations (including BBS2: 
p.Ser70Asn). These results suggest that the two BBS variants identified in the family 
with acrocallosal syndrome have been previously shown to be potentially pathogenic, 
and therefore it is possible that the presence of these variants could be altering or 
exacerbating the phenotypes observed within the affected family members potentially by 
interacting with the identified variant in KIF7. Furthermore, due to the fact that the 
p.Arg830Trp variant identified in AHI1 has previously been reported to have a 
significant effect on phenotypic variability in nephronophthisis cases by contributing to 
retinal degeneration, it is possible that this variant might also be interacting with any of 
the other variants present including BBS2, BBS4 and KIF7. 
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The contributions of these variants with regard to phenotypic variability in this case of 
acrocallosal syndrome are at present, unclear; however the evidence present in the 
current literature strongly suggests that the effects of each variant may act in 
combination to modify the phenotypic outcome of each patient in this case. This 
evidence therefore provides a possible explanation to the wide variety of phenotypes and 
severities among the family members.    
 
Though further studies in a larger cohort of KIF7-associated acrocallosal patients will be 
required to confirm oligogenic inheritance in acrocallosal syndrome, the hypothesis is 
that variants in other ciliopathy genes will prove to have an epistatic effect in this 
disorder, and that the phenotypic variability among the affected individuals of this 
disorder can be explained by the unique combination of ciliopathy variants they inherit.  
95 
 
Chapter Four:  
FAMILIAL PHEOCHROMOCYTOMA 
AND PARAGANGLIOMA 
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4.1 What are Pheochromocytomas and Paragangliomas?  
Pheochromocytoma and paragangliomas are rare neuroendocrine tumours that arise from 
the neural-crest derived chromaffin cells of the sympathetic and parasympathetic 
nervous system (Korpershoek 2011). During embryonic development, the neural crest 
cells migrate along pre-determined molecular pathways and differentiate into a variety 
of different cell types including intra-adrenal and extra-adrenal chromaffin cells 
(Korpershoek 2011; Díaz-Flores et al. 2008). The chromaffin cells within the adrenal 
medulla receive sympathetic input and can secrete adrenaline and noradrenaline into the 
blood stream. Subsequently, pheochromocytomas can also be associated with excessive 
secretion of catecholamines including dopamine, adrenaline, noradrenaline or a 
combination which can lead to severe hypertension and anxiety if left untreated 
(Korpershoek 2011).  
 
PCC/PGL tumours display a high degree of heritability, and it is currently thought that 
approximately 40% of tumours harbour a germline mutation in a known susceptibility 
gene, either through the inheritance of a pathogenic mutation from a parent, or through 
the development of a de novo germline mutation (Jafri & Maher 2012; Crona et al. 2015; 
Dahia 2014). There are currently at least 14 genes which have been reported to be 
associated with the pathogenesis of PCC/PGL tumours, (Astuti et al. 2001; Niemann & 
Müller 2000; Burnichon et al. 2010; Baysal et al. 2000; Hao et al. 2009; Latif et al. 
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1993; Zhuang et al. 2012; Wallace et al. 1990; Donis-Keller et al. 1993; Qin et al. 2010; 
Comino-Méndez et al. 2011; Crona et al. 2013; Clark et al. 2014; Castro-Vega et al. 
2014), and it is believed that this number will increase, as some tumours with a strong 
pattern of heritability do not carry any altering germline mutation in any of these genes. 
 
PCC/PGL tumours are mostly benign and in many cases, can be treated successfully 
with surgical resection of the tumour; however approximately 10-15% can show 
metastatic potential (Dahia, 2014). It has been reported that patients with SDHB 
mutations are predicted to have a higher risk of disease recurrence and malignancy, and 
therefore they are associated with a poorer prognosis (Lepoutre-Lussey et al. 2015); 
however, apart from this, there are few known genetic indicators of metastatic potential 
that can be used to predict clinical outcomes in most PCC/PGL tumours.  
 
Many hereditary PCC/PGL tumours form as part of one of several autosomal 
dominantly inherited syndromes including multiple endocrine neoplasia (MEN2A and 
MEN2B), Von-Hippel Lindau disease (VHL) and Neurofibromatosis type 1 (NF1).  
Each of these syndromes is associated with mutations in different genes, which result in 
a variety of clinical characteristics in addition to the formation of PCC/PGL tumours. 
For example, patients with NF1 (associated with mutations in the NF1 gene) can often 
be recognised by their visually apparent clinical features, including the presence of 
hyperpigmented spots (known as café-au-lait) on the skin and neurofibromas. Patients 
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with MEN2A often initially present with medullary thyroid carcinoma, while patients 
with MEN2B are likely to have additional visible characteristics, such as mucosal 
neuromas (Maher 2014). Patients with VHL disease are associated with the development 
of renal cell carcinomas (RCC) and hemangioblastomas. Interestingly, VHL-related RCC 
and hemangioblastomas often harbour highly deleterious and truncating mutations in 
VHL, while PCC/PGL tumours more often contain missense mutations (Dahia 2014).  
  
PCC/PGL tumours normally exhibit one of two transcriptional profiles: cluster 1 
contains tumours characterised by a pseudohypoxic signature, and cluster 2 is made up 
of tumours characterised by an enriched pattern of kinase receptor signalling through 
hyperactivation of various molecular pathways, including PI3-K, mTOR and MAPK 
(Jochmanová et al. 2014).  
 
4.1a Cluster 1 Pheochromocytomas and Paragangliomas 
Cluster 1 tumours are most often associated with mutations in either VHL, SDHA, 
SDHB, SDHC, SDHD, SDHAF2, FH and HIF2A, as disruption to these genes can often 
generate a pseudohypoxic environment through the stabilisation of Hypoxia-inducible 
factors (HIFs) (Dahia 2014).  
 
Hypoxia refers to the situation in which the cellular environment does not contain a 
sufficient concentration of oxygen, thereby requiring it to undergo various adaptive 
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responses in order to continue and maintain normal cellular processes. A state of 
pseudohypoxia arises when alterations occur to components of the oxygen-sensing 
pathway, causing these adaptive responses to occur unnecessarily in the presence of 
sufficient oxygen concentrations (normoxia). HIFs are heterodimeric transcription 
factors, made up of an α-subunit and a β-subunit. They function as part of an adaptive 
cellular response to a hypoxic or pseudohypoxic environment by initiating the 
transcription of numerous target genes. In the presence of normoxia, PHDs (prolyl-
hydroxylase domains) hydroxylate the HIF-α subunits at specific proline residues, which 
enable HIF to be recognized and targeted for proteasomal degradation by VHL 
(Marxsen et al. 2004)  
 
4.1a.i VHL and PCC/PGL 
VHL encodes pVHL, the recognition component of a tumour suppressor complex with 
E3-ubiquitin ligase activity, that targets HIF-1α and HIF-2α for proteasomal degradation 
(Maxwell et al. 1999; Kaelin & Ratcliffe 2008).  For this reason, loss of VHL causes an 
accumulation of HIF, consequently resulting in a pseudohypoxic environment and 
constitutive HIF transcription. This is discussed in more detail in section 5.2c.   
 
4.1a.ii Mutations in TCA-cycle Enzymes and PCC/PGL 
HIF stabilisation can also occur through mutation to genes encoding several 
tricarboxylic acid cycle enzymes. To date, mutations in SDHA, SDHB, SDHC, SDHD, 
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SDHAF2 and FH have all been implicated in increased susceptibility to 
pheochromocytoma and paraganglioma (Burnichon et al. 2010; Astuti et al. 2001; 
Niemann & Müller 2000; Baysal et al. 2000; Hao et al. 2009; Castro-Vega et al. 2014, 
Clark et al. 2014). Succinate dehydrogenase is an evolutionarily conserved, 
heterotetrameric enzyme comprised of four subunits; A, B, C and D. When assembled, 
the focal role of this complex is to carry out the conversion of succinate to fumarate as 
part of the TCA cycle. Therefore, mutations to any part of the complex hinders this 
reaction and causes a consequential accumulation of succinate in the cytosol of the cell 
(Selak et al. 2005). The role of fumarate hydratase (FH), is then to convert fumarate to 
malate in the cycle; similarly therefore, loss of function mutations to FH also result in an 
accumulation of both succinate and fumarate (Castro-Vega et al. 2014; Clark et al. 
2014). The increasing levels of succinate prevent the association of PHDs with HIFs, 
thereby preventing HIF hydroxylation, leading to HIF stabilisation (Selak et al. 2005).  
 
FH inactivation has been shown to act in a similar manner to SDHX inactivation, in that 
both succinate and fumarate accumulate, which similarly results in stabilisation of HIF 
(Clark et al. 2014). This is summarised in figure 13, will be discussed in more detail in 
section 4.3c. 
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4.1a.iii HIF2A in PCC/PGL Pathogenesis 
It has long been suspected that components of the hypoxia pathway might play a 
tumourigenic role in PCC/PGL, due to the high frequency of pseudohypoxic 
transcriptional signatures exhibited in PCC/PGL tumours. However, causative mutations 
have only recently been identified. The first HIF2A mutations found to be associated 
with PCC/PGL tumours were found in 2 patients who also had polycythaemia (a 
condition associated with an abnormal increase in the concentrations of haemoglobin in 
the blood). One of these patients also had somatostatinoma (a malignant pancreatic 
tumour).  Following these reports, a further two patients were subsequently discovered 
who also had HIF2A mutations, PCC/PGL tumours, polycythaemia and 
somatostatinoma. It was later suggested that these conditions may have a non-
coincidental clinical association (Zhuang et al. 2012).  
 
The majority of PCC/PGL-associated mutations in HIF2A have been found to be 
somatic/mosaic, and have been observed to cluster in close proximity to the specific 
proline residue (531), which is located at a critical HIF-2α hydroxylation site (Maher 
2013). Mutations occurring at or within close proximity to this site are likely to alter the 
conformation of the critical hydroxylation domain, thus enabling HIF-2α to avoid 
proteasomal degradation. Consistently with this suggestion, in vitro studies have shown 
that HIF2A mutations at these specific residues result in reduced associations with 
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PHDs, reduced VHL binding and a consequential increase in HIF stability. This will be 
discussed in more detail in sections 5.2c, 5.2g, 5.3a and 5.3e. 
 
HIF-1α and HIF-2α collectively regulate approximately 200 transcriptional targets, and 
therefore constitutive activation of this pathway by either mutation in VHL, SDHX, FH 
or HIF2A can result in an extensive downstream signalling cascade that can initiate the 
activation of multiple pathways governing angiogenesis, energy metabolism, cell 
proliferation and apoptosis (Maher, 2013). Although mutations in these genes explain 
many PCC/PGL tumours that strongly display characteristics classically associated with 
cluster 1, a large proportion of tumours that exhibit a pseudohypoxic transcriptional 
signature do not carry a mutation in any of these genes. This suggests that there are 
additional components of the hypoxia pathway that are likely to play a role in PCC/PGL 
development and progression that have yet to be elucidated.  
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Figure 13. Summary of Cluster 1 PCC/PGL Tumourigenic Pathways; adapted from 
(Dahia 2014) 
 
 
4.1b Cluster 2  
4.1b.i RET and PCC/PGL  
RET encodes a receptor tyrosine kinase protein which plays an essential role during the 
development of the neural crest; however it also functions to activate various cellular 
pathways involved in cellular proliferation and neuronal migration. Germline loss-of-
function RET mutations are a common cause of a condition known as Hirschprung’s 
disease (a condition characterised by intestinal blockages), while gain-of-function 
mutations are associated with the development of MEN2.  
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Approximately 95% of the mutations responsible for PCC/PGL development in MEN2A 
are due to mutations occurring within exons 10 and 11 (Dahia 2014). Mutations in these 
exons, which make up the cysteine-rich extracellular domain of RET, result in ligand-
independent dimerization of RET, which causes its constitutive activation (Bryant 
2003). In contrary, mutations in MEN2B nearly all occur within the exonic region 
encoding the intracellular domain of RET (most commonly, p.Met918Thr) which leads 
to hyperactivation of downstream targets of RET including mTOR and RAS. The 
downstream signalling cascade initiated by constitutive RET activation leads to a 
multitude of pro-tumourigenic cellular consequences including increased signals for 
growth, proliferation, differentiation and survival. Although RET mutations are strongly 
indicated in MEN2A and MEN2B syndromes, they can also found in up to 5% of 
sporadic PCC/PGL cases (Dahia 2014).  
 
4.1b.ii NF1 and PCC/PGL 
As discussed previously, Neurofibromatosis type 1 (NF1) is a condition that predisposes 
to multiple tumour types, including among others, PCC/PGL. The NF1 gene encodes 
neurofibromin (NF1), a GTPase activating protein that functions as a molecular on/off 
switch of RAS; NF1 initiates the exchange of the active GTP for inactive GDP, thus 
terminating RAS signalling.   
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Loss-of-function NF1 mutations therefore disrupt the abilities of NF1 to terminate RAS 
signalling, thus leading to constitutive RAS pathway activation. The tumourigenic 
effects of RAS pathway activation are discussed in further detail in sections 5.2e and 
5.3b; however in brief, constitutive RAS signalling can activate various pathways, 
including the mTOR pathway, which can then initiate cell growth and proliferation. 
Consistently, studies in NF1-deficient mice show that they develop PCC/PGL tumours 
with high penetrance (Jacks et al. 1994). It is currently estimated that up to 25% of 
sporadic tumours carry an NF1 mutation, which makes it the most frequently mutated 
gene in PCC/PGL tumours.  
 
4.1b.iii TMEM127 and PCC/PGL  
The TMEM127 gene encodes a ubiquitously expressed transmembrane protein that 
localises to endosomal domains; however, its function currently remains unknown (Qin 
et al. 2010). Loss of function mutations in TMEM127 have been discovered to play a 
role in PCC/PGL tumours, and are thought to exert their tumourigenic effects by causing 
constitutive mTOR pathway activation. This was originally suggested due to the 
similarities in the tumourigenic phenotypes between TMEM127-deficient tumours and 
NF1-deficient tumours; however the mechanism by which this occurs remains unknown.   
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4.1b.iv MAX and PCC/PGL 
MAX is a protein that is sometimes found as a homodimer but predominantly forms a 
heterodimer with c-MYC. The MAX-MYC heterodimer has been reported to increase 
the transcription of more than 1000 target genes which are involved in a variety of 
cellular processes including cell growth, metabolism and angiogenesis (Blackwood et al. 
1992; Dahia 2014). Although the exact mechanism by which MAX mutations result in 
the development of PCC/PGL currently remain elusive, it has been suggested that 
PCC/PGL tumour susceptibility in the presence of MAX mutations is due to the 
increased transcription of MYC target genes which lead to sustained cellular 
proliferation, growth and increased angiogenesis (Dahia 2014).  
 
As previously mentioned, there are currently at least 14 genes which have been 
described to play a role in PCC/PGL tumours; however many apparently sporadic 
tumours display strong hereditary characteristics but do not harbour any altering 
mutations in any of the currently known genes. This is indicative of the presence of 
other PCC/PGL associated genes playing a role in these tumours.  
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Figure 14 Summary of Cluster 2 PCC/PGL Tumourigenic Pathways; adapted from 
(Dahia 2014) 
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4.2 Exome Sequencing & Familial Pheochromocytoma  
4.2a Familial Pheochromocytoma and Exome Sequencing: Primary Aims  
This part of the study aimed to identify novel causative mutations associated with the 
inheritance of pheochromocytoma and paraganglioma. This was carried out by 
investigating the exome sequencing data of 11 affected but unrelated patients who did 
not carry any known mutation in any known pheochromocytoma or paraganglioma 
susceptibility gene.  
 
By observing similarities in the exome sequencing data between the 11 affected 
individuals, it was hoped that a selection of potential candidate genes could be identified 
and screened in a further cohort of affected individuals. It was hoped that carrying out 
gene screens in a larger panel of individuals might then reveal the presence of additional 
variants. Confirming the absence of any identified variants in normal, healthy controls 
might then indicate that the gene is playing a disease-associated role.  
 
The identification of a novel gene associated with the inheritance of pheochromocytoma 
and paraganglioma could provide a wealth of knowledge with regard to the biology and 
pathogenesis of these tumours. This information could then potentially highlight 
molecular pathways that could be targeted therapeutically, which could create a more 
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personalised approach to treatments in patients carrying mutations in the associated 
gene.  
 
4.2b  Results  
4.2b.i Patient Samples 
Eleven unrelated patients with inherited pheochromocytoma were selected for exome 
sequencing. These samples were selected because they were suspected to have a familial 
link to the disease, but did not carry any alteration in any of the known susceptibility 
genes. This combination of circumstances therefore made these patients ideal candidates 
for the identification of novel, germline variants associated with increased susceptibility 
to pheochromocytoma and paraganglioma. 
 
Approximately 3 to 5µg of DNA of each sample was sent to the Biomedical Research 
Centre at Guy’s Hospital, where they performed exome sequencing. As before, the 
group in Guy’s hospital identified and quality filtered all single nucleotide substitutions 
and small insertion deletions using a combination of the SamTools software package and 
their in-house software tools. They then annotated the variants with respect to genes and 
transcripts using the Annovar tool, and provided an excel spreadsheet containing all 
information. 
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In addition to the 11 samples sent for exome sequencing, a cohort of 77 patients with 
familial PCC/PGL was used for the mutational screening of candidate genes. The 77 
patients in the cohort of familial PCC/PGL samples did not carry any alteration in any 
known PCC/PGL susceptibility gene.  
 
4.2b.ii Filtering the Exome Sequencing Data  
The first step when attempting to analyse this large data set was to combine all of the 
data from all patient samples into one document for easy comparisons. After combining 
all of the data sets into a single document, the total number of variants amounted to 
263,798. A series of filters were then applied to remove unlikely candidate variants in 
order to achieve a more manageable selection of genes. The method of filtration is 
outlined in figure 15.   
 
Initially, all synonymous variants were removed as these changes result in the 
substitution of an identical amino acid, and therefore they are unlikely to have any effect 
on protein function.  
 
Inherited forms of pheochromocytoma and paraganglioma are rare in the general 
population, and so it was expected that variants associated with increased susceptibility 
to these tumours are also likely to be rare; therefore the next filter removed any variants 
deemed to be common within the general population. This was done by removing 
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variants associated with high minor allele frequencies. As mentioned previously, it is 
commonly accepted that variants portraying a MAF ≥5% are considered common, a 
MAF between 1-5% are regarded as low frequency variants, and a variant with a MAF 
<1% is considered to be rare (Wessel et al. 2015; Consortium 2014; Auer & Lettre 
2015). Therefore, to ensure only rare variants were kept, any variant reported to have a 
MAF >1% was excluded.  
 
In addition to removing variants reported to have a high MAF, variants were also 
removed if they had been found to occur frequently within the in-house data from the 
Biomedical Research Centre at Guy’s Hospital. It was decided that variants that had 
been previously identified within the in-house data more than 10 times would be 
excluded. High frequencies of certain variants found in the in-house data may 
correspond to unreported common polymorphisms that have either not yet been 
described in dbSNP or 1000genomes or do not have current allele frequencies available. 
Another possibility is that variants found to occur at a high frequency in-house may 
relate to common regions of sequencing error, leading to false positive readings.  
 
It is important to note that there is a possibility that some variants found within the in-
house data may in fact be more relevant to our study than a simple polymorphism found 
in the healthy population. This is because samples sequenced with the exome sequencing 
service are likely to be associated with a particular disorder, and therefore the in-house 
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variants will have likely been found in people associated with disease; therefore, there is 
a small possibility that some of these alterations could be pathogenic. It is not known 
what type of samples have been sequenced with this service previously, and it is 
therefore possible that other researchers may have submitted pheochromocytoma and 
paraganglioma samples for exome sequencing, giving rise to the possibility that certain 
disease-associated variants of interest may be found at a higher frequency in the in-
house data than we would expect to find in SNP databases. Therefore, it cannot be 
completely assumed that variants within the in-house data are due to common 
polymorphisms or regions of error.  
 
In order to choose an ideal exclusion cut-off for in-house findings, all mentioned 
variables were considered. As no variant was reported to occur more than 1000 times in-
house, it was estimated that 10 findings of a particular variant would correspond to a 
minor allele frequency of approximately 1%. Therefore, including variants with up to 10 
in-house findings was determined to be a suitable limit which would allow the exclusion 
of as many false positive alterations and unreported common polymorphisms as 
possible, while ensuring potential variants of interest were retained.  
 
All homozygous variants were also excluded due to the fact that an autosomal dominant 
pattern of inheritance was expected. Following the application of all of these filters, the 
number of variants across the 11 patients combined amounted to 3809 variants, 
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including 2697 missense variants, 566 splicing variants, 67 nonsense variants, 126 
frameshift variants and 346 non-frameshift variants.  
 
The next decision was to concentrate primarily on variants that were most likely to 
affect protein function; so primary focus was given to frameshift, nonsense and splice 
site variants. Splicing variants were only included where the altered nucleotide was no 
more than 3 base pairs away from the intron-exon boundary as even though possible, it 
is unlikely that alterations further than this will cause aberrant splicing. Following the 
application of these filters, 766 variants remained; 361 of which were classified as novel.     
 
Finally, in a last attempt to reduce the number of candidate variants, the remaining genes 
were examined in order to identify genes of potential functional relevance by prioritizing 
those involved in major cancer pathways; particularly kinase signalling, metabolic 
pathways and hypoxia pathways as these are known to be aberrant in many cases of 
PCC/PGL.  
 
Genes were also considered interesting if they had previously been associated with 
related tumour types, particularly kidney tumours, as there is a degree of overlap 
between kidney cancer and pheochromocytoma susceptibility genes. An additional focus 
was to concentrate on variants which had a MAF of <0.1%, as it was thought that it 
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would be most effective to concentrate on variants least commonly identified in the 
general population.   
 
In addition to the aforementioned selection criteria, certain factors were also considered 
to be desirable when identifying candidates. One of these desirable criteria was if one 
gene was common to more than one individual, but not more than 3. This was because, 
similarities between affected individuals that are absent from the general population 
might signify a link between the particular gene and the pathogenesis of the disease; 
however the presence of a gene in more than 3 out of 11 individuals (>27%) is more 
likely to indicate that the gene is highly subject to variation or that this is a common 
sequencing error. Another possibility for high numbers of variants in the same gene may 
be that the gene is very large, and therefore, statistically has a higher chance of acquiring 
random variation. Genes that are highly variable have a lower probability of contributing 
cancer susceptibility, as disturbances to protein function may be quite frequent in the 
general healthy population also. Therefore, when trying to identify PCC/PGL 
susceptibility candidate genes, those that were present in more than one individual, but 
not more than 3, were considered interesting.   
 
These final preferential conditions were not set as filters, but acted more as supportive 
factors when attempting to identify potential candidates. No gene was ever officially 
excluded from the first round of 3809 filtered variants (outlined in figure 15); however 
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due to the sheer volume of alterations present in the data, main focus and attention was 
given to those variants which had passed through the most highly stringent criteria.   
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Figure 15. Filtration of Variants for Familial PCC/PGL Exome Sequencing Data 
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4.2b.iii Candidate Gene Prioritization  
A number of genes were identified based on the selection criteria outlined previously; 
they are summarised in Table 3. Concentration was initially focused on the nonsense 
mutations, as they are rare and often result in nonsense-medicated decay; thus they are 
likely to be detrimental to protein function.  
 
The first stage of screening was to confirm the presence of the variant in the 
corresponding individual in order to exclude the possibility of a false positive. This 
involved designing specific primers to include the region of interest for each of the 
candidate variants chosen (primer list found in supplementary table 1). The selected 
regions were then amplified by PCR in the associated DNA samples, and analysed by 
direct sequencing.  
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Patient 
ID 
Gene 
Variant 
Annotation 
Variant Type 
MAF               
(dbSNP, 
1000g, EVS) 
COSMIC Notes 
1F ADAMTSL3 
NM_207517:e
xon18:c.C2230
T:p.R744X, 
StopGain Novel 
p.R744L in 1 Lung 
cancer sample (2.4% 
tumours mutated) 
Demonstrated to play important roles 
in angiogenesis and cell migration. Has 
previously been found to be frequently 
mutated in colorectal cancer 
(GeneCards 2015) 
2F ARHGEF5 
NM_005435:e
xon2:c.28_29i
nsGCTGAGGA
GGCCCAGCGT
GGAG:p.A10_
S11delinsGX 
StopGain Novel - 
The encoded protein may form a 
complex with G proteins and stimulate 
Rho-dependent signals. (GeneCards 
2015) 
2F CA12 
NM_001218:e
xon7:c.C718T:
p.R240X, 
StopGain 0.02% EVS 
p.R240Q in 1  
Pancreatic Cancer 
sample 
This gene encodes carbonic anhydrase. 
has been found overexpressed in 10% 
of clear cell renal carcinomas. 
(GeneCards, 2015) 
3F CNTN6 
NM_014461:e
xon7:c.C728A:
p.S243X, 
StopGain - 
Gene mutated in 
2.2% of tumours in 
COSMIC 
This gene encodes a neuronal 
membrane protein that functions as a 
cell adhesion molecule. It may play a 
role in the developing nervous system. 
(GeneCards, 2015) 
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2F ERF 
NM_006494:e
xon4:c.C1603T
:p.Q535X, 
StopGain - - 
ERF is a transcriptional repressor, 
regulated by RAS/ERK pathway. 
Members of the ETS family of 
transcription factors, such as ERF, 
regulate cell proliferation and 
differentiation. May regulate other 
genes involved in cellular proliferation. 
(GeneCards, 2015) 
6F KIF16B 
NM_024704:e
xon19:c.C2728
T:p.Q910X, 
StopGain 0.01% EVS Q910Q (synonymous) 
The protein encoded by this gene is a 
kinesin-like protein that may be 
involved in intracellular trafficking. 
(GeneCards, 2015) 
4F ME2 
NM_002396:e
xon8:c.C808T:
p.R270X, 
StopGain - - 
This gene encodes a protein involved 
in the TCA cycle. It is responsible for 
converting malate to pyruvate. 
(GeneCards, 2015) 
4F PCGF5 
NM_032373:e
xon3:c.T197A:
p.L66X, 
StopGain - - 
Component of PRC1-like complex,. 
Thought to maintain the 
transcriptionally repressive state of 
many genes. PRC1 complex acts 
through chromatin remodelling and 
modification of histones (GeneCards, 
2015) 
4F, 5F, 
6F,  
TMEM158 
NM_015444:e
xon1:c.219del
G: 
p.Cys74Alafs*
10, 
Frameshift Novel - 
Transcription of this gene is 
unregulated in response to Ras 
pathway activation. Proposed to 
function in a neuronal survival 
pathway. Transmembrane protein, like 
TMEM127; identical frameshift in 3 
patients. Was found to be false 
positive, result of sequencing error 
120 
 
(GeneCards) 
5F UBE2C 
NM_181801:e
xon6:c.C412T:
p.Q138X, 
StopGain - - 
Ubiquitin conjugating enzyme. 
Involved in targeting abnormal or 
short-lived proteins for degradation. 
Ubiquitination involves at least three 
classes of enzymes:ubiquitin-activating 
enzymes, ubiquitin-conjugating 
enzymes, and ubiquitin-protein ligases. 
(GeneCards) 
 
Table 3. A Table Outlining the Candidate Variants Identified from Exome Sequencing Data 
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4.2b.iv Confirming Variants  
Primers were designed for each of the variants in order to determine if the alterations 
were true variants or false positives.  
 
The first filtration process highlighted three identical frameshift deletions 
(p.Cys74Alafs*10) in TMEM158 in 3 patients. This was immediately identified as a 
potential candidate as it passed through all of the stringent criteria and, in addition, it 
was reported that the transcription of this gene is regulated by RAS pathway activation; 
a pathway known to be aberrant in many cancers, including PCC/PGL (Weizmann 
Institute of Science n.d.). In addition, it seemed coincidentally similar to transmembrane 
protein, TMEM127, a known PCC/PGL susceptibility gene (Qin et al. 2010); therefore, 
although little is known about TMEM158, it seemed logical to investigate these three 
alterations. In order to confirm the mutation, primers were designed to flank the region 
of interest. The region was then amplified in the three patients by PCR and then 
sequenced using conventional Sanger sequencing.  Upon examination of the results, the 
three patients displayed a wild-type genotype, which meant that the frameshift 
(Cys74Alafs*10) was in fact a false positive variant.  
 
All of the nonsense variants were tested in the same manner by designing primers for the 
regions of interest, amplifying them in the appropriate patients and screening by direct 
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sequencing. All of the nonsense variants were confirmed in their associated individuals 
as true variants (summarised in figure 16).  
 
 
Figure 16. Confirmation of several variants of interest by direct Sanger sequencing.  
 
4.2b.v Screening Genes of Interest in Additional Samples  
The confirmation of variants in the associated individuals was the first step to take when 
attempting to determine if the gene was likely to be playing a role in the development of 
familial PCC/PGL. Nine variants in nine genes were confirmed to be true alterations. It 
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was not logical or feasible to carry out full gene screening of all of the 9 genes in the 
panel of 77 familial DNA samples as this would prove to be a very high workload, and 
this was not considered to be financially effective. It was therefore necessary to 
prioritise the genes using a candidate gene approach to determine which genes were 
likely to be associated with these tumours. Due to the fact that all 9 genes had passed 
through most of the stringent criteria of the gene filtration process, selecting which 
genes to screen was largely based on functional relevance and associations with cancer, 
as reported in the COSMIC database (a database of previously reported, somatically 
acquired mutations in cancer). After in-depth consideration of each gene, it was decided 
that UBE2C, ERF and ME2 were the best candidates, and so primers were designed to 
flank each coding exon of these genes and they were then screened in a panel of 77 
patients with inherited PCC/PGL.  
 
4.2b.va UBE2C and UBE2QL1   
UBE2C is an E2 ubiquitin-conjugating enzyme that plays a critical role in the ubiquitin 
proteasome system. The ubiquitin proteasome system (UPS) is a physiological 
mechanism that regulates numerous critical cellular signalling pathways, including cell 
cycle progression, transcriptional regulation and differentiation (Liu et al. 2015). The 
ubiquitination process requires the function of three different classes of enzyme; the 
ubiquitin-activating enzymes (E1), ubiquitin conjugating enzymes (E2), and ubiquitin 
ligases (E3) (Hershko & Ciechanover 1998). Together, these enzymes orchestrate a 
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coordinated system to couple ubiquitin molecules to specific protein targets. This 
enables a variety of cellular functions to take place, including the programmed 
degradation of cell-cycle regulatory proteins, and the ubiquitin-mediated degradation of 
various tumour suppressors, oncogenes and signal-transduction system components 
(Hershko & Ciechanover 1998). Given the vast array of protein targets that affect 
numerous critical pathways, it is easy to comprehend the oncogenic potential of 
disruptions to the ubiquitination process. Consistently with this, mutations in UBE2QL1, 
also an E2-conjugating enzyme, had recently been described as a gene associated with 
renal cell carcinoma (Wake et al. 2013). The fact that there is a large overlap with many 
of the susceptibility genes for PCC/PGL and renal cell carcinoma, in addition to the 
functional relevance of the ubiquitination process in tumourigenesis, made UBE2C an 
interesting candidate to pursue. Although mutations in UBE2QL1 had not been 
identified in the exome sequencing data, this was also selected as candidate due to its 
similarities to UBE2C, and it’s associations with RCC.  
 
Primers were designed for all 6 coding exons of the UBE2C gene, and were used to 
screen 77 familial PCC/PGL samples for mutations. In addition, this gene was also 
screened in a Spanish cohort of familial PCC/PGL samples by Dr. Mercedes Robledo et 
al as part of a collaboration; and therefore in total, UBE2C was screened in a cohort of 
316 PCC/PGL patients. A summary of the mutation screening is outlined in table 4.  
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Table 4. Variants Identified in UBE2C (NM:181801, NP:861517) from 316 familial 
PCC/PGL patients. Variants of unknown significance are outlined in green and 
previously reported polymorphisms are outlined in purple. “DIV” refers to a deep 
intronic variant. Where possible, the frequency of the identified variant from the cohort 
is included. Further information on the previously reported polymorphisms can be found 
in supplementary table 2. 
Exon Primers Conditions Variants Frequency 
1 
F:GCCAGTGGGTAGG
TCTAGCA 
 
R:GAGCTCCTGGTGT
GTTCTCC 
T.D (65°C - 
55°C) 
1. p.Ala10Ser 
2. p.Ser23Arg 
1. 1/316 
2. 5/316 
2 
F:ATTCAGGTGGGAG
AAGATGC 
 
R:TGGTGTAGGTGGG
GTGTATG 
T.D (65°C - 
55°C) 
c.129+109delC 
(DIV) 
- 
3 
F:GAAAGCTCACCCAC
TGACCT 
 
R:TGCACAGAGGGAA
AGAACAA 
T.D (65°C - 
55°C) 
No Variants - 
4 
F:ATGAGCCCAGGAG
TTTGAGA 
 
R:CAGGGAGTCCTGA
CAGGTTC 
T.D (65°C - 
55°C) 
No Variants - 
5 
F:GTGGACACCCAGG
GTAACAT 
 
R:CTGGGCTCCTTTTG
TTTGAG 
T.D (65°C - 
55°C) 
No Variants - 
6 
F:CCAGCTTGGTCAAC
AGAGT 
 
R:GCCTACCCTGAGTA
CCTCC 
T.D (65°C - 
55°C) 
No Variants - 
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The mutation screening results for UBE2C revealed one variant of unknown 
significance, one known polymorphism and one deep intronic variant from 316 patients. 
In silico investigations using PolyPhen (a web-based tool that predicts the functional 
impact of mutations) suggested that the missense alteration (p.Ala10Ser) was likely to be 
benign (figure 17).  
 
 
 
Figure 17. PolyPhen Prediction of p.Ala10Ser Variant Identified in UBE2C. This in 
silico tool predicted that the substitution of Alanine for Serine at codon position 10 in 
the UBE2C gene would have a benign effect on protein function.  
 
 
Primers for all coding exons of UBE2QL1 and their reaction conditions were provided 
by Dr. Naomi Wake. Mutation screening was then performed in a cohort of 38 familial 
PCC/PGL samples. Mutation screening did not reveal any variants of significance (data 
not shown).  
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4.2b.vb ETS2 Repressor Factor (ERF) 
ERF is part of the ETS family of transcription factors; one of the largest protein families 
of transcriptional regulators. There have been over 200 target genes associated with the 
ETS transcription factors, collectively making them responsible for the regulation of 
numerous cellular processes including cellular proliferation, differentiation, 
development, hematopoiesis, apoptosis, metastasis, tissue remodelling, angiogenesis and 
transformation (Sementchenko & Watson 2000). The majority of the ETS family of 
proteins function to activate transcription; however, ERF acts as a transcriptional 
repressor with tumour suppressor abilities. Studies have shown that the tumour 
suppressor activities of ERF are highly regulated by the RAS/ERK signalling pathway; a 
pathway which is commonly activated in RAS-associated pheochromocytomas. It was 
therefore hypothesised that the nonsense alteration (p.Gln535*) identified in the exome 
sequencing data in ERF may potentially disrupt ERF function, therefore causing a 
consequential reduction or loss of its tumour suppressive protection. The fact that 
activation of the RAS/ERK pathway has been shown to promote tumour progression in 
certain pheochromocytomas suggests that ERF, a downstream target of the same 
pathway, may also have a role in these tumours.  
 
Primers were designed to flank all coding exons of the ERF gene. The fourth exon was 
divided into four overlapping separate primer sets due to its large size. All coding 
regions of ERF were PCR amplified and sequenced by direct Sanger sequencing in order 
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to determine if any further loss of function mutations could be identified in a cohort of 
PCC/PGL patients. The primers, their conditions and the sequencing results are outlined 
in table 5.  
  
ERF 
Exon 
Primers Conditions Variants Frequency 
PolyPhen 
Prediction 
1 
F:CCCGGAGTGCGAT
ATTAACC 
 
R:CCACGAGAAGCAA
CAGGTCT 
With GC-
Rich, 58°C, 
35 cycles 
No Variants - - 
2 
F:TTGACTTGGCTGAG
GTGAGA 
 
R:TCAGACCCAATGCT
TGTTCC 
T.D (65°C - 
55°C) 
1. p.Glu19Val 
(false positives) 
1. 7/77 1. Prob Dam. 
3 
F:ACGTACCTGACCTT
CCCAAT 
 
R:GGAAGATGAAGAT
GAAGAGCAG 
T.D (65°C - 
55°C) 
1. p.Leu81Leu 1. 2/77 - 
4(i) 
F:CTACATGCCCCTTC
AGGCTA 
 
R:GGGGATAGACTCG
GAAGACA 
T.D (65°C - 
55°C) 
1. c.373 -1 G>A 
2. p.Arg205Arg 
1. 1/77 
2. 5/77 
1. Benign 
 
4(ii) 
F:TAGTGATGGCACGT
CAGAGC 
 
R:TTGTAGACGCTTTG
GGTGTG 
T.D (65°C - 
55°C) 
1. p.Arg205Arg 1. 5/77 - 
4(iii) 
F:AGGCTCCCACTTCT
CCTTCA 
T.D (65°C - 
55°C) 
1. p.Ala410Ala 
2. p.Ser327Ser 
1. 3/77 
2. 6/77 
- 
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R:CCGTCTTCCTCATC
CTCATC 
 
4(iv) 
F:CACCACAGATC
AAGGTGGAG 
 
R:GGCAGGGAAG
AGACAAGAGA 
T.D (65°C - 
60°C) 
1. p.Glu470Val  
1. 26/77 (also 
found in 
healthy 
controls) 
1. Poss Dam 
 
Table 5. Summary of Variants Identified in ERF. ERF (NM_006494, NP_006485) was 
sequenced in 77 familial PCC/PGL patients. The primers used and their conditions are 
included in columns 2 and 3 (TD refers to touchdown PCR reactions). Previously 
reported, known polymorphisms are included in purple, novel, synonymous variants are 
noted in orange and variants of unknown significance are outlined in green. Where 
possible, the frequency of variants identified in the cohort and their predicted functional 
consequence is also outlined.  
 
  
The mutation screening process was carried out using whole genome amplified DNA. 
Any queries were repeated using both the whole genome amplified DNA and the 
original stock DNA samples in order to exclude the possibility of false positives that 
may have been acquired during the whole genome amplification process.  
 
The sequencing results initially revealed 7 identical missense alterations in exon 2 
(p.Glu19Val), and 26 identical missense alterations in exon 4iv (p.Glu470Val). In silico 
investigations showed that these variants were absent from SNP databases including 
dbSNP and the exome variant server; in addition, both p.Glu19Val and p.Glu470Val 
were predicted to be probably damaging and possibly damaging respectively by 
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PolyPhen. PCR amplification and Sanger sequencing reactions were repeated in both the 
whole genome amplified DNA and the original stock DNA samples. These variants were 
confirmed in both whole genome amplified DNA samples and the original stock 
samples. These results confirmed that 9.1% of the PCC/PGL cohort tested positive for 
the p.Glu19Val alteration and 33.8% tested positive for the p.Glu470Val alteration.  
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Figure 18. Variants in ERF: p.Glu19Val in exon 2- Identified in 7 individuals and 
p.Glu470Val in exon 4iv- Identified in 26 individuals.  
 
Although these variants were absent from SNP databases, it was necessary to examine a 
large set of healthy, ethnically matched control samples in order to explore the 
possibility that these variants may be the result of unreported common polymorphisms. 
A cohort of 192 healthy, ethnically matched control chromosomes was screened for the 
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p.Glu19Val and p.Glu470Val alterations. The results of the sequencing showed that both 
variants were found to be present within the healthy control samples, which suggested 
that p.Glu19Val and p.Glu470Val were likely to be unreported, common 
polymorphisms. The presence of these variants in healthy controls was a strong 
indication that these alterations were unlikely to be associated with disease. 
 
In addition to these variations, one splicing alteration (c.373 -1>A) was identified, 1 
nucleotide upstream from exon 4 (shown in figure 19). This was particularly interesting, 
as an alteration within such close proximity to the intron-exon boundary could 
potentially disrupt the splicing within this region, possibly resulting in a truncated 
protein that could disrupt ERF function.  
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Figure 19. Electropherogram Showing a Heterozygous Splicing Alteration in ERF 
(c.373+1G>A). 
 
 The PCR amplification and direct Sanger sequencing reaction was primarily repeated 
using the whole genome amplified sample which confirmed that this alteration was not 
an artefact, and that the variant was genuinely present within this sample. However, to 
determine if this alteration was truly present in the individual (and not an artefact that 
had been acquired during the WGA process), repeats were carried out using the original 
stock DNA. Multiple repeats in the original stock DNA revealed that although the 
variant was present in the WGA DNA sample, the variant was not actually present in the 
original stock DNA sample.  
 
In addition to the aforementioned variants detected, several synonymous variants were 
also identified; however, as none of these synonymous changes were located within 
close proximity to any intron-exon boundaries, it was unlikely that they will have had 
any observable effects on protein function. Several common SNPs were also identified 
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within the cohort, as can be expected; however, no further variants of significance were 
found to be present in the cohort of 77 familial PCC/PGL patients.  
 
4.2b.vc ME2 
Primarily, ME2 was selected as a candidate gene because the information in The Cancer 
Genome Atlas (TCGA) showed that many tumours had been found to harbour deletions 
and mutations in ME2 as outlined in figure 20. However, the most persuasive aspect of 
this gene was that it is known to be involved in the tricarboxylic acid cycle (TCA-cycle). 
ME2 catalyses the oxidative decarboxylation of malate into pyruvate (discussed further 
in section 4.3c. It is well known that mutations in genes acting within the TCA-cycle can 
be associated with increased pheochromocytoma and paraganglioma susceptibility, 
including mutations in SDHA, SDHB, SDHC, SDHD, SDHAF2 and FH. It is reasonable 
to expect that disruptions to different parts of the same pathway might generate similar 
biological consequences; it was therefore hypothesized that alterations to ME2 function 
may result in deregulation of the TCA-cycle, thereby yielding similar outcomes as 
mutations in SDHx or FH with regard to tumour predisposition.  
 
Primers were designed for all coding exons of ME2 in order to amplify the selected 
regions by PCR reaction in a cohort of familial PCC/PGL patients. After PCR 
amplification of these regions, were screened for mutations by direct Sanger sequencing.  
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Mutation screening was performed in a panel of 77 whole genome amplified familial 
PCC/PGL samples. As artificial variants can sometimes be acquired during the whole 
genome amplification process, any queried variants were repeated in original stock DNA 
samples to ensure accurate results.  
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Figure 20. Cancer Alteration Summary taken from The Cancer Genome Atlas (89 Studies for ME2) This figure displays 
the high frequencies of deletions and mutations in ME2, in a variety of cancer samples. 
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Exon Primers Conditions Variants 
1 Non-Coding - - 
2 
F: ATACCCGATGGACATGAAGG 
 
R:TCTGAACAACCTTAGCATAAAGC 
T.D (65°C - 60°C) None 
3 
F:TGTCATTGCTACCCCAGTAAG 
 
R:CACCGAAGTGAAAGAAACACAA 
T.D (65°C - 60°C) None 
4 
F:GATGTGAGAATGGGGCTCAA 
 
R:AGGTGGGAAATGTGATTTGG 
T.D (65°C - 60°C) None 
5 
F:GCTTGGAAATTATACCATGTCTTG 
 
R:TGAGAGCAACAATGAAAAACTG 
T.D (65°C - 60°C) None 
6 
F:GTGCCCCATTTTTGACAACT 
 
R:ACAGGTATGAGCCACCATGC 
T.D (65°C - 60°C) None 
7 
F:AGCCTGGGTGACAAGAGTGA 
 
R:TCGCCTCCTGCTTATCTACA 
T.D (65°C - 60°C) None 
8 
F:GGGAATATTAGGTGGAAAGCTG 
 
R:GCAGCTGTCCCTGTAAGAAAAA 
T.D (65°C - 60°C) None 
9 
F:CAACTATTGTGGGTTTTGCTG 
 
R:TGAAAGAGCATAGTGAGCCTG 
T.D (65°C - 60°C) None 
10 
F:TCAAGCATTGCATCGTACTC 
 
R:CTGTTGAAAAGAGAGTGGAAGG 
T.D (65°C - 60°C) None 
11 
F:GGAAGGTATGGGTTGAAGAGG 
 
R:CATGGTAATGATGACTGGCAAC 
T.D (65°C - 60°C) None 
12 
F:TTGCATTGCTGAGATAGTGC 
 
R:CATGCTGTAATCTCTAGGGAAACC 
T.D (65°C - 60°C) None 
13 
F:CACCTCAATTTTCTCATCCACA 
 
R:TCCCATTCCAAAGAATTCCA 
Std. 58°C 
p.Gly450Glu 
(10/55) 
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Table 6. Summary of Variants Identified in ME2. ME2 (NM_002396, NP_002387) was 
sequenced in 77 familial PCC/PGL patients. The primers used and their conditions are 
included in columns 2 and 3. Only one known polymorphism was identified, and is 
included in purple. Frequency data for the known polymorphism (rs649224) can be 
found in supplementary table 2. 
 
14 
F:TTGCGATGTGGATGGATTAC 
 
R:CCCATTCTCTCTCTGCCTTT 
T.D (65°C - 60°C) None 
15 
F:CCCCAATGCTTTTTCCATTT 
 
R:GGGCCTAAAATTTCTTCTTTGC 
T.D (65°C - 60°C) None 
16 
F:AAAGGCCACTCTTTCAGCAA 
 
R:TTCCCTGGAGCACAGAAAGT 
T.D (65°C - 60°C) None 
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After analysing the electropherograms of all 77 familial PCC/PGL samples, the final 
analysis revealed that apart from the original nonsense mutation (p.Arg270*) identified 
in the exome sequencing data, and one reported common polymorphism (p.Gly450Glu), 
no further variants were identified. 
 
4.3 Discussion of Familial Pheochromocytoma and Exome Sequencing 
4.3a UBE2C and Pheochromocytoma  
4.3a.i The Ubiquitin Pathway and Cancer  
UBE2C and UBE2QL1 play key roles in the ubiquitination process; a system which is 
essential to the function of numerous cellular processes. Cell growth and proliferation 
for example, are regulated by the ubiquitin-mediated degradation of tumour suppressors, 
proto-oncogenes and various components of signal transduction pathways (Hershko & 
Ciechanover 1998). As previously mentioned, the ubiquitination process requires the 
functional combination of three enzymes; ubiquitin activator enzymes (E1), ubiquitin-
conjugating enzymes (E2), and t ubiquitin ligase enzymes (E3).  
 
The first step in ubiquitination is the ATP-dependent activation of a ubiquitin molecule; 
this is done through the creation of a thioester bond between the active cysteine residue 
on the E1 enzyme and the c-terminus of the ubiquitin molecule. The activated ubiquitin 
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is then attached to the active cysteine residue of an E2 enzyme by another thioester bond 
in a subsequent reaction. The E2 then acts as an escort for the ubiquitin molecule in 
order to bring it within close proximity to the substrate protein. The E3 proteins then act 
as a platform upon which the substrate and the charged E2-ubiquitin complex can come 
together. The E3 then initiates the E2 to ligate the ubiquitin molecule to a specific lysine 
residue on the target protein (Ye & Rape 2009). 
 
 In general, the nature of the ubiquitin linkages will govern the fate and function of the 
target protein associated. Target proteins can become mono-ubiquitinated (where one 
single ubiquitin is added to 1 substrate molecule), multi-monoubiquitinated (where one 
ubiquitin is added to many substrate molecules) or finally, polyubiquitinated (the 
addition of multiple ubiquitin molecules to one substrate in a chain) (Ye & Rape 2009). 
In many circumstances, monoubiquitination is associated with regulating DNA repair, 
histone function, gene expression and receptor endocytosis (Sadowski et al. 2012). 
Multi-monoubiquitination was previously thought to be solely involved with receptor 
endocytosis; however recent evidence suggests that it can also target proteins for 
proteasomal degradation in some instances (Dimova et al. 2012; Sadowski et al. 2012). 
The addition of a poly-ubiquitin chain of four or more ubiquitins linked through the 
Lys48 substrate is generally a rapid mechanism to efficiently target proteins for 
proteasomal degradation (Pickart 1998; Sadowski et al. 2012). The versatility of the 
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ubiquitin pathway enables it to regulate a vast array of functions, which is why 
disruptions to the system can often result in diseases and malignant transformations.  
 
Both UBE2C and UBE2QL1 are classed as E2 conjugating enzymes; the class of 
enzymes responsible for associating the ubiquitin molecule with the target protein 
substrate in the presence of the E3 ligase enzyme. All E2 conjugating enzymes contain 
an active core domain, which includes a catalytic cysteine residue responsible for 
binding to the ubiquitin molecule by thioester bond (Xie et al. 2014). It is therefore 
conceivable to hypothesize that alterations to these genes may lead to deregulation of 
their associated ubiquitination pathway, and therefore also disruption of the molecular 
pathways in that require functional UBE2C or UBE2QL1; these disruptions may then 
lead to tumourigenic transformation.  
 
4.3a.ii UBE2QL1 as a Pheochromocytoma and Paraganglioma Susceptibility Gene 
Although little is known regarding the function of UBE2QL1, it has been shown to be 
homologous to other E2-ubiquitin enzymes, like UBE2C. In addition, it has been shown 
to contain a catalytic cysteine residue that binds to ubiquitin in a similar manner to other 
E2 enzymes (Wake 2013). UBE2QL1 was shown to act as a tumour suppressor, and it 
was found to be downregulated in renal cell carcinoma (Wake et al. 2013). In addition, 
Wake showed that interestingly, cells that stably expressed UBE2QL1 displayed a 
significant decrease in mTOR activation, and it was therefore suggested that the 
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tumourigenic activity of inactivated UBE2QL1 may occur through a mechanism 
involving the activation of the mTOR pathway. 
 
 It is well known that the mTOR pathway is often activated in PCC/PGL tumours, and so 
the suggestion that UBE2QL1 may regulate its activation seemed interesting when 
considering it as a potential PCC/PGL susceptibility gene. In addition, the fact that it had 
been associated with renal cell carcinoma was of particular relevance due to the known 
overlap of genes associated with PCC/PGL and renal cell carcinoma. Although no 
variants in UBE2QL1 had been identified in the exome sequencing data, it seemed an 
interesting candidate to investigate further in a larger cohort of patients. 
 
 UBE2QL1 was screened using primers provided by Dr. Wake in a cohort of 38 patients 
with inherited PCC/PGL. No alterations were identified from the mutation screening 
process; however, there are several reasons as to why this could be. Wake 2013 had also 
observed a lack of intragenic mutations in UBE2QL1, despite finding it to be largely 
down-regulated in renal cell carcinoma. Wake suggests that the lack of intragenic 
mutations may be due to the fact that disruptions to regulators or components in 
pathways acting upstream may result in its deregulation rather than a loss of function 
mutation within the coding region of the gene itself. In addition, Wake mentioned that 
UBE2QL1 does not contain many coding region polymorphisms, and suggests that this 
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could be due to the fact that it has undergone strong negative selection during evolution, 
thereby indicating that it has an important physiological role that is essential to life.  
 
Therefore, although it was an interesting gene with the potential to be related to 
PCC/PGL susceptibility, the results from the mutation screening in 38 patients suggests 
that intragenic mutations in UBE2QL1 are not likely to be commonly associated with 
inherited PCC/PGL; although it is possible that studies in a larger sample size may 
reveal associations of lower frequency. Nevertheless, it would be interesting to know 
whether the expression of UBE2QL1 is down-regulated in PCC/PGL tumours as it is in 
renal cell carcinoma tumours. This would suggest that although not playing a direct 
causative role, it is possibly contributing to tumour progression through a pathway 
potentially involving mTOR activation. This could also indicate the presence of 
upstream alterations that might be reducing UBE2QL1 expression, as suggested by Dr. 
Wake.  
 
4.3a.iii UBE2C as a Pheochromocytoma and Paraganglioma Susceptibility Gene 
UBE2C has been shown to be an exclusive partner of the anaphase promoting complex 
(APC); an E3 ubiquitin ligase that marks various cell cycle proteins for degradation via 
the 26s proteasome (Xie et al. 2014). UBE2C is essential for the destruction of mitotic 
cyclins and various other mitosis-related substrates involved in cell cycle progression. 
Interestingly, UBE2C is degraded by a process of autoubiquitination, which is dependent 
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on a destruction-box motif that is located between residues 129-132 (Xie et al. 2014). 
Although this alteration likely results in nonsense-mediated decay and non-expression of 
the protein product, it was interesting that the nonsense (p.Gln138*) was located in close 
proximity to the destruction box motif.  
 
Although this alteration was predicted to disrupt protein function, there have been many 
cases in which genes have been found to play dual oncogenic and tumour suppressive 
roles in cancer, and therefore, the possibility that potentially activating mutations may be 
involved was also considered.  
 
Literature has suggested that UBE2C has been found to be amplified in several tumour 
types, although this has not been studied extensively. Regardless of this, given its 
functional roles in the ubiquitin pathway, and close relation to a gene found to play a 
role in renal cell carcinoma, it was considered an interesting candidate. It was hoped that 
investigations into UBE2C would reveal one of two potential outcomes; the first being 
that additional, specifically located, alterations may be identified that could lead to 
amplification of UBE2C, or alternatively, the finding of further loss-of-function 
alterations that would suggest a potentially conditional tumour suppressive role for 
UBE2C in PCC/PGL samples.  
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UBE2C was screened for mutations in a cohort of 316 patients with familial PCC/PGL 
(in collaboration with Mercedes Robledo et al). Although a variant of unknown 
significance was identified in the cohort, (p.Ala10Ser) it was suspected to have a benign 
effect on protein function, as predicted by in silico tools, (PolyPhen and SIFT). In 
addition, even if this variant was found to be pathogenic, the finding of one variant from 
316 (0.3%) would suggest that alterations in UBE2C may only be apparent in fewer than 
0.5% of cases. It was therefore concluded that alterations in UBE2C were unlikely to be 
associated with the inheritance of PCC/PGL.  
 
4.3b ERF and Pheochromocytoma  
4.3b.i ERF as a Candidate Gene 
ERF is a ubiquitously expressed transcriptional repressor that is thought to act 
downstream of the RAS/ERK pathway. In the absence of ERK activity, ERF 
accumulates in the nucleus in its active form, where it performs its transcriptional 
repressive functions; however when the RAS/ERK pathway is activated, ERK directly 
phosphorylates ERF, causing it to translocate to the cytoplasm to resume its inactive 
form (Verykokakis et al. 2007). Verykokakis et al 2007 showed that one of the targets of 
nuclear ERF transcriptional repression is c-MYC; they showed that in the absence of 
ERK activity, ERF represses the transcription of c-MYC within the nucleus.  This 
finding is of particular relevance because mutations in MAX (Myc-associated factor X) 
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have been associated with increased PCC/PGL susceptibility (Comino-Méndez et al. 
2011).  
 
Taking into consideration that ERF has been shown to be involved in regulating c-MYC 
transcription, it seems possible that ERF loss of function mutations could therefore result 
in overexpression of c-MYC and a consequential increase in the transcription of c-MYC 
target genes, much in the way that is proposed to be the tumourigenic pathway caused 
by mutations in MAX (outlined in section 4.1b.iv). The lack of concrete evidence with 
regard to the ways in which MAX mutations cause PCC/PGL means that these theories 
remain speculative; however these possibilities rendered ERF an attractive candidate 
gene for PCC/PGL susceptibility.  
 
4.3b.ii Mutation Screening of ERF  
The coding regions of ERF were screened in a cohort of 77 familial PCC/PGL patients. 
Due to the large amount of DNA required for numerous reactions, the DNA samples 
were whole genome amplified for use in routine PCR and sequencing reactions. 
Performing these whole genome amplification reactions is clearly beneficial with regard 
to conserving quantities of valuable DNA samples; however the reactions are not 
without their disadvantages. A reaction which aims to replicate an exact DNA sequence 
multiple times will inevitably be subject to errors, as was discovered in one patient who 
had seemingly acquired a splicing alteration (c.373-1 G>A), 1 nucleotide upstream of 
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exon 4. It is statistically, highly unlikely that the whole genome amplification process 
would remove a variant of interest, and therefore although these occasional acquired 
false positive alterations were a hindrance, the whole genome amplification process 
enabled large numbers of reactions to be performed whilst minimising the depletion of 
valuable DNA stocks; thus it was still regarded to be a valuable technique which 
allowed maximum efficiency with regard to this study. 
 
In general, mutational hotspots are most often found in oncogenes and not tumour 
suppressors, and therefore, the finding of multiple identical alterations (26 individuals 
with p.Glu470Val) seemed suspicious. Consistently, this alteration was also identified in 
a panel of ethnically matched healthy controls; and therefore, this indicated that this 
alteration was likely to be an unreported common polymorphism. It was therefore 
decided that the p.Glu470Val alteration was unlikely to be contributing to the disease in 
these patients. The reasons as to why these variants are currently absent from the 
mutational databases remains unknown; however, given the large numbers of unreported 
SNPs which are found to occur within Guy’s hospital’s in-house data of the exome 
sequencing data received, it is justifiable to assume that there could be many unreported 
SNPs that have yet to be added to the SNP databases.  
 
In conclusion, the only variant of unknown significance identified was a synonymous 
variant (p.Leu81Leu); however, this variant was not in close proximity to any intron-
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exon boundary, and so it was unlikely to have any functional effects to the ERF protein.  
In the absence of any further mutational evidence identified from ERF within the 
PCC/PGL cohort of 77 patients, it was decided that this gene was unlikely to be playing 
a direct role in the susceptibility of inherited PCC/PGL; however, given the roles of ERF 
in regulating the transcription of c-MYC, it would be interesting to know whether ERF 
function is disrupted in tumours overexpressing MYC.  
 
4.3c ME2 and TCA-Cycle Mutations and Pheochromocytoma  
In the 1920’s Otto Warburg made the observation that tumour cells exhibited 
abnormally high levels of glycolysis and lactate production, even in the presence of 
oxygen; a phenomenon termed “The Warburg Effect” (Warburg 1956; Racker 1974). 
Since then, research has shown that functional mitochondria are essential to tumour 
progression. This has also been demonstrated in studies using ethidium bromide, a 
known inhibitor of mitochondrial DNA transcription, to deplete mitochondrial DNA 
from tumour cells. These experiments showed that the depletion of functional 
mitochondria in tumour cells diminished their tumourigenic phenotypes; and in 
particular, the cells lost their ability to grow in an anchorage-independent fashion and 
became more sensitive to cytotoxic drugs (Cavalli et al. 1997). Furthermore, the 
tumourigenic phenotype was shown to return following the transfer of fully functional 
mitochondria into the cells, which strongly linked the necessity of functional 
mitochondria for tumour progression.  
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The components of the tri-carboxylic acid cycle (TCA-cycle or Krebs cycle) are of 
particular interest as this pathway couples glycolysis occurring in the cytosol and 
oxidative phosphorylation occurring in the mitochondrion; in addition, many of the 
enzymes and proteins involved in the TCA-cycle have been shown to be associated with 
various tumour predispositions.  
 
The TCA-cycle can be described as a pathway that aims to generate energy by 
metabolising carbohydrates, lipids and amino acids. In brief, prior to entry into the TCA-
cycle, pyruvate generated from glucose during glycolysis is oxidised to form acetyl-coA. 
The acetyl-coA combines with oxaloacetate to form citric acid; this reaction is catalyzed 
by citrate synthase. The enzyme aconitase then utilises the newly formed citric acid in a 
reaction to form isocitrate, which in turn is converted to α-ketoglutarate by the enzyme 
isocitrate dehydrogenase. The α-ketoglutarate is then converted to succinyl-CoA in a 
reaction catalyzed by α-ketoglutarate dehydrogenase. The succinyl-CoA is converted to 
succinate, which is then oxidised to fumarate by succinate dehydrogenase (SDH). 
Fumarate hydratase hydroxylates fumarate in order to produce malate. At this point, 
malic enzymes, including ME2, catalyse the oxidative decarboxylation of malate back 
into pyruvate, which then leaves the cycle as a source of potential energy. Finally malate 
is converted into oxaloacetate by malic dehydrogenase to complete the cycle; this whole 
process is outlined in figure 21. 
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Figure 21. A Summary of the TCA Cycle This is a schematic summary of the TCA cycle 
including mitochondrial enzymes known to be associated with cancer (adapted from 
Gaude & Frezza 2014). The boxes coloured in orange represent parts of the cycle where 
ME2 is involved. Abbreviations include: CS (citrate synthase), Aco (aconitase), IDH 
(isocitrate dehydrogenase), αKDH (α-ketoglutarate dehydrogenase), SDH (succinate 
dehydrogenase), FH (fumarate hydratase), ME (malic enzyme), MDH (malate 
dehydrogenase), PDH (pyruvate dehydrogenase), HLRCC (hereditary leiomyomatosis 
and renal cell cancer), PGL/PCC hereditary paraganglioma and pheochromocytoma. 
  
151 
 
FH inactivation has been shown to act in a similar manner to SDHX inactivation, in that 
both succinate and fumarate accumulate and inhibit PHDs. This results in the 
stabilisation of HIF, consequentially generating a pseudohypoxic environment in which 
HIF target genes are transcribed (Gottlieb & Tomlinson 2005; Pollard et al. 2005; Selak 
et al. 2005). Bardella et al 2012 demonstrated that loss of FH function in human renal 
cells indeed displayed HIF1-α stabilisation and exhibited a pseudohypoxic environment; 
however in addition, the cells were also resistant to apoptosis, even when exposed to 
various apoptotic stimuli. Bardella et al 2012 mentions, that although upregulation of 
HIF has been described in FH-defective tumours, this does not explain how FH-
defective cells avoid apoptosis; particularly as homozygous germline mutations in FH 
have been shown to be lethal to developing neurons (Bourgeron et al. 1994).  
 
Their experiments showed that contrary to their original beliefs, the apoptotic resistance 
was occurring by a mechanism that was independent of both HIF-1α and HIF-2α. 
Bardella et al 2012 discovered that the apoptotic resistance was mediated by the 
activation of AMP-activated protein kinase (AMPK). This finding was surprising, 
particularly as AMPK has historically been reported to act as a tumour suppressor by 
regulating cellular energy homeostasis and suppressing cell growth and proliferation 
through the mTOR pathway (Hardie 2011). Bardella et al 2012 demonstrated that 
apoptotic resistance in FH-deficient renal cells was not affected by deregulating either 
HIF1-α or HIF2-α; however when AMPK was deactivated, the FH-deficient cells were 
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no longer resistant to apoptosis. These results are likely to be representative of FH-
related pheochromocytomas and paragangliomas, and as mentioned previously, there is 
a degree of overlap of these tumours and renal cell carcinomas with regard to their 
susceptibility genes and methods of tumourigenesis. 
 
 To determine whether an increase in AMPK activation could be responsible for 
tumourigenesis, Bardella et al 2012, also showed that the AMPK activation in FH-
deficient renal cells occurred independently of HIF stabilisation and was a direct result 
of fumarate accumulation; furthermore in vivo, they also showed AMPK was indeed 
activated in both renal cysts present in FH-deficient mice and also in papillary renal cell 
carcinoma samples from Hereditary leiomyomatosis and renal cell cancer (HLRCC) 
patients (Bardella et al. 2012).    
 
Malic enzymes are tetrameric proteins that are activated by the binding of fumarate and 
inhibited by the binding of ATP (Chang & Tong 2003). Their main function is to 
catalyse the oxidative decarboxylation of malate to pyruvate while simultaneously 
causing the reduction of NAD(P)+ to NAD(P)H. There are three different isoforms of 
malic enzymes, including ME1 which resides in the cytosol, ME2 and ME3; both of 
which reside in the mitochondria (Zheng & Fisher 2015). The malic enzymes are 
evolutionarily conserved and exhibit comparable structural similarities across different 
species, which indicates that these enzymes play significant biological roles. Although 
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information about malic enzymes regarding their structural and functional aspects at a 
molecular level have been documented (Chang & Tong 2003), there remains much to be 
elucidated regarding the physiological significance and biological roles that malic 
enzymes play, particularly in the context of cancer. Some studies have reported 
observing increased expression of ME2 in certain tumours (Chang et al. 2014), which 
seems to contradict the theory that loss of function mutations in ME2 may increase 
susceptibility to pheochromocytoma and paraganglioma. Chang et al 2014, for example, 
reported finding increased expression of ME2 in cases of cutaneous melanoma; however 
more importantly, and of particular relevance to inherited PCC/PGL given the effects of 
FH-inactivation, they found that ME2 negatively regulated AMPK activity. Chang et al 
2014, found that AMPK activation was increased when ME2 expression was depleted, 
which suggests that interestingly, loss of ME2 invokes the same increase in AMPK as is 
found in FH-deficient tumours, and therefore, cells harbouring loss of function ME2 
alterations may also gain the abilities of apoptotic resistance.   
 
  The dual roles of AMPK have been discussed in a review by Liang & Mills, 2013, and 
they suggest that AMPK may act as a conditional tumour suppressor or oncogene. It is 
possible therefore, that within tumours that acquire predispositions from mutations in 
TCA-cycle enzymes, that AMPK activation plays an oncogenic role in the 
transformation of cells, as displayed by the increase in AMPK activation observed in 
FH-deficient tumours. The unexpected oncogenic roles of AMPK in renal cell 
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carcinoma are particularly interesting when considering ME2 as a potential causative 
gene, as it is possible that the process occurring in in renal tumours will reflect the 
activity in PCC/PGL. Therefore, as ME2 is closely related to FH within the TCA-cycle 
and both have been shown to increase AMPK activity when depleted suggests that 
germline mutations in ME2 may act in a similar manner to germline FH mutations. The 
hypothesis is therefore, that loss of function mutations in ME2 may lead to the disruption 
of the TCA-cycle and promote AMPK activation resulting in apoptotic resistance and 
tumourigenesis of pheochromocytomas and paragangliomas.  
 
Despite these convincing associations, investigations into ME2 did not uncover any 
further mutations other than the original nonsense (p.Arg270*) identified from the 
exome sequencing data; however, it should be noted that the sample size used for 
screening consisted of 77 patients. In comparison, the study by Castro-Vega et al 2014, 
carried out mutation screening of the FH gene in 598 patients, identifying 5 pathogenic 
alterations; a frequency of 0.8%. It is therefore not unreasonable to believe that 
mutations in ME2 may still confer increased susceptibility to pheochromocytoma and 
paraganglioma, and the lack of further mutational evidence may be due to the limited 
sample size.  Given the similarities between FH-depletion and ME2-depletion with 
regard to AMPK, it seems a likely possibility.  
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Little is known about the roles of malic enzymes with regard to cancer biology, and so 
reports of ME2 amplification in some tumours cannot eliminate the possibility that ME2 
depletion may also have a conditional tumourigenic role in different tumours, especially 
as AMPK has been shown to play contradictory dual roles in different tumours. 
Furthermore, information in the TCGA database shows a high percentage of deletions 
and mutations in ME2 for a variety of tumours, and only a small percentage of 
amplifications (figure 20), suggesting that ME2 is more often dysfunctional in tumours 
than overexpressed. The recent surprising oncogenic associations with the previously 
assumed tumour suppressor, AMPK in FH-associated renal tumours makes it a fair 
assumption that ME2 may be playing a larger role in some tumours than is currently 
thought. Therefore, it would be of great benefit to investigate ME2 in a cohort large 
enough to confidently identify mutational frequencies of less than 1% of the sample 
population.    
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Chapter Five:  
SPORADIC PHEOCHROMOCYTOMA 
AND PARAGANGLIOMA 
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5.1 Introduction – Sporadic Cancer  
5.1a Genetic Landscape of Sporadic Pheochromocytoma and Paraganglioma 
As previously mentioned, it is thought that up to 60% of the patients who develop 
PCC/PGL carry either a germline or somatic mutation in a known PCC/PGL gene; in 
addition, many of these tumours occur sporadically without any clear familial history 
(Crona et al. 2013). The genetic landscape of a large proportion of many sporadic 
tumours without a germline mutation remains elusive. In contrast to sporadic RCC, 
where the majority of cases harbour somatically acquired alterations in VHL, sporadic 
PCC/PGL tumours rarely contain somatic VHL mutations. Of sporadic PCC/PGL, 
approximately 20-25% may harbour somatic alterations in NF1, 5% are found to carry 
somatic alterations in RET, and another 5% exhibit somatic HRAS alterations 
(Burnichon et al. 2012; Burnichon et al. 2011; Crona et al. 2013; Dahia 2014).  
 
Although both inherited and somatic mutations in PCC/PGL susceptibility genes are 
usually found to occur in a mutually exclusive pattern, there have been some rare 
instances in which two somatic mutations have been found to occur in two different 
susceptibility genes in the same tumour (Burnichon et al. 2012). Thus Burnichon et al 
2012 identified cases in which a single tumour exhibited somatic alterations in both NF1 
and RET, and another instance in which somatic VHL alterations were found to occur 
with somatic NF1 variants. It is possible that tumour cells harbouring two mutations in 
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different susceptibility genes may possibly provide a growth advantage, which may 
exacerbate both the phenotype and prognosis. It is also possible, as previously described 
in section 1.3c, that these two mutations may be representative of two independent 
clonal expansions, that each provide separate growth advantages to the cell, and 
therefore may have undergone positive selection at different tumoural time points.  
 
Studies into the genetic landscape of both hereditary and somatic PCC/PGL tumours has 
to date mostly focused on explaining the contributions of the highly penetrant germline 
susceptibility genes, and there has been relatively little research into roles of somatic 
alterations in PCC/PGL tumourigenesis (Luchetti et al. 2015). It is therefore clear that, 
although genetic research into PCC/PGL tumours has provided a wealth of knowledge 
and understanding with regard to tumour biology and tumourigenesis, there still remains 
much to be elucidated.  
 
This part of the study aimed to shed light on the potential drivers of sporadic PCC/PGL 
tumours with the use of exome sequencing. It was hoped that by analysing the full 
exomes of multiple PCC/PGL tumours, that commonly altered genes or aberrant 
pathways may be highlighted that might be contributing to tumour progression. The 
successful clarification and interpretation of the complex genetic makeup of sporadic 
PCC/PGL tumours may enhance current understandings of sporadic tumour biology and 
pathogenesis, and most importantly could potentially be of clinical benefit to patients. 
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5.2 Results  
5.2a Patient Samples  
Tumour DNA from 13 unrelated patients with apparent sporadic pheochromocytoma 
and paraganglioma was sent for exome sequencing (PCC= 8, PGL=5). In addition, two 
tumour DNA samples from two unrelated patients with inherited paraganglioma were 
also sent for exome sequencing. Three of the total 15 tumour samples contained known 
SDHB mutations; the remaining 12 samples were mutation negative for any of the 
known PCC/PGL susceptibility genes.  
 
As described above, some single tumours have previously been found to harbour two 
somatic alterations in two known PCC/PGL genes (Burnichon et al. 2012); for this 
reason, sequencing tumour DNA known to carry pathogenic SDHB mutations should not 
have hindered our abilities to detect further tumour-associated mutations. Furthermore, 
as previously described, PCC/PGL patients who carry SDHB mutations are often 
associated with more aggressive tumours, higher risks of malignancy and recurrent 
disease; therefore, sequencing these tumours may reveal further mutations that may be 
contributing to metastatic disease. 
 
For each sample, approximately 3-5µg of tumour DNA was sent to the Biomedical 
Research Centre at Guy’s Hospital, where they performed exome sequencing. As before, 
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the group in Guy’s hospital identified and quality filtered all single nucleotide 
substitutions and small insertion deletions using a combination of the SamTools 
software package and their in-house software tools. They then annotated the variants 
with respect to genes and transcripts using the Annovar tool, and provided an excel 
spreadsheet containing all information. 
 
A panel of 55 tumour DNA samples (PCC=30, HNPGL=20, PGL=5) was used for 
mutation screening of candidate genes selected from the exome sequencing data. 
Corresponding normal blood DNA was available for 34 of these samples. From the 
panel of 55 patients, 7 were known to carry pathogenic alterations in known PCC/PGL 
susceptibility genes, and a further 5 were known to carry variants of unknown 
pathogenicity in a known PCC/PGL susceptibility gene. The remaining apparently 
sporadic 43 tumour DNA samples did not carry any mutation in a known susceptibility 
gene.  
 
5.2b Gene Prioritization  
The exome sequencing data of 13 patients with apparently sporadic PCC/PGL and 2 
patients with inherited PGL was combined into a single document in order to view all 
variants and generate comparisons between the samples. In total, from all 15 samples, 
prior to filtration, there were 394,673 variants. It was therefore necessary to apply a 
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series of filters to the data in order to exclude unlikely variants and retain variants of 
interest, which may be contributing to tumour progression.  
 
 Within the data, there were 188,337 synonymous and non-coding alterations and so 
these were excluded first as they are unlikely to have any effect on protein function. As 
was done previously, all variants with a MAF >1% were also excluded, as variants that 
are common within the general population are unlikely to be damaging and therefore 
unlikely to contribute to tumour progression. Removing all common variants reduced 
the number of candidates from 206,336 to 25,409; of these remaining variants, 2706 
were described as novel. Following this, variants were then disregarded if they had been 
found over 10 times within the in-house findings in order to exclude as many false 
positives and unreported common polymorphisms as possible, while retaining potential 
variants of interest. This step reduced the number of variants to 9400 potential 
candidates. Due to the extremely large number of potential candidates, more stringent 
filtration criteria was then applied that selected genes with a MAF ≤0.1%, in order to 
select very rare variants within the general population. This final filter reduced the 
number of variants down to 3884 candidates.  
 
Following the first stages of variant filtration, the next strategy was not to remove any 
alterations, but to apply a series of selection criteria in order to determine which genes 
are most likely to be contributing to tumour progression out of the potential 3884 
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possibilities. The remaining candidates were then scrutinised in order to ascertain which 
fulfilled the largest proportion of the selection criteria.  
 
Selection criteria included genes known to be involved in cancer pathways (particularly 
kinase signalling, metabolic and hypoxia pathways), as these are well known to be 
aberrant in PCC/PGL tumours. In addition, genes were considered interesting if they 
displayed variants in more than one, but not more than 3 individuals. This was because it 
was thought that driver mutations in a particular gene may be present in more than one 
individual, particularly if similar pathways are being disrupted in these tumours; 
however identical alterations in a TSG in more than 3 individuals has a high probability 
of being due a false positive, or possibly an unreported common polymorphism. There is 
a possibility of finding identical alterations in an oncogene, and so identical variants 
could not be discarded; however, large numbers of identical variants are more likely to 
be false positives or common polymorphisms of no clinical relevance. Therefore, 
identical variants in a maximum of 3 individuals was considered to be a generous cut off 
point to exclude false positives, while retaining potential tumour-associated oncogenic 
variants.  
 
Genes that were found to be highly mutated in the The Cancer Genome Atlas (TCGA) 
database were considered interesting, as this indicates that they may potentially have a 
role in tumour progression. Finally, the type of variant was also considered with 
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particular attention on variants that were likely to have a clear loss-of-function 
consequence (frameshift, nonsense, and splicing alterations that were no more than 3bp 
from the intron/exon boundary). Finally, when genes passed through these criteria, the 
gene function was considered in order to assess the likelihood of it having a potential 
role in tumour development or progression. 
 
5.2c HIF Pathway and Sporadic PCC/PGL 
As explained in section 4.1a, pseudohypoxia arises when HIF pathways are activated in 
the absence of hypoxia. The response to hypoxia is regulated by Hypoxia-inducible 
factors (HIFs); heterodimeric transcription factors that become activated in response to a 
hypoxic or pseudohypoxic environment, and they function to regulate the cell’s adaptive 
responses by initiating the transcription of numerous target genes.  
 
HIFs are made up of an α-subunit and a β-subunit; both of which belong to a family of 
transcription factors known as the basic-helix-loop-helix (bHLH) PAS proteins (Wang et 
al. 1995; Ratcliffe 2013). The β-subunit is a stable, constitutively expressed protein that 
often forms heterodimers with other members of the bHLH family in order to perform 
various cellular functions (Jochmanová et al. 2013). The α-subunit consists of three 
subunits, HIF-1α, HIF-2α and HIF-3α, and is solely involved in the hypoxic response. 
HIF-α is largely regulated by prolyl hydroxylases (PHDs) that hydroxylate the subunits 
at specific proline residues under normoxic conditions. This process of hydroxylation 
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then enables pVHL, the recognition component of a tumour suppressor complex with 
E3-ubiquitin ligase activity, to recognise the substrates and initiate their subsequent 
ubiquitination through proteasomal degradation (Maxwell et al. 1999; Kaelin & Ratcliffe 
2008).  Following the discovery of the association of pVHL and HIF, it was soon 
suggested that the angiogenic tumourigenesis of VHL disease-associated tumours may 
occur through a mechanism involving the stabilisation of the HIF-α subunit and an 
accumulation of HIF-1 as a direct consequence of VHL inactivation, thereby resulting in 
the subsequent transcription of a multitude of target genes, including those involved in 
angiogenesis.  
 
In keeping with these predictions, both VHL and SDHX mutations have been shown to 
result in an accumulation of HIF and increased HIF activity (Maxwell et al. 1999; Selak 
et al. 2005). Given the roles of both VHL and the SDHX genes in PCC/PGL 
tumourigenesis, it seemed reasonable to hypothesise that specific activating mutations 
directly affecting the HIF complex might reciprocate the same consequences as VHL and 
SDHX mutations, and therefore may also contribute to PCC/PGL tumour development 
and progression.  
 
Multiple studies have outlined the role of dysregulation of HIF2-α in tumour 
progression; but up until recently, there had been no previous reports of mutations in 
HIF2A directly having an association with a particular neoplasm. The first publication 
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that reported this was released during this PhD investigation; it described the 
identification of gain-of-function somatic alterations in HIF2A in patients with 
paraganglioma associated with congenital polycythaemia (Zhuang et al. 2012). The 
wealth of functional relevance of HIF-2α in PCC/PGL associated pathways, in addition 
to the release of recent publications outlining its association with these tumours initiated 
the decision to carry out further investigations into the involvement of HIF2A mutation 
in PCC/PGL tumours in the hope to gain a deeper understanding of its role in 
tumourigenesis. 
 
HIF-2α is hydroxylated by PHDs at 2 specific proline residues; one is located in exon 9, 
and the other in exon 12, and therefore it can be inferred that variants occurring within 
these regions are likely to alter HIF-2α function. Interestingly, the exome sequencing 
data revealed two novel missense alterations in HIF2A; one in exon 9 in an individual 
with paraganglioma (p.Ser372Asn) and the second in exon 12 in an individual with 
pheochromocytoma (p.Pro531Thr). Interestingly, the p.Ser372Asn alteration identified 
in the exome sequencing data was found to be in an individual that also carried a 
pathogenic SDHB mutation (p.Trp200Cys). 
 
A publication by Zhuang et al 2012 released at the time of these findings also identified 
the same p.Pro531Thr variant, which provided a further indication that this particular 
variant was playing a pathogenic role in the associated individuals. It was therefore 
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decided that exons 9 and 12 should be screened in the cohort of 55 PCC/PGL tumour 
DNA samples in order to determine whether any further novel alterations were present 
that could potentially be driving tumour progression.  
 
5.2d Mutational Screening of HIF2A in Sporadic PCC/PGL  
Two sets of primers were designed to flank exon 9 and exon 12 respectively. These 
regions were PCR amplified primarily in the individuals implicated in the exome 
sequencing data to confirm the presence of their variant by Sanger sequencing. The 
results revealed that both p.Pro531Thr and p.Ser372Asn were true variants and present 
in the non-amplified tumour DNA of the associated individuals (displayed in figure 22).  
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Figure 22. Confirmation of Variants Identified in HIF2A: A: Shows a reference 
sequence for a specific region in HIF-2α, exon 9 and the p.Ser372Asn alteration 
identified. B: Shows a reference sequence for a specific region in HIF-2α, exon 12 and 
the p.Pro531Thr alteration identified.  
 
Mutational screening was then carried out in a cohort of 55 whole genome amplified 
PCC/PGL tumour DNA samples. Interestingly, in exon 9, one additional missense 
variant p.Pro407Arg was identified in the same individual that carried the p.Pro531Thr 
alteration (figure 22). This second identified variant was re-tested in the original stock 
DNA of this sample, and found to be a true alteration. 
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Figure 23. Confirmation of p.Pro407Arg Identified in HIF2A Exon 9 This image 
shows a reference sequence for HIF2A exon 9, and the p.Pro407Arg alteration 
identified. The peak of the altered allele is fairly low level, which could be indicative of 
mosaicism. 
 
Mutation screening of exon 12 revealed one further variant (p.Phe583Leu) in one 
individual with sporadic paraganglioma. This variant was confirmed in the original stock 
DNA of that tumour sample. In addition, corresponding normal blood DNA was 
available for this sample and so this was also tested for the presence of the variant. The 
results revealed that the variant was present in the blood DNA sample, confirming that 
the variant was not an acquired somatic alteration. However, it does appear that the 
variant allele is enriched in the tumour DNA, as the peak for the variant allele is higher 
in the electropherogram of the tumour DNA in comparison to the peak found in that of 
the blood (figure 24).   
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Figure 24. Electropherograms of HIF-2α Exon 12. This image shows a reference 
sequence for HIF-2α exon 12, the p.Phe583Leu alteration identified in the tumour DNA 
and the same alteration found in the corresponding blood DNA.  
 
Therefore, in total, from the panel of 55 tumour DNA samples (48 assumed sporadic), 
four alterations were identified in HIF2A in three individuals. Two alterations were 
identified from the exome sequencing data, and two further variants were identified from 
the mutation screening of exons 9 and 12. A summary of these variants is outlined in 
Table 7. 
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Sample Alteration Exon 
Identification 
Method 
Somatic 
Status 
PolyPhen 
Previously 
Reported 
1T p.Pro531Thr 12 Exome N/A 
Probably 
Damaging 
Yes 
1T p.Pro407Arg 9 Sanger N/A 
Predicted 
Benign 
No 
2T p.Ser372Asn  9 Exome N/A 
Predicted 
Benign 
No 
3T p.Phe583Leu 12 Sanger Germline 
Predicted 
Benign 
No 
 
Table 7. Summary of Alterations Identified in HIF2A From a Cohort of 55 
Apparently Sporadic PGL/PCC Samples. Four alterations were identified in three 
individuals. The p.Pro531Thr alteration, which had previously been reported in the 
publication by Zhuang et al 2012, was predicted to be probably damaging by PolyPhen. 
The remaining three novel variants were all predicted to be benign. It was not possible 
to determine the somatic status of the first three variants, as there was no constitutional 
blood DNA available for these samples; therefore they are marked as N/A.  
 
5.2e HRAS 
As previously mentioned in section 4.1b, there are two major molecular pathways that 
are associated with the formation of PCC/PGL tumours, enabling them to be separated 
into two distinct groups based on the genetic mutations present. Cluster 1 involves 
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aberration of the hypoxic pathway while cluster 2 includes tumours characterised by 
abnormal activation of the PI3K-AKT-mTOR and RAS/ERF/ERK kinase signalling 
pathways. Cluster 2 tumours are most often associated with mutations in RET, NF1, 
MAX and TMEM127; all of which cause activation of the kinase signalling pathways 
mentioned.  
 
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved 
serine/threonine kinase that becomes activated in response to various mitogenic stimuli. 
This then initiates the activation of numerous cellular metabolic pathways that promote 
cell cycle progression and drive cell proliferation (Shimobayashi & Hall 2014). The 
mechanism of tumourigenesis in cluster 2 therefore often involves mutations that cause 
aberrant, constitutive activation of the mTOR pathway, ultimately leading to increased 
cell growth and tumour development.  
 
The RAS family of proteins consists of HRAS, KRAS and NRAS; these proteins are 
GTPases that act as molecular switches. They largely function by coupling cell surface 
receptors to intracellular signalling effector pathways in order to promote cell growth, 
proliferation and survival (Pylayeva-Gupta et al. 2011). RAS proteins are auto-
regulatory as they have the intrinsic ability to initiate GTP hydrolysis; this enables them 
to cycle between an active GTP-bound state and an inactive GDP-bound state.  
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RAS proteins are among the most commonly mutated genes in cancer, and are known to 
contain specific oncogenic mutational hotspot regions. These oncogenic hotspots include 
the residues Glycine-12 (Gly12), Glycine-13 (Gly13) and Glutamine-61 (Glu61) (Gripp 
& Lin 2012). Glu61 is a catalytic residue that is essential for GTP-hydrolysis and a 
substitution at this location for any amino acid other than glutamine will cause a 
conformational change that prevents GTP-hydrolysis from occurring. This prevents RAS 
from cycling into the GDP-bound state, and therefore results in a constitutively active 
RAS pathway that continuously initiates a pro-tumourigenic downstream signalling 
cascade (Scheffzek et al. 1997; Pylayeva-Gupta et al. 2011). Substitutions occurring at 
residues Gly12 and Gly13 prevent the association of GTPase Activating Proteins 
(GAPs). GAPs are proteins which initiate the activation of GTP hydrolysis, and for this 
reason, loss of GAP association will also prevent RAS from cycling into the inactive 
GDP-bound state, which also results in a constitutively active RAS pathway (Pylayeva-
Gupta et al. 2011).  
 
During the course of this study, a paper was released which reported finding mutations 
at these key residues in HRAS associated with sporadic cases of PCC/PGL (Crona et al. 
2013). Interestingly, upon investigation, one individual in the exome sequencing data 
from the sporadic PCC/PGL tumour DNA samples in our study was found to carry one 
of the same missense mutations that was outlined in the paper (p.Gly13Arg). This 
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finding then raised the question as to whether additional variants in the RAS family 
might also be driving tumour progression in sporadic PCC/PGL tumours.  
 
In order to investigate this, primers were designed to flank exonic hotspot regions of 
HRAS, KRAS and NRAS. The primers were used to PCR amplify these regions in a 
cohort of 55 tumour DNA samples from patients with apparently sporadic PCC/PGL. 
The samples then underwent Sanger sequencing in order to determine if any variants of 
interest were present. In addition to the original p.Gly13Arg variant present in the exome 
sequencing data, three samples were identified that carried the substitution of 
p.Glu61Arg; this in total amounted to 4 individuals with activating HRAS mutations; 
one with p.Gly13Arg and 3 with the p.Glu61Arg substitution. The somatic/germline 
status of these variants could not be confirmed as no constitutional blood DNA was 
available for these patients (table 8).No variants of interest were found in KRAS or NRAS 
in the cohort of sporadic PCC/PGL tumour DNA samples.  
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Figure 25. Electropherograms Outlining Variants Identified by Sanger Sequencing in 
HRAS. The images show a region of reference sequence for HRAS, exon 2 and the 
corresponding region in an affected individual harbouring a p.Gly13Arg homozygous 
alteration. The subsequent images show a region of reference sequence for HRAS, exon 
3, and the corresponding region in an affected individual harbouring a heterozygous 
p.Glu61Arg alteration.  
 
Following these findings, an opportunity arose in collaboration with Andrea Luchetti of 
the Department of Medical Genetics at the University of Cambridge, to investigate these 
samples using the IonAmpliSeq cancer hotspot panel v2 (Life Technologies, UK). This 
next generation sequencing panel targets the mutational hotspot regions of 50 known 
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cancer associated genes including HRAS, KRAS and NRAS. This method enables these 
regions to be sequenced in parallel with higher coverage than would be achieved with 
whole exome sequencing. Furthermore, this method is also more sensitive to the 
presence of mosaic variants than Sanger sequencing. The collaborators in Cambridge 
used the same cohort of 55 tumour DNA samples, and also included a further 30 tumour 
DNA samples with apparently sporadic PCC/PGL. Of the total 85 samples, 21 were 
known to carry germline pathogenic alterations in a known susceptibility gene.   
 
In addition to the alterations identified through Sanger sequencing, IonAmpliSeq also 
identified two further p.Gln61Arg alterations in two more individuals. These two 
alterations had not been apparent in the original Sanger sequencing data; possibly due to 
the fact that these were mosaic alterations. This raised the total number of variants 
identified in HRAS to 6 out of a total 85 tumour DNA samples from patients with 
sporadic PCC/PGL; one with p.Gly13Arg, and 5 with p.Gln61Arg. This amounted to an 
overall frequency of 7.1%.  
 
In addition to the variants in HRAS, the IonAmpliSeq data also revealed one activating 
mutation in BRAF, (p.Val60Glu), and two tumours harbouring missense alterations in 
TP53 (p.Arg337His) (Luchetti et al. 2015). No HRAS mutations were identified in any 
of the 21 patients that carried a pathogenic germline mutation (Luchetti et al. 2015). 
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Amino Acid 
Alteration 
Nucleotide 
Alteration  
Gene  
Somatic 
Status 
Identified 
by 
p.Gln61Arg c.182A>G HRAS N/A Sanger Seq. 
p.Gln61Arg c.182A>G HRAS N/A Sanger Seq. 
p.Gln61Arg c.182A>G HRAS N/A Sanger Seq. 
p.Gly13Arg c.37G>C HRAS N/A Exome Seq. 
p.Gln61Arg c.182A>G HRAS Somatic IonAmpliSeq 
p.Gln61Arg c.182A>G HRAS Somatic  IonAmpliSeq 
p.Val600Glu c.1799T>A BRAF Somatic IonAmpliSeq 
p.Arg337His c.1010G>A TP53 Somatic IonAmpliSeq 
p.Arg337His c.1010G>A TP53 Somatic IonAmpliSeq 
 
Table 8. A summary of variants identified in HRAS and other cancer genes using a 
combination of Sanger sequencing and the IonAmpliSeq cancer hotspot panel. This 
data was published in collaboration with Luchetti et al 2015, and some information has 
been taken from this publication. The somatic status of some of the individuals remains 
unknown as the corresponding blood DNA was not available for these samples, and so 
they are marked as N/A. 
 
5.2f KEAP1 and CUL3 
Following investigations into HIF2A and HRAS, the exome sequencing data for the 
sporadic tumour DNA samples was reviewed in order to determine whether any further 
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candidate genes of interest were present.  Following rigorous filtration of the sporadic 
PCC/PGL exome sequencing data, the remaining variants were scrutinized in order to 
prioritise and identify likely PCC/PGL candidate genes. Genes were assessed based on 
their predicted functional impact on the encoded protein, with the criteria that nonsense 
and frameshift alterations are more likely to have a deleterious effect on protein function 
than missesnse alterations. In addition, genes were also analysed based on the functional 
relevance of their encoded proteins, in order to assess the likelihood of their potential 
involvement in tumourigenesis.  
 
Following this process, one gene was noticed to be particularly interesting; Kelch-like 
ECH-associated protein (KEAP1). KEAP1 is best known for its associations with CUL3 
and Nrf2 as part of a crucial adaptive response pathway to cellular stress; a pathway 
essential for the prevention of human diseases including cancer (Zhang 2010). It has 
been suggested that KEAP1 frequently exists in a complex with CUL3, and that in the 
absence of cellular stress, this complex associates with Nrf2 and promotes its 
degradation via the ubiquitin pathway (Cullinan et al. 2004; Kansanen et al. 2013) 
 
KEAP1 contains many cysteine residues, several of which are essential to its function; 
namely residues Cys151, Cys273 and Cys288, as these are involved in sensing cellular 
stress. In the presence of cellular stress, excess concentrations of ROS for example, 
these cysteine residues on KEAP1 become modified, causing a conformational change 
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in the protein structure of KEAP1 and consequential dissociation from Nrf2. This 
reverses the proteasomal degradation of Nrf2, enabling it to translocate to the nucleus 
and initiate the activation of Nrf2 downstream target genes, which then enable the cell to 
adapt to the stresses that are apparent (Zhang 2010; Kansanen et al. 2013; Cullinan et al. 
2004).  
 
Genomic alterations in KEAP1 which affect of any of the key cysteine residues Cys151, 
Cys273 or Cys288 have been reported to disrupt protein function by altering the 
conformation of KEAP1 in a similar manner to the presence of cellular stress. This 
results in the inability of the KEAP1-CUL3 complex to associate with Nrf2, and 
therefore Nrf2 is not degraded via the ubiquitin pathway but remains constitutively 
active (Kansanen et al. 2013). Cullinan et al 2004 showed that the individual role of 
KEAP1 is to act as an adaptor or bridge which enables the association of CUL3 with 
Nrf2. CUL3 then acts as an E3 ubiquitin ligase protein and initiates the ubiquitin-
mediated degradation of Nrf2 (Cullinan et al. 2004). Cullinan et al 2004 showed that 
targeted inhibition of either CUL3 or KEAP1 in vitro lead to an accumulation of Nrf2 
and an increase in the transcription of Nrf2 downstream signalling targets; this suggests 
that both proteins must be functional for the successful ubiquitination of Nrf2.  
 
In addition to its roles in the cell’s adaptive responses to stress, Nrf2 has been shown to 
have many pro-tumourigenic functions including inhibition of apoptosis, and 
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involvements in cellular proliferation (Martinez et al. 2014). Consistently with this, 
hyperactivation of Nrf2 and increased expression of Nrf2 downstream target genes has 
been described in numerous different cancers and is thought to occur via several 
different mechanisms. One example is by the presence of somatic mutations to KEAP1 
that prevent Nrf2 proteasomal degradation (Hast et al. 2014). Another mechanism, of 
particular interest to this study, is the activation of Nrf2 caused by an accumulation of 
fumarate; a process that has been reported to be part of the tumourigenic pathway in FH-
deficient renal tumours (Sporn & Liby 2012; Adam et al. 2011). In these cases, FH 
inactivation leads to an accumulation of fumarate which acts as a form of cellular stress, 
and therefore causes post-translational modifications to the key cysteine residues of 
KEAP1 by succination (Adam et al. 2011). This alters the conformational structure of 
KEAP1 thereby preventing the KEAP1-CUL3 complex from associating with Nrf2, and 
so also prevents its proteasomal degradation, resulting in constitutive activation 
(Kansanen et al. 2013; Cullinan et al. 2004).     
 
The recent discovery that FH inactivation has also been shown to be associated with 
PCC/PGL tumours suggested a hypothesis that alterations in KEAP1, or CUL3 for that 
matter, could potentially be involved in the development of PCC/PGL tumours. One of 
the key reasons for choosing KEAP1 as a candidate gene, aside from its reported 
tumourigenic role in FH-deficient renal tumours was the fact a nonsense alteration was 
detected in KEAP1 nonsense in the exome sequencing data for an individual with 
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sporadic HNPGL. Interestingly, the nonsense mutation was found to affect one of the 
key stress-sensing cysteine residues, (p.Cys273*). As this alteration was likely to cause 
nonsense-mediated decay, it was considered likelt that this variant would disrupt KEAP1 
function. The hypothesis that mutated KEAP1 was a potential driver of tumourigenesis 
in PCC/PGL was therefore based on a combination of the suggested involvement of 
KEAP1 in FH-deficient renal tumours, the fact that FH had recently been implicated in 
the development of PCC/PGL tumours, and the presence of a nonsense variant; a variant 
highly likely to disrupt protein function. In addition, given the close association of 
KEAP1 and CUL3, and the fact that Cullinan et al 2004 had previously shown that 
disruption to either protein could lead to hyperactivation of Nrf2, CUL3 was also 
selected as a candidate gene that may be playing a tumourigenic role in PCC/PGL 
tumours.   
 
In order to carry out mutation screening, primers were designed to flank the coding 
exons of KEAP1 and CUL3. The primers were used to PCR amplify regions of interest 
in a panel of 55 tumour DNA samples from patients with PCC/PGL (30=PCC, 
20=HNPGL, 5=PGL). As described previously, 48 individuals in this panel were 
suspected to have sporadic cases of PCC/PGL, while 7 patients were known to carry 
pathogenic alterations in a known PCC/PGL susceptibility gene.  In addition, these 
regions were also amplified in the constitutional blood DNA samples from 83 patients 
with suspected familial PCC/PGL.  
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KEAP1 
Exon 
Primers Conditions 
Variants 
Frequency 
Familial Sporadic 
2 
F:TATCTTGCAAAA
CGAGGCCC 
 
R:AAGGGGAGAC
AGTGATGAGC 
Std58°C None None - 
3 
F:GTCAGCGGCAG
TGATAAGTT 
 
R:CGGATCTCAGT
GTCTTGGGA 
Std58°C None N/A - 
4 
F:CACGAAGGTCA
GCTATAATGGC 
 
R:GGGTGTTCCTG
GGTGCTC 
Std60°C 
1.p.Leu471Leu 
 
2. p.Leu471Leu 
3. p.Asp479Asp 
1. 12/83 
2. 14/55 
3. 3/55 
5 
F:GTTCCCAAAGC
CAGACCC 
 
R:GCAAAAGCAAA
AGCAGTCCA 
Std60°C None 
1. p.Tyr537Tyr 
3. p.Ile519Val 
1. 10/55 
3. 1/55 
6 
F:ATGTGGTGTGA
CAGGTGGTG 
 
R:TGCTGTCTTTT
CTTTTAGTCCCG 
Std60°C 
1. p.Thr590Thr 
2. p.Gly605Gly 
None 
1. 1/83 
2. 1/83 
 
Table 9. A Table Outlining The Variants Identified in KEAP1 (NM_203500, 
NP_987096) in the Cohort of 55 tumour DNA and 83 Constitutional Blood DNA 
Samples from Patients with Sporadic or Inherited PCC/PGL. Variants in purple are 
known reported polymorphisms, variants outlined in orange represent unreported 
synonymous alterations and variants in green represent unreported variants of unknown 
clinical significance. More information is provided for the reported polymorphisms in 
supplementary table 2.  
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From the combined total of 143 blood and tumour samples analysed, several common 
single nucleotide polymorphisms, and some synonymous alterations were identified. 
None of the unreported synonymous variants identified (p.Thr590Thr, p.Gly605Gly) 
were within close proximity to any splice sites, and it was therefore predicted that they 
would be unlikely to cause any detrimental effects to KEAP1 function. One 
heterozygous variant of unknown clinical significance was identified in a sporadic 
paraganglioma sample (c.1555A>G; p.Ile519Val) (figure 26). As no constitutional blood 
DNA was available for this patient, it was not possible to determine the 
somatic/germline status of the variant. Furthermore, the alteration was predicted to have 
a benign effect on protein function by the in silico mutation prediction software tools; 
SIFT and PolyPhen (figure 27).  
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Figure 26. Electropherograms Outlining a Variant of Unknown Significance 
Identified in KEAP1.  The images show a region of reference sequence for KEAP1, 
exon 5 and the corresponding region in an affected individual harbouring the 
p.Ile519Val alteration.  
 
 
 
Figure 27.  PolyPhen Mutation Prediction Software. The alteration of p.Ile519Val in 
KEAP1 is predicted to have a benign effect on protein function. This prediction is based 
on a combination of factors including the degree of conservation of this amino acid 
across different species, and the location of the amino acid in relation to the important 
functional domains of the protein.  
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As no further variants were found that were predicted to have any altering effect on 
protein function, KEAP1 was excluded from further analysis. 
All coding exons of CUL3 were analysed in the same panel of 55 tumour DNA and 83 
constitutional blood DNA samples from a combination of patients with suspected 
sporadic and inherited forms of PCC/PGL. The results are outlined in Table 10. 
 
CUL3 
Exon 
Primers Conditions 
Variants 
Frequency 
Familials Sporadics 
1 
F:CTGCCCGCCTTAAAT
GTGAC 
 
R:AGCCCCTTCATCACC
CTAAAA 
Std57°C with 
GC-Rich 
 
 
None 
 
None 
- 
2 
F:CAGGTAAGATTGGA
GGGAGGT 
 
R:CCGGTCAAAGTGCA
ATATGGT 
Std60°C None None - 
3 
F:TCACTGGAGGGTTG
GGAAAT 
 
R:TGACCTTAAATGATA
TGCCCACC 
Std53°C 
None 
(Sequenced by 
Atif Alsaedi) 
None 
(Sequenced 
by Atif 
Alsaedi) 
- 
4 
F:GAGAGGTGCTGGAA
AGTTGC 
R: 
GGATTTTCCCAATGTG
CTCAAC 
T.D 65°C - 
55°C 
1.p.Arg173Arg None 1. 3/83 
5 
F: 
ATTGGAGATTGGTCAC
TTCAGT 
Std60°C None None - 
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R: 
GTGAGGTAGTGTGCTG
ATGG 
6 
F: 
ACACTGTAGAAACCCA
GCTAAA 
R: 
AGGACTAAAGAGAGC
CCACA 
Std60°C 
1. c.685+37 
C>T (DIV) 
2.c.685+39C>G 
(DIV) 
3. c.685+37 
C>T (DIV) 
 
4.c.685+39C
>G (DIV) 
1. 24/83 
2. 31/83 
3. 13/55 
4. 18/55 
7 
F: 
GCGTGAACAGAGATTC
GTGT 
R: 
ACAGCATGGTAAAAGT
GGCC 
Std60°C None  None - 
8 
F: 
AGAAACAGTGAGGAG
GTTCTTT 
R: 
ACGTTTGGGCATGTCA
AGTA 
Std60°C None None - 
9 
F: 
TGAACCGTAGTACTGC
TTTTGT 
R: 
AGTGTAGTCTGTGTTC
TTCTCCA 
Std60°C 
1.c.1179+48 
T>C 
2. c.1179+48 
T>C 
1. 70/88 
2.36/55 
10 
F: 
TGATAACCACAGGCAC
AGAG 
R: 
CAACTGTCATCTGCTA
AGTGGA 
T.D 65°C - 
55°C 
None 
1.p.Ile479Ile 
2. 
p.Thr483Thr 
1. 1/55 
2. 1/55 
11 
F:AAACAGAACAGAAA
GCAAATCCT 
 
R:TGCCTGCTTTACTTT
- N/A N/A - 
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ACTCATCA 
12 
F:GTGTGGGGCCTTTGT
CATTT 
 
R:TGTGAGACAGGCAG
AGAAACA 
Std.60°C 1. p.Val501Ile 
2. 
p.Val501Ile 
1. 17/83 
2.16/55 
13 
F:CCAGGAAATGATTGT
GTCTTTGT 
 
R:TGCTCTGTATTTTCG
GGCAA 
- N/A N/A - 
14 
F:TGCTTGGTCAGTTTA
CTTGCT 
 
R:CATGCAGCACCAGA
AAAGGA 
T.D 65°C - 
55°C 
1.p.Gln598Gln 
2.p.Gln598Gl
n 
1. 11/34 
2. 20/55 
15 
F:ACTCTTGTCTCCTCAT
AAAGCCT 
 
R:CATTGGTTCCGAGA
GTGTGC 
Std 58°C None None - 
16 
F:TCTGATTTGAGGAAG
TGTGTTGT 
 
R:TGTTGGAAACTCTCA
AAGGGA 
Std 60°C None None - 
 
Table 10. A Table Outlining the Variants Identified in CUL3 (NM:003590, 
NP:003581) from a Cohort of 55 Tumour DNA and 83 Constitutional Blood DNA 
samples from Patients with Sporadic or Inherited PCC/PGL. Previously reported 
known polymorphisms are outlined in purple, unreported synonymous variants are 
outlined in orange. No pathogenic variants or variants of unknown pathogenicity were 
identified during this screening. Some exons were not able to be completed, and 
therefore are marked with N/A. 
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The sequencing data revealed several common polymorphisms and several deep intronic 
variants. However, it should be noted that, due to the time restrictions of this project, it 
was also not possible to sequence every exon to completion in every sample. Help was 
received from Mr. Atif Alasaedi to sequence CUL3 exon 3. However, exons 11 and 13 
were unable to be sequenced. It is expected that this is due to inefficient primer sets. A 
minimum of 20 patients were sequenced for all other exons in each cohort of familial 
and sporadic PCC/PGL samples (supplementary table 3). The incompletion is largely 
due to the fact that it is difficult to obtain successful, clean sequencing for every sample 
in the first round of sequencing, and it is inevitable that some samples will fail (due to 
factors such as incorporation of dye blobs for example, or through occasional, 
unavoidable human errors). 
 
5.2g Cullin-2 and VHL  
As previously mentioned, cluster 1 PCC/PGL tumours are well known to exhibit 
pseudohypoxic environments, often showing increased expression of hypoxia-associated 
target genes. This can be achieved through a variety of mechanisms including genetic 
inactivation of VHL through the occurrence of a deleterious mutation, or, as recently 
discovered, specific activating mutations occurring in the hotspot regions of HIF2A 
(Comino-Méndez et al. 2013). An intriguing aspect to pseudohypoxic PCC/PGL 
tumours is that VHL mutations are only identified in less than 10% of tumours, which 
cannot account for the high frequency with which pseudohypoxic tumour environments 
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are displayed (Rowbotham et al. 2014). Therefore, it is hypothesized that additional 
mechanisms that give rise to this phenotype may be present that have not yet been 
elucidated. There is currently little known about the contributory role of other 
components of the hypoxia pathway in PCC/PGL tumour development and progression. 
Therefore, given the high rate of pseudohypoxic environments in PCC/PGL tumours in 
combination with the disproportionately low number of inactivating VHL mutations or 
activating HIF2A mutations, it seemed logical to suggest that disruptions to other parts 
of the hypoxia pathway may be contributing to this phenotype. 
 
The pVHL protein has been shown to exist in a complex along with elongation proteins 
(elongin B / elongin C), CUL2 (a member of the cullin family) and ring finger protein 
RBX1; which together form the VCB-CR complex (Gossage et al. 2014). This complex 
then acts an E3 ubiquitin ligase that promotes the targeted ubiquitination and 
proteasomal degradation of HIF-1α and HIF-2α under normoxic conditions (Gossage et 
al. 2014). Although no CUL2 knock-out mouse models have been examined to date, 
previous studies have shown that targeted inhibition of CUL2 in epithelial cells leads to 
the stabilisation and accumulation of HIF, much in the same way as VHL (Curtis et al. 
2014; Chen et al. 2015).  This finding gives weight to the hypothesis that inactivating 
genetic mutations in CUL2 might potentially provide an explanation for a proportion of 
the unexplained pseudohypoxic environments observed in many PCC/PGL tumours 
lacking VHL or HIF-2α alterations. 
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The exome sequencing data of our study contained one missense alteration in CUL2 
(c.1051C>G, p.Leu351Val) from the cohort of 12 tumour samples; however this 
alteration was predicted to have a benign effect on protein function by in silico 
prediction software tools, SIFT and PolyPhen. Regardless of this prediction, it seemed 
intriguing to investigate the potentially progressive role of CUL2 alterations in 
PCC/PGL patients; particularly given the recent findings of HIF2A alterations in 
PCC/PGL tumours. Therefore, primers were designed to flank all coding exons of 
CUL2, for use in direct sequencing as part of the mutational screening process in a panel 
of 55 tumour and 83 constitutional blood DNA samples from familial and sporadic 
PCC/PGL patients.  
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CUL2 
Exon 
Primers Conditions 
Variants Freque
ncy Familial Sporadic 
2 
F:GACTCCGTCTCAAA
GCAAACA 
 
R:TGCCATAAAAGAG
GTGATGAACT 
TD 65°C - 55°C None None - 
3 
F:CCCTCTGGATTTTA
ACCTCTCTG 
 
R:GCAACAGAGCAAG
ACCCTG 
Std53°C None None - 
4 
F:CGCTCGGCTCAGTT
TATTCT 
 
R:TAGACCTTTCCCCA
CAGCAG 
Std60°C 
1. p.Lys109Glu 
2. Glu106Glu 
None 
 
1. 1/83 
(benign
) 
2. 1/83 
5+6 
F:TGCATTTCTTCCTG
GTGATTAGA 
 
R:GCTAGCCAAATCA
GTGTCCT 
Std60°C None None - 
7 
F:TGTTGATAAGGCTA
GTAGAGTGG 
 
R:TGGCTCTGCAATTG
TACACT 
Std60°C 
1. c.613-6C>T 
(32/88) 
2.c.613-6C>T 
(21/55)  
1. 
19/88 
2. 8/55 
8+9 
F:TGATGGGCTCGTAT
CTACTTTG 
 
R:AACCAGGCCAGAT
ACAAAATAGA 
Std54°C None None - 
10 
F:CCTTTGCCATGTTT
AATTCAGCC 
 
R:TCAAGGGTGACTA
GAGGATGA 
TD 65°C -60°C None None - 
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11 
F:CTTGGGTGGCTGG
GAGGT 
 
R:GACATTTCTTTCGT
TGGCATGGT 
TD 65°C - 60°C None None - 
12 
F:CCAGCCTTCAACAC
CAAAGT 
 
R:CACGGGACATTCTA
CAAGCA 
Std60°C None  None  - 
13 
F:TGCTGTGTTTTATG
TGGCGG 
 
R:CCTAGGTGAGTTTC
GAGTGGT 
Std58°C 1. p.Thr386Thr  2. p.Thr386Thr  
1. 
20/83 
2. 
15/55  
(rs1693
5840)   
14+15 
F:TGTCCGCTGATCTT
ACCTTGT 
 
R:ACACAATGCTGCAA
TGAACATC 
TD 65°C - 60°C 
1. DIV: 
c.1488+36G>A 
c.489-41A>G 
2. DIV: 
c.1488+36G>A 
c.489-41A>G  
1. 
34/83 
2. 
34/55 
16 
F:AGACCTAGCAATAC
CGACACA 
 
R:GCCCAGCCCAAATC
AATAGG 
Std58°C None N/A - 
17 
F:GGTTTGGAATGAA
ATGTGCCA 
 
R:CCTAAAGGGCAGA
CTGACTATAA 
Std60°C None None - 
18 
F:CCAGATGGGCTTTA
ATGTCTCT 
 
R:AAGTGGTTGGCTA
Std60°C None  None - 
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GAGAAATGT 
19 
F:TCCTCACCTCCCCA
AGAAAC 
 
R:AGTGAATACAAGT
GCTTTCCAGA 
- N/A N/A - 
20 
F:AGTTATGAGAGTG
GAGGCTTTT 
 
R:TGCCAACAACAAAC
CAGAAAA 
TD 65°C - 60°C 1.p.Ser650Ser  2. p.Ser650Ser 
1. 
34/83 
2. 
12/55 
21 
F:AGGACGACAGAGT
GAAACCC 
 
R:CATGAGCCACTGT
GCCCA 
Std58°C None  None  - 
22 
F:TGGCCCATTTGTTG
AAACCT 
 
R:CCAAATGGTGATG
GCAATGATC 
TD 65°C - 60°C None None - 
 
Table 11. A Summary of Variants Identified in CUL2 from the Cohort of 55 Tumour 
DNA and 83 Constitutional Blood DNA samples from familial and sporadic PCC/PGL 
patients. Previously reported polymorphisms are outlined in purple, unreported 
synonymous variants are outlined in orange and unreported variants of unknown 
clinical significance are outlined in green  (DIV refers to a deep intronic variant). It was 
not possible to complete sequencing for exon 19, and therefore this is marked with N/A.  
 
In a similar situation to CUL3, there were no particular variants of interest identified in 
CUL2; other than one variant of unknown clinical significance, that was predicted to 
have a benign effect on protein function by SIFT and PolyPhen. However, as previously, 
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it was not possible to obtain clean, confident sequencing for all samples on every plate 
with the time restrictions, and therefore, sequencing data for some exons was not 
obtained. Sequencing for exon 19 was not obtained as it was not possible to obtain 
sufficient amplification at the PCR stage. This is likely due to poor primer design; 
however, given there was insufficient time to investigate this further. The smallest 
combined sample size of familials and sporadic samples sequenced for an exon was 48. 
(A summary of sequencing can be found in supplementary table 3) 
 
The variant of unknown significance identified (p.Lys109Glu) was predicted to have a 
benign effect on protein function by in silico software prediction tools, SIFT and 
PolyPhen (figure 28).  
 
 
 
 
 
 
 
   Figure 28.  PolyPhen Prediction of p.Lys109Glu on CUL2 Function.  
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Although this work could potentially be continued by other members of Prof. Maher’s 
team, the lack of potentially pathogenic alterations identified during this screening 
process have dampened the hypothesis that loss of function exonic alterations in CUL2 
are playing a contributory role in the development or progression of PCC/PGL tumours. 
Therefore, it is unlikely that investigations into CUL2 will be continued. 
 
5.3 Discussion of Sporadic Pheochromocytoma and Exome Sequencing 
5.3a HIF-2α and Sporadic Pheochromocytoma and Paraganglioma 
Unlike alterations in tumour suppressor genes, where numerous different mutations at 
various locations can result in truncated proteins with loss of function, cancer-related 
mutations occurring in oncogenes are often present in specific ‘hotspot’ regions that lead 
to a very specific activation or overexpression of the protein. Therefore, the initial 
identification of a variant in the exome sequencing data in HIF2A at a critical residue 
was highly interesting.  
 
Exome sequencing data received for 15 tumour DNA samples (13 with apparent 
sporadic PCC/PGL) revealed the presence of two alterations in HIF2A (p.Pro531Thr, 
and p.Ser372Asn). The 531 residue corresponded to a primary hydroxylation site (as 
displayed in figure 29); this indicated that this alteration was highly likely to affect 
protein function. Furthermore, during this project, several publications became available 
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describing the identification of novel activating mutations in HIF-2α present in somatic 
cases of PCC/PGL. The studies identified several specific variants that resulted in 
increased HIF activity, including the same p.Pro531Thr variant found in the exome 
sequencing data of this study (Zhuang et al. 2012; Comino-Méndez et al. 2013, Lorenzo 
et al. 2013). Keeping in mind that alterations with pathogenic potential tend to cluster in 
critical proteomic regions, the finding of a variant located at a critical residue, that was 
also described to be pro-tumourigenic in other, reputable studies strongly indicated that 
the p.Pro531Thr alteration was likely to be acting as a driver in this particular tumour 
(Toledo et al 2013, Zhuang et al 2012). 
 
Further mutational screening of HIF2A by Sanger sequencing of exons 9 and 12 enabled 
the identification of two further alterations (p.Pro407Arg and p.Phe583Leu). 
Interestingly, the p.Pro407Arg was also found to affect a residue in close proximity to 
another key hydroxylation site (Pro405), as illustrated in figure 29; and furthermore, it 
was found to exist in the same tumour that harboured the p.Pro531Thr alteration.  
 
If these two variants (p.Pro531Thr and p.Pro407Arg) are present on different alleles, (in-
trans), then one possibility is that the individual may be a compound heterozygote for 
HIF2A. It is also possible that one of the variants could have been inherited, which may 
have instigated genomic instability resulting in the coincidental acquirement of the 
second alteration. It could also be the case that both variants are present in a singular 
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tumoural clone and that their intraclonal redundancy is exerting a pro-tumourigenic 
effect through HIF-2α stabilisation. Alternatively, and the more likely possibility, given 
the low peak heights in figure 22 and figure 23, is that these two alterations are 
representative of two independent clonal populations, in which the co-operative effects 
of both may confer a growth advantage to the tumour; a particularly attractive 
suggestion, given that both of the variants occur at, or within close proximity to the two 
specific proline residues associated with hydroxylation.  
 
 
Figure 29. Protein Schematic of HIF-2α Including Location of Protein Domains 
adapted from (Rocha 2007). This schematic illustrates the protein domains of HIF-2α, 
and annotates variants identified in this study. (Diagram not to scale)  
 
 
In HIF2A, as mentioned, codons 531 and 407 encode 2 critical residues that regulate 
HIF-2α stability through hydroxylation; therefore alterations at this point can have a 
substantial effect on protein function. Consistently, Toledo et al. 2013 showed that stable 
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expression of mutants at the 531 residue lead to increased stability of HIF-2α under 
normoxic conditions, caused by a conformational change to the hydroxylation sites in 
HIF-2α, which then prevented its recognition by PHDs. In addition, they showed that the 
specific substitution of Proline for Threonine in particular, lead to significantly larger 
tumour formation in xenograft mouse models in comparison to other substitutions at the 
same residue, suggesting that the specific alteration is particularly damaging (Toledo et 
al. 2013). It is therefore assumed that p.Pro532Thr is pathogenic, and is likely to have 
played an active role in the tumour in which it was identified in our study. With recent 
findings in the literature, it is assumed that the protumourigenic effects of this mutation 
prevent the association of HIF-2 α with PHDs and a consequential inability to be 
degraded by pVHL; this then leads to an accumulation of HIF-2α, ultimately resulting in 
the activation of a downstream signalling cascade mediated by the transcription of 
numerous HIF target genes (Kondo et al. 2002).   
 
It would be interesting to know whether or not these variants were somatically acquired 
alterations or present in the germline; however, as no constitutional blood DNA was 
available for this patient, it was not possible to determine the somatic/germline status of 
these variants. However, in the electropherogram of the p.Pro531Thr alteration, it 
appears that the peak representing the variant allele is low; suggestive of the fact that 
this variant is more likely to be a somatically acquired alteration, which supports the 
initial hypothesis that the two independent clonal populations are the likely reason for  
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the presence of both variants. This would also provide an explanation as to why the 
p.Pro407Arg variant was not picked up initially in the exome sequencing data. For 
example, the tumour biopsy used to acquire the tumour DNA used in this study may 
have selected a small proportion of the tumour, and therefore there may have been a 
biased representation of the variants present. Therefore, the p.Pro407Arg variant may 
have been diluted amongst the more prominent cellular populations, and so it may have 
been called as a low quality read that was subsequently excluded during variant calling. 
 
All of these hypotheses could be explored in future studies by investigating the 
downstream effects of both variants in known susceptibility pathways in vitro to 
determine the effect of harbouring two activating mutations located at these two specific 
proline residues by comparing them to cells separately harbouring each alteration alone.  
 
The p.Ser372Asn alteration has not previously been reported, but based on its position, it 
is predicted to affect the PAS domain of the HIF-2α protein; the region in which HIF-1β 
binding occurs (figure 29). The significance of this alteration is uncertain, particularly as 
in silico predictions from SIFT and PolyPhen have suggested that the pathogenicity of 
this variant is likely to be benign. However, although this particular variant has not 
previously been described, a different variant, 2 nucleotides away, at residue 374 has 
previously been found to be associated with PCC/PGL in individuals with 
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polycythaemia (a condition associated with elevated levels of haemoglobin) (Lorenzo et 
al. 2013). The study of Lorenzo et al 2013, reported that they did not find any evidence 
of loss of heterozygosity or the presence of any additional somatic alterations, which 
they suggested was indicative that this variant played a predisposing role as opposed to a 
causative role in this disease.  
Due to the close proximity of residues 372 and 374, it is possible that the tumourigenic 
outcomes observed by Lorenzo et al 2013 associated with the 374 residue may also 
indicate that alterations to 372 may have a similar tumourigenic outcome,   
However, it should be noted that the 374 residue in HIF2A is highly conserved, 
suggesting a functionally important role; however the 372 residue is only moderately 
conserved (different in zebrafish and horse), and therefore it is also possible that 
regardless of their close proximity, this residue may be less functionally important 
(figure 30). All things considered, it would be necessary to carry out further 
investigations into the downstream effects of this variant in vitro in order to fully 
understand the tumourigenic implications of this variant. 
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Figure 30. Multiple Sequence Alignment of HIF2A including residues 372 and 374 
 
The patient found to carry the p.Ser372Asn alteration was also positive for a pathogenic 
SDHB alteration, which may suggest one of two options with regard to the HIF-2α 
alteration: the first possibility is that the inherited SDHB mutation resulted in the 
development of PCC/PGL and the HIF2A alteration identified in the tumour DNA was 
acquired and may be driving tumour progression. The second option is that both the 
p.Ser372Asn alteration and the pathogenic SDHB alteration (p.Trp200Asn) were 
inherited and that the cooperative effects of both variants contributed to tumour 
development. The corresponding normal blood DNA was unavailable for this individual, 
however, the electropherogram for this variant does seem to show an equal distribution 
between the variant and wildtype allele, which could be an indication that this alteration 
is present in the germline. It is interesting to consider the possibility that both may be 
germline; particularly as pathogenic HIF-2α variants have not previously been reported 
to occur in combination with other inherited PCC/PGL susceptibility genes; however, it 
will not be possible to know for sure without access to the corresponding normal blood 
DNA of this individual.      
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5.3b HRAS and Sporadic Pheochromocytoma and Paraganglioma 
HRAS is one of the most commonly mutated genes in human cancer and disruption of 
the RAS/RAF/ERK and PI3K/AKT/mTOR kinase signalling pathways have been well 
documented to be associated with the development of PCC/PGL. However up until 
recently, mutations in HRAS had not previously been found to occur in PCC/PGL 
tumours. This may be due to the fact that many previous genetic studies into sporadic 
cases of PCC/PGL had largely focused on the presence of known susceptibility genes in 
tumour DNA. However, the recent publication by Crona et al 2013 demonstrated that 
somatic alterations in HRAS do indeed contribute to tumour progression, and as of yet 
germline alterations in HRAS have not been associated with the development of the 
inheritance of PCC/PGL. However, this is likely to be due to the fact that germline 
alterations in HRAS are associated with Costello syndrome; a condition belonging to a 
group of disorders known as the RASopathies (Gripp & Lin 2012). Interestingly, neither 
pheochromocytomas nor paragangliomas have been associated with Costello patients, 
which suggests that although the same pathway is disrupted, there must be additional 
genetic or environmental factors contributing to the non-penetrance of HRAS-associated 
PCC/PGL in these patients. It is likely that HRAS plays a specific, essential role during 
embryogenesis that becomes obsolete later in life, which is why germline and acquired 
HRAS alterations do not result in the same clinical phenotype. 
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Tumour DNA samples from 55 patients with apparently sporadic PCC/PGL were 
screened for mutation in HRAS, KRAS and NRAS by Sanger sequencing. These samples 
and a further 30 PCC/PGL DNA samples were also screened by Andrea Luchetti using 
the ampliseq IonTorrent cancer hotspot panel. No variants of interest were identified in 
KRAS or NRAS; however, our collaborative efforts revealed a total of 6 alterations from 
85 patients in HRAS (1=p.Gly13Arg and 5=p.Gln61Arg). In total, this amounted to a 
total frequency of approximately 7.1%. In combination with mutations reported in the 
current literature, it is estimated that the mean frequency of HRAS/BRAF mutations in 
sporadic PCC/PGL is 8.9% and in PCC/PGL with an inherited gene mutation 0% 
(Luchetti et al. 2015; Oudijk et al. 2014; Crona et al. 2013). These figures suggest that 
HRAS/BRAF mutations and inherited PCC/PGL genes mutations might occur in a 
mutually exclusive  manner (Luchetti et al. 2015).  
 
Due to the fact that the mutations identified are known to affect two essential residues 
responsible for GTP-hydrolysis, our data in combination with current literature, 
indicates that mutations to these particular residues will likely result in the aberration of 
GTP-hydrolysis in HRAS resulting in the constitutive activation of the RAS pathway. 
This signals to a large downstream signalling cascade of various pathways including the 
RAS/RAF/ERK and PI3K/AKT/mTOR pathways which ultimately generates a complex 
web of pro-tumourigenic cellular consequences including increased cellular proliferation 
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and growth, RAS-induced apoptotic resistance and increased angiogenesis (Pylayeva-
Gupta et al. 2011).  
 
The identification of HRAS as a driver of tumourigenesis in PCC/PGL may have future 
clinical implications and could potentially highlight a novel therapeutic opportunity; 
although most common methods of treatment usually involve surgical removal of the 
tumour. The first descriptions of BRAF mutations in PCC/PGL may also contribute new 
perspectives on PCC/PGL progression; particularly as BRAF causes ERK kinase 
activation as part of the RAS/RAF/ERK signalling pathway, which indicates that 
constitutive RAS pathway activation can occur through mutation to various parts of the 
pathway. It would therefore be interesting to use a different targeted next generation 
sequencing panel containing more genes indicated in this pathway in order to determine 
whether any further somatic mutations can be identified in related genes in PCC/PGL 
tumours. 
  
The collaborative finding of these mutations in HRAS associated with sporadic 
PCC/PGL highlighted the benefits of performing mutation screening using more than 
one technology. There are clear benefits and shortcomings to Sanger sequencing, whole 
exome sequencing and targeted next generation sequencing; however in this particular 
instance, the combination of these technologies was able to deliver positive results that 
would not likely have been achieved otherwise. Using the targeted next generation 
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sequencing panel to sequence the hotspot regions of known cancer genes meant that 
many patient samples could be sequenced in parallel with higher depth and greater 
coverage than would have been achieved with exome sequencing alone. This targeted 
method is also more sensitive to picking up mosaicism; a clear advantage over Sanger 
sequencing, where these types of variant can be missed. Using an NGS panel generates 
results much faster at a lower overall cost than would be achieved by Sanger sequencing 
as it sequences multiple reads in parallel. It seems reasonable to assume that genes 
already known to play a role in other cancers may also be likely to play a role in 
PCC/PGL tumours; however aside from the HRAS, BRAF and TP53 alterations reported, 
no variants were identified in any of the other known cancer genes. This fact emphasises 
the genetic complexities of cancer, in that established connections between genes and 
aberrant molecular pathways in one tumour type cannot always be applied to others. For 
this reason, targeted next generation sequencing, although a powerful tool in its own 
right, is at its most useful when a regions and genes of interest have already been 
identified, and it is not often effective as a tool for novel gene discovery. 
 
 
5.3d KEAP1 and CUL3 as Drivers of PCC/PGL Tumour Progression  
All coding exons of KEAP1 and CUL3 were analysed by Sanger sequencing in a total of 
55 tumour and 83 constitutional blood DNA samples from patients with suspected cases 
of sporadic or inherited PCC/PGL. Although one heterozygous alteration (c.1555A>G; 
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p.Ile519Val) was identified in the tumour DNA of a patient with sporadic 
paraganglioma, the variant was not predicted to affect protein function. There are several 
possibilities that could explain the finding of a single alteration from a panel of 138 
patients. For example, the variant could simply have been inherited as a rare, benign 
polymorphism. Alternatively, the variant could also have occurred as a sporadic event in 
the tumour. The possibility that this variant could be playing a tumourigenic role in the 
progression of a minute proportion of PCC/PGL patients (<1%) can also not be 
excluded.  
 
CUL3 was investigated toward the late stages of this project, and therefore as a result of 
time restrictions to the project, some exons could not be sequenced successfully; 
however, the minimum number of successful patients in an incomplete exon was 20. 
Although not ideal, a minimum cohort of 20 was still considered to be a reasonable 
number of patients, which would enable the detection of higher frequency variants, 
although perhaps not those at low frequency. Unfortunately, exons 11 and 13 were not 
able to be sequenced as no PCR products could be obtained.  
 
KEAP1 and CUL3 were not investigated for the presence of epigenetic alterations or for 
the presence of larger exonic duplications or deletions, and so the possibility that 
KEAP1 or CUL3 protein function is potentially disrupted by these factors cannot be 
ruled out. However, the lack of further intragenic alterations in either of these genes in 
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the total cohort of 138 patients meant that it was not viable to continue investigations 
into KEAP1or CUL3 as potential drivers of PCC/PGL 
 
Recent studies have found relatively low levels of exonic mutations in CUL3 and 
KEAP1, but have found high numbers of tumours with copy number loss and 
hypermethylation of the promoter regions of both KEAP1 and CUL3 (Martinez et al. 
2014; Sporn & Liby 2012). Inactivating mutations affecting KEAP1 and CUL3 have 
been identified in a wide variety of tumour types including ovarian, thyroid, head & 
neck and non-small cell lung tumours (Martinez et al. 2014). Furthermore, Martinez et 
al 2014 also showed a marked enrichment of Nrf2 target genes in ovarian tumours 
harbouring disruptions to KEAP1-CUL3 complex; this highlights the likely effects of 
Nrf2 pathway hyperactivation and is suggestive that this is contributing to tumour 
progression in these cases. Given these findings in other tumours, it would be interesting 
to investigate the expression levels of KEAP1, CUL3 and Nrf2 in PCC/PGL tumours in 
order to determine if activation of this pathway correlates with disease severity; 
particularly in FH-deficient PCC/PGL tumours as this was found to be the mechanism of 
tumourigenesis in FH-deficient renal tumours (Adam et al. 2011).   
 
Given the findings in this study in combination with the information available in current 
literature, it cannot be said with certainty whether or not disruptions in KEAP1 or CUL3 
are playing a role in the development or progression of PCC/PGL; however it is 
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hypothesized that copy number loss and hypermethylation may potentially be identified 
if KEAP1 and CUL3 are investigated in a larger sample size of PCC/PGL patients. 
  
 
5.3e Cullin-2 and PCC/PGL  
CUL2 was screened in a cohort of 55 tumour DNA and 83 constitutional blood DNA 
samples from individuals with sporadic and familial forms of PCC/PGL. Although not 
every exon was sequenced to completion in the entire cohort of patients, the lowest 
number of patients sequenced in an exon was 48; which was considered to be acceptable 
given the lack of time. The lack of potentially pathogenic alterations found from those 
sequenced meant it was not economically or temporally feasible to continue to complete 
the sequencing in these individuals. Furthermore, shortly after completing the first stages 
of the mutation screening process, some publications were released which had also 
investigated CUL2 as a potential driver of PCC/PGL tumourigenesis. It was therefore 
decided that a review of the current findings in this project and a comprehensive review 
of the literature should be performed in order to determine the feasibility and practicality 
of continued investigations into CUL2.  
 
The variant of unknown significance that was identified (p.Lys109Glu) has been 
investigated using in silico mutation prediction software tools in order to generate a 
rough prediction of its deleterious potential. In silico tools, SIFT and PolyPhen 
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suggested that this variant of unknown significance was predicted to have a benign 
effect on protein function. Although in silico tools are not completely reliable, they are 
useful for supporting theories of pathogenicity. They use a combination of factors to 
produce the predicted score, including levels of conservation of the amino acid across 
species and the location of the amino acid in relation to the essential functional domains 
of the protein. In these cases for CUL2, although it cannot be said with full confidence, it 
is predicted that (p.Lys109Glu) is unlikely to have a major effect on protein function, 
and so it was decided not to pursue investigations into this gene any further.  
 
Other deciding factors for terminating investigations into the potential roles of the 
genetic inactivation of CUL2 in PCC/PGL tumourigenesis, included the fact that a 
relevant publication was recently released during the CUL2 mutation screening process. 
Rowbotham et al 2014 also investigated disruptions to various parts of the hypoxia 
pathway in order to determine potential involvement in the progression of PCC/PGL 
tumours. They found that in a panel of 171 PCC tumours, approximately 60% were 
found to harbour copy number loss alterations to at least one component of the hypoxia 
pathway, and that these alterations correlated with increased expression of hypoxia 
target genes (Rowbotham et al. 2014). Surprisingly, and of relevance to this study, they 
did not find any form of genetic mutation, copy number loss or hypermethylation to 
occur in CUL2. It was suggested that perhaps epigenetic inactivation of CUL2 may be 
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playing a role in tumour development; however without comprehensive expression 
studies of CUL2 in PCC/PGL tumours, it is not possible to know for sure.  
 
In conclusion, CUL2 did initially seem a reasonable candidate gene for involvement in 
the progression or development of PCC/PGL tumours, given its association with VHL 
and its involvement in the hypoxia pathway. The fact that other labs were 
simultaneously investigating the role of CUL2 in PCC/PGL tumours supports our initial 
theories of its associations with these tumours. Unfortunately, although other researchers 
have identified different components of the hypoxia pathway to be associated with 
PCC/PGL tumours, multiple parts to their investigations have discounted the likelihood 
of the involvement of CUL2. The fact that no clearly pathogenic variants were identified 
in our cohort of 138 PCC/PGL patients in combination with the lack of alterations 
identified in the recent literature from a further 171 patients is strongly suggestive that 
genetic inactivation of CUL2 does not play a role in the pathogenesis or progression of 
PCC/PGL.  
 
Therefore, taking into account the lack of clearly pathogenic variants found in CUL2 in a 
total number of 309 PCC/PGL patients (171 samples from the literature, and 55 tumours 
and 83 constitutional blood DNA samples from this study) it is hypothesised that 
inactivation of CUL2 by genetic mutation is unlikely to play a role in the pathogenesis or 
progression of these tumours.  
210 
 
5.3f Sporadic PCC/PGL and Exome Sequencing  
There are clearly many potential benefits to be gained from exome sequencing projects 
investigating the genetic contributions to the development and progression of somatic 
tumours. Successful identification of novel genes and variants that are found to play an 
active role in these tumours may uncover valuable, previously unknown, information 
regarding tumour biology. These findings may also shed light on novel mechanisms of 
tumour progression, which may then potentially lead to opportunities for therapeutic 
intervention. These successes have been achieved on many occasions by various 
different studies.  
 
It should be noted that along with the potential benefits of these types of studies also 
come vast challenges and difficulties, which must be overcome. The most prominent 
challenges faced during this study included the filtration and prioritization of the vast 
number of candidate variants in addition to the limitations of manpower with regard to 
carrying out mutational screening. Although no novel genes were identified to play a 
role in the progression of somatic PCC/PGL tumours, this study did uncover several 
beneficial discoveries. Firstly, this study identified novel alterations occurring in both 
HIF-2α and HRAS; both of these discoveries may be of clinical relevance in the near 
future with regard to diagnostics and even possibly therapeutic choices. The use of the 
IonTorrent cancer hotspot panel facilitated the successful identification of these novel 
alterations in HRAS, and also provided the data necessary to observe that alterations in 
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HRAS segregated with somatic tumours. This discovery in particular may benefit 
patients in the future, not only to assist diagnostics and guide treatment plans, but may 
also provide HRAS positive PCC/PGL patients with the valuable information and peace 
of mind that their family members are unlikely to be at an increased risk of developing 
these tumours.  
 
In conclusion, although these projects have their challenges, the potential for them to 
produce results of clear clinical benefit is unmistakable. With continued investigations 
into the predisposition, development and progression of these tumours, it is hoped that 
effective preventative and therapeutic treatments may be developed to help and support 
those affected.  
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Chapter Six:  
DISCUSSION 
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6.1 Summary of Findings 
In a brief summary of all findings, exome sequencing was employed as an investigative 
tool in an attempt to identify genes associated with a range of different disorders, 
including rare, autosomal recessive disease and both familial and sporadic cancer. Due 
to the different genetic natures and complexities between these disorders, there was quite 
a significant variation in the degrees of success of each section of the project. These will 
be summarised briefly in the following sections.  
 
6.1a Evaluation of Exome Sequencing for use in Recessive Disease-Gene Discovery 
Exome sequencing was used to screen one individual from a consanguineous family 
who was affected with Acrocallosal syndrome in the hope of identifying a causal variant 
responsible for their disease. Exome sequencing was used as it initially enables an 
unbiased approach to gene discovery.  The fact that acrocallosal syndrome is an 
autosomal recessively inherited disorder was of great benefit, as it allowed the removal 
of all heterozygous alterations, and so only rare homozygous alterations remained. This 
reduced the number of candidates from 28,588 to 9; a substantial reduction of 99.97% of 
variants. This process was facilitated further by the fact that DNA from multiple 
additional family members was available, thus providing the opportunity to carry out 
segregation studies, thus enabling the confident exclusion of non-segregating variants. 
Consanguineous families, as mentioned previously, will share many of their alterations, 
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and therefore offer a powerful means of gene detection. This in combination with a rare, 
autosomal recessively inherited disorder meant that the odds of identifying the disease 
gene were quite favourable. Consistently with this, a homozygous deletion 
(c.653_662delCACGGTCTT, p.(His218_Phe221delinsLeu)) was detected in KIF7 in the 
affected individual, and was successfully shown to segregate with the disease status 
within the family.  
 
A publication was released at the time of this discovery, describing mutations in KIF7 
associated with the inheritance of acrocallosal syndrome (Putoux et al. 2012). However, 
interestingly, it was suggested that the presence of modifier genes may be playing a role 
in the wide array of phenotypic variability that is often observed in this condition. As a 
result of this, our continued investigations managed to identify the presence of 
alterations in AHI1: c.C2488T p.Arg830Trp; BBS2: c.G209A p.Ser70Asn and BBS4 
c.A1414G p.Met472Val; variants which have all previously been shown to be present in 
other ciliopathies. Whether these alterations are truly contributing a modifying effect to 
the phenotype observed in the affected individual from this study will remain 
speculative until more comprehensive analytical studies have been performed in larger 
cohorts of affected individuals.  
 
These findings demonstrated the power of exome sequencing to successfully identify 
disease variants in autosomal recessive disease. This data was published in the European 
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Journal of Medical Genetics in 2013; and it is hoped that these findings will be of some 
clinical benefit to patients affected with ciliopathies such as acrocallosal disease.  
 
6.1b Evalutation of Challenges and Successes of Exome Sequencing for use in 
Disease-Gene Discovery for Inherited Cancer 
Following the successful gene identification with autosomal recessive disorders, it was 
considered that the powerful abilities of next generation sequencing technology could be 
used to investigate the genetic causes of inherited cancers. Pheochromocytoma is one of 
the most genetically heterogeneous cancers, and the number of genes conferring 
increased susceptibility to these tumours is constantly growing. As many tumours with a 
strong pattern of heritability do not harbour a mutation in any of the known 
susceptibility genes, it is likely that there are many genes yet to be discovered.  
 
Familial cancers are often inherited in an autosomal dominant pattern with incomplete 
penetrance, which can add a certain complexity to gene identification studies. In 
addition, the cancer genome has a highly genetically heterogeneous landscape that can 
be influenced by multitude of factors including environmental exposures. These highly 
variable aspects to these disorders mean that employing exome sequencing to carry out 
gene discovery investigations can be extremely challenging in comparison to studies in 
autosomal recessive disorders. Firstly, the autosomal dominant inheritance patterns 
mean that no heterozygous variants can be excluded from the data, which greatly 
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increases the number of potential candidates. Furthermore, the incomplete penetrance in 
cancer means that variants cannot be excluded based on their presence in unaffected 
individuals alone. The highly diverse and complex mechanisms of tumourigenesis also 
means that multiple different molecular pathways containing vast numbers of genes may 
potentially be playing a tumourigenic role, which again, expands the number of possible 
candidates exponentially. Nevertheless, our approach was to compile groups of DNA 
samples from a number of affected individuals, who had clear indications of an inherited 
form of PCC/PGL, but who did not carry a germline mutation in any susceptibility gene. 
In the absence of available DNA from comprehensive families with PCC/PGL patients, 
our approach was to attempt to identify certain genetic similarities between unrelated, 
affected individuals in the hope that disease variants would be enriched in the disease 
population in comparison to healthy controls.  
Exome sequencing was therefore performed for 11 unrelated PCC/PGL patients which 
resulted in a collective quantity of 263,798 variants. Even following the vigorous and 
highly stringent variant filtration methods applied to reduce this number, there were still 
a potential 3809 variants (766 of which were either frameshifts, nonsense or splicing). 
At this point, it was necessary to apply a candidate gene approach; however, many of the 
genes present were uncharacterised and therefore, without any functional evidence, 
could not be investigated. A further challenge to this study was the fact that 
heterozygous variants are associated with a higher frequency of false positive results in 
comparison to homozygous variants. This is because 100% of the reads should map to 
217 
 
the altered allele for a homozygous variants, while heterozygous variants are usually 
called when 50% of the reads map to the altered allele. For this reason, during the 
inevitable errors that are encountered during the sequencing process, it is easier for false 
positive heterozygous variants to be called. This can be countered by performing deeper 
sequencing so that that the quantity of false reads may be diluted. Even with sufficient 
read depths, averaging between 30-100, numerous false positives were encountered 
(data not shown). A higher frequency of false positives were encountered for missense 
variants, as statistically, a single base change that results in an amino acid substitution is 
likely to be more common than a specific single base change that results in a nonsense. 
Frameshifts were the least likely to be false positives. These factors in addition to the 
deleterious potential of these variants supported our main strategy to primarily focus on 
nonsense, frameshift and splicing variants, which collectively amounted to 766 variants. 
These 766 variants were then scrutinized in order to determine any potential functional 
relevance with related cancer pathways, which resulted in the selection of UBE2C, ERF, 
and ME2.  
 
Comprehensive mutational analysis of these genes in a panel of 77 familial 
pheochromocytoma samples did not reveal any variants of interest apart from several 
variants of unknown significance (that were also detected to be benign by in silico 
mutation prediction tools).  
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The lack of variants could be due to many reasons, and does not necessarily signify that 
these genes are not contributing to PCC/PGL progression in some cases. For example, 
many studies that have successfully identified novel PCC/PGL susceptibility genes have 
reported mutation frequencies of less than 1.5% of patients (i.e MAX: 1.12% of patients, 
FH: 0.83% of patients and TMEM127: 0.9% patients) (Castro-Vega et al. 2014; Comino-
Méndez et al. 2011; Qin et al. 2010). These studies managed to successfully identify 
these genes either by including large sample sizes (598 patients were screened to 
discover FH), or through the use of large families containing multiple affected 
individuals, followed by segregation studies. For these reasons, a cohort of 77 patients, 
meant that it was unlikely that a sufficient number of patients would have been 
identified in order to successfully establish a statistically significant connection between 
PCC/PGL susceptibility and low frequency variants (present in <1% of patients).  
 
The possibility that any of these genes contain large duplications or deletions, or harbour 
alterations to promoter/enhancer regions has not been explored. It is also possible 
therefore that these genes are altered in PCC/PGL tumours, but perhaps not by 
intragenic mutation. In order to confidently determine that these genes are not playing a 
PCC/PGL-related tumourigenic role, larger studies in larger cohorts of patients (ideally 
large families) would need to be performed to rule out the possibilities of low frequency 
intragenic mutations. In addition, studies in these larger cohorts would need to be carried 
out using MLPA to rule out the possibility of duplications or deletions which may not 
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have been picked up through Sanger sequencing. Investigations into the relevant levels 
of protein expression in PCC/PGL tumours for ERF, ME2, UBE2C and UBE2QL1 
would provide a further indication as to whether these proteins are aberrant in these 
cancers. Finally, methylation and loss of heterozygosity (LOH) studies could also have 
been performed to determine whether the second allele had been lost in the tumours 
(which would have supported a potential tumourigenic role). Many further studies could 
have been performed; however, as there was not a substantial amount of evidence 
available, it was not justifiable to carry out these investigations for this particular study.  
 
6.1c Evaluation of Exome Sequencing as a Tool to Investigate Drivers of Sporadic 
Cancer 
Following investigations into familial cases of PCC/PGL, it was decided that exome 
sequencing technology would be used in an attempt to identify potential drivers of 
tumourigenesis in sporadic cases of PCC/PGL. It was thought that there would be a 
greater possibility of identifying tumour-associated variants by sequencing tumour 
DNA, particularly as there are likely to be multiple variants driving tumour progression, 
whereas in inherited cases, it is likely that only a single germline mutation was involved 
in conferring increased susceptibility.   
 
The approach was therefore to sequence DNA from multiple tumours in order to 
determine whether similar patterns of variants could be identified across multiple 
tumours. As most PCC/PGL tumours fall into a distinct molecular profile (either 
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pseudohypoxic or enriched kinase signalling), it was decided that genes present in these 
pathways would be prioritised.   
 
A similar series of challenges were encountered during the gene prioritisation process as 
when this was performed for the familial PCC/PGL exome sequencing data. Even after 
rigorous variant filtration methods, the number of candidate variants was reduced from 
394,673 to 3884; however this was still an extremely large number. Studies into sporadic 
cancer aim to identify genes that have occurred somatically, and therefore these 
alterations should be present in the tumour DNA, but absent from the normal tissue or 
corresponding constitutional blood DNA. It is therefore a useful technique to sequence 
corresponding normal DNA along with the tumour DNA so that variants that are 
common to both samples can be excluded. This can remove vast numbers of candidates, 
allowing the researcher to focus solely on somatic variants. However, this was not a 
viable option for this project, as there was no normal DNA available for many of the 
samples sequenced. It was therefore considered most efficient to sequence DNA from a 
larger number of tumours.  
 
Several publications that were released during the course of this study instigated 
investigations into HIF2A and HRAS; both of these genes were found to be mutated in 
the exome sequencing data (p.Pro531Thr and p.Ser372Asn) in HIF2A and (p.Gly61Arg) 
in HRAS. It cannot be known as to whether these variants would have been selected as 
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candidate genes in this study; however, it is possible that HIF2A would have passed 
through many of the selection criteria applied to this study. There were two different 
variants present in two different tumours, the variants were absent from SNP databases, 
and furthermore the functional relevance of the gene in hypoxic pathways was very 
appropriate. However, the variant in HRAS is more questionable, as only one missense 
variant was identified in the exome sequencing data; in this case, there were a mammoth 
number of other genes that also fit this criteria.  Nevertheless, the findings of other 
groups can instigate multiple additional studies, which can then discover further 
information that can also be of clinical benefit. Thus, our further investigations into 
these genes uncovered novel, unreported variants (p.Pro407Arg and p.Phe583Leu in 
HIF2A and p.Gln61Arg in HRAS) that may be contributing to tumour progression.  
 
The application of a targeted next generation sequencing approach using a cancer gene 
panel in the cohort of sporadic PCC/PGL patients proved to be a very useful technique 
for identifying variants rapidly, at low cost in large number of individuals. Furthermore, 
this technique was more sensitive to mosaic alterations, and so, it was able to identify a 
further 2 (p.Gln61Arg) alterations in HRAS  that had previously been missed by Sanger 
sequencing, in addition to 1 variant in BRAF and 2 variants in TP53 (genes which had 
not been sequenced by Sanger). This approach can be very effective, particularly for use 
in routine diagnostics due to the large numbers of genes covered, high depth and 
accuracy. However, this technique is not as effective when attempting to carry out gene 
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discovery (highlighted by the fact that no other alterations were observed in any of the 
genes on this panel).  
 
6.1c.i Clinical Relevance of Findings in HIF2A and HRAS 
These findings have expanded upon the literature and have increased current 
understandings of the PCC/PGL tumourigenic landscape. For example, HRAS mutations 
are only found in sporadic cases of PCC/PGL (as germline mutations are associated with 
Costello syndrome). Furthermore, HRAS mutations and mutations in known 
susceptibility genes currently appear to occur in a mutually exclusive manner. By 
observing multiple PCC/PGL patients carrying these mutations, associations may be 
made between these mutations and common tumourigenic characteristics, for example, 
patterns in the risks of malignancy or recurrent disease may be highlighted. This would 
then potentially enable patients to have access to a more comprehensive and informed 
prognosis. Furthermore, the finding of mutual exclusivity between HRAS and inherited 
mutations can provide clear indications on risks of inherited disease for additional 
family members. These findings in HRAS, as a collaborative effort with Andrea 
Luchetti, were published in the International Journal of Endocrinology in August, 2014. 
The collective use of exome sequencing, the IonTorrent targeted cancer panel, and 
Sanger sequencing facilitated the identification of multiple HRAS variants by enabling 
the massively parallel sequencing of many individuals with deep coverage. This 
223 
 
combinational approach highlights the benefits of using multiple methods of analysis to 
investigate genetic disease.  
 
Interestingly, the findings from the HIF2A screening indicated two tumours, each 
containing two variants of interest; one tumour containing a pathogenic SDHB mutation 
(p.Trp200Asn) and a variant in HIF2A (p.Ser372Asn), and a second tumour containing 
(p.Pro531Thr) and (p.Pro407Arg) both in HIF2A. Unfortunately, the somatic/germline 
status of these alterations could not be identified in the absence of any constitutional 
blood DNA; however, as discussed earlier, it is likely that these variants represent 
independent clonal populations within the tumour. This information may provide a 
biological insight into the mechanisms of tumour progression in these individuals. 
Furthermore, and of clinical relevance, the (p.Pro407Arg) variant was present in an 
individual who had exome sequencing performed on their tumour DNA; however the 
(p.Pro407Arg) variant was not picked up. This could indicate that the tumour biopsy 
performed contained a biased representation of the variants present. This also highlights 
an important issue that may be encountered in the clinical environment when attempting 
to genetically characterise tumours for treatment choices. It is important to consider, as 
genetic intratumoural diversity may present a hindrance to personalised therapeutic 
approaches. Continued investigations that aim to characterise commonly mutated genes 
in these tumours may enable the development of specific combinational therapies that 
can be applied to target multiple aberrant pathways so that these situations can be 
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addressed clinically. It is hoped that the findings from this study may be of benefit in 
combination with future studies that collectively can translate into the clinical 
environment to improve preventative, diagnostic, prognostic and therapeutic strategies in 
the management of PCC/PGL patients.  
 
6.1c.ii Evaluation of the Candidate Gene Approach 
The candidate gene approach is sometimes criticised for its lack of reproducibility and 
its potential to incorporate subjectivity and bias. However, it is often difficult to avoid 
this when carrying out projects such as this. For this reason, the use of multiple 
techniques can dilute the effects of bias; for example, use of multiple different filtration 
techniques, use of bioinformatics tools, and incorporating other technologies such as the 
targeted cancer gene panel. Although limited success was seen following the screening 
of KEAP1, CUL3 and CUL2, this does not necessarily mean that poor choices of 
candidates were selected; particularly as other reputable groups had also simultaneously 
been carrying out studies into the associations between these genes and PCC/PGL 
(Martinez et al 2014, Rowbotham et al, 2014). This not only suggests that the gene 
selections were within reason, but also that the lack of intragenic mutations identified in 
their studies also supports the absence of pathogenic intragenic mutations from this 
study. 
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6.1d Final Comments on Exome Sequencing to Investigate Disease 
In conclusion, there can be numerous potential benefits that can be gained from exome 
sequencing projects; as demonstrated by the successes achieved with autosomal 
recessive disease and the relative successes from identifying novel mutations in HIF2A 
and HRAS; however these projects can also come with a substantial number of 
challenges. These projects are highly dependent on resources; for example, exome 
sequencing for use in the investigations of familial disease can be most successful in the 
presence of large comprehensive families containing multiple affected individuals. 
Exome sequencing can also be a powerful tool to investigate sporadic disease in the 
presence of large quantities of affected individuals displaying similar characteristics. 
However, it is not always possible to have access to such valuable groups of people. 
Nevertheless, as genetic investigations are continued, and novel discoveries continue to 
stem further projects, the genetic landscape of such diseases is becoming increasingly 
clear.  
 
With the advent of new ventures such as the 100,000 Genomes Project, the genetic 
contributions to disease will only become clearer. It is hoped that in the near future, as 
costs continue to fall and throughput continues to rise, technologies such as exome 
sequencing will become even more accessible within the research environment, so that 
projects such as the one completed here, may continue to identify novel genes and 
pathways that can be targeted therapeutically to improve the lives of patients. It is 
226 
 
predicted that next generation sequencing may not only continue to provide novel 
informative discoveries, but may also become commonplace in the clinical environment, 
both as an investigative tool and also as a tool that can be used to efficiently predict and 
diagnose, and treat disease.  
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Gene Primer Sequence 
Product 
Size 
Annealing 
Temp 
KIF7 
F: CTCTGCCTGCCCTCCTG 
323bp 
58.2°C 
R: GTGTGCTGGACACTCCCC 56.0°C 
RALGAPA2 
F: GAGCAGGACAAAAGCCATTC 
282bp 
54.2°C 
R: CCAATTCTATTTGTTGGCGTGT 56.4°C 
RYK 
F: GCTTCTGCTTGCGCTGTT 
229bp 
50.1°C 
R: CACGGCTCGCAGACTGAT 50.1°C 
TMEM158 
F: CTCCAATGCTTCAGTCAACG 
212bp 
54.2°C 
R: AGAGCAGTAGGTCGCACTGG 55.8°C 
ARHGEF5 
F: TGAATGCCCCACACTTAACA 
373bp 
53.4°C 
R: GGGTCCTCATCTTCTTGAGC 57.5°C 
CA12 
F:CAGGTCCTGGGGTTAGATGA 
344bp 
57.4°C 
R: AGGATGATGGGGACTGAGGT 57.4°C 
CAPS2 
F:GAGGGCTATAAGCAGTATAGTCAGAG 
376bp 
60.82°C 
R: CCCAAGGTACGTGAAAAACTTC 56.0°C 
CNTN6 
F: ACAGGTGTGATGGGGGAATA 
381bp 
55.4°C 
R: GTGCTGCCTAAATGGGTCTC 57.5°C 
ERF 
F: GGATGAGGGTGAGGACAAGA 
374bp 
57.5°C 
R: CCACTTTGCCCAGAGCTTAG 57.5°C 
PCGF5 
F: AAGGTGTGGCAACCAAGTTC 
368bp 
55.4°C 
R: CCCTCTTTCTACTACCATGTAGCTC 60.1°C 
UBE2C 
F: GGCTGAGGCAAGAGAATCAC 
381bp 
57.5°C 
R: GCTCAACCGAGGCTTAATTT 53.4°C 
HIF2A Ex.9 Primers from Graeme Clark     
HIF2A Ex. 12 
F:TGGAATAGTGTTTGTGAGGTCGT   
678bp 
43.0°C 
R: GGGCTAAATGGGGTATCAGA 50.0°C 
HRAS EXON 2 
F:ATTTGGGTGCGTGGTTGA 
420bp 
66.2 °C 
R:CCTCTAGAGGAAGCAGGAGACA 64.3 °C 
HRAS EXON 3 
F:AGAGGCTGGCTGTGTGAAC 
450bp 
69.1°C 
R:GCAGCGGCATCCAGGACAT 68.3°C 
KRAS EXON 2 
F:GTGTGACATGTTCTAATATAGTCA 
450bp 
57.4°C 
R:GAATGGTCCTGCACCAGTAA 63.2°C 
KRAS EXON 3 
F:CGTCATCTTTGGAGCAGGAA 
500bp 
57.9°C 
R:ACTCCACTGCTCTAATCCCC 58.5°C 
NRAS EXON 2 
F:GCTAAGGATGGGGGTTGCTA 
374bp 
61.0°C 
R:TCCGACAAGTGAGAGACAGG 58.9°C 
NRAS EXON 3 
F:GGACAAACCAGATAGGCAGAA 
384bp 
59.2°C 
R:CCTCATTTCCCCATAAAGATTC 58.8°C 
Supplementary Table 1.  Table of primers and their conditions not included in main 
body of text. 
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Gene Exon Polymorphism dbSNP Ref MAF 
UBE2C 1 p.Ser23Arg rs11537645 G=0.0433/217 
ERF 4.i p.Arg205Arg rs11557114 C=0.0855/428 
ERF 4.ii p.Arg205Arg rs11557114 C=0.0855/428 
ERF 4.iii p.Ala410Ala rs35493131 G=0.1016/509 
ERF 4.iii p.Ser327Ser rs61735151 A=0.0779/390 
ME2 13 p.Gly450Glu rs649224 A=0.1562/782 
KEAP1 4 p.Leu471Leu  rs1048290 G=0.4918/2463 
KEAP1 4 p.Asp479Asp rs35074907  A=0.0096/48 
CUL2 13 p.Thr386Thr rs16935840   T=0.1494/748 
CUL2 20 p.Ser650Ser rs12830  T=0.2837/1421 
 
Supplementary table 2. Information From dbSNP on the Reported Polymorphisms 
Identified in this Study. The information includes the polymorphisms identified, dbSNP 
reference and the minor allele frequencies for each variant.
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Supplementary table 3. A table summarising the numbers of patients sequenced for 
each exon of CUL2 and CUL3. Dark green boxes indicate that no sequencing was 
obtained for these exons.  
Gene Exon 
Sporadics 
Sequenced  
Familials 
Sequenced 
CUL2 2 31 29 
CUL2 3 55 83 
CUL2 4 20 64 
CUL2 5 40 23 
CUL2 6 40 23 
CUL2 7 21 32 
CUL2 8 55 72 
CUL2 9 55 72 
CUL2 10 55 83 
CUL2 11 55 83 
CUL2 12 20 28 
CUL2 13 55 83 
CUL2 14 32 70 
CUL2 15 32 70 
CUL2 16 22 83 
CUL2 17 55 83 
CUL2 18 31 81 
CUL2 19     
CUL2 20 34 74 
CUL2 21 25 83 
CUL2 22 55 83 
CUL3 1 22 35 
CUL3 2 48 26 
CUL3 3 40 83 
CUL3 4 31 47 
CUL3 5 27 37 
CUL3 6 55 77 
CUL3 7 20 22 
CUL3 8 50 71 
CUL3 9 47 72 
CUL3 10 42 29 
CUL3 11     
CUL3 12 48 61 
CUL3 13     
CUL3 14 52 34 
CUL3 15 48 83 
CUL3 16 27 54 
